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Parkinson’s disease (PD) is a progressive neurological movement disorder 
characterised by degenerating dopaminergic neurons in the midbrain’s substantia 
nigra pars compacta (SNpc). In the majority of cases, PD is thought to be caused by 
a plethora of overlapping factors that combine to cause toxicity in SNpc neurons.  
The enzyme nicotinamide N-methyltransferase (NNMT) is expressed at higher levels 
in the brain of PD patients. However, whether this association is indicative of a 
causative role in PD is unclear. The biochemical effects of NNMT expression were 
determined by comparing the NNMT-V5 expressing S.NNMT.LP cell line with its 
parent SH-SY5Y. Furthermore, the potential for NNMT to potentiate toxicity of β-
carbolines (βC), a group of endogenous compounds with increased prevalence in 
PD, and 4-phenylpyridine (4PP), an environmental analogue of the neurotoxin 1-
methyl-4-phenylpyridine, were determined by MTT and ATP assay. Finally, the 
ability of purified NNMT to metabolise the βC norharman (NH) via 2N-methylation 
was determined via enzyme assay and the toxicity of 2N-methylated NH (2-MeNH) 
was determined via MTT and ATP assay. 
S.NNMT.LP cells contained a significantly higher ATP content than SH-SY5Y cells (p < 
0.01). No difference was seen between S.NNMT.LP and SH-SY5Y toxicity to the βC 
tetrahydronorharman or 4PP. However, 200 µM NH significantly lowered ATP but 
not cell viability in S.NNMT.LP cells compared with SH-SY5Y (p < 0.01). NNMT was 
found to be capable of producing 2-MeNH from NH and S.NNMT.LP cells were 
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significantly protected from 2-MeNH toxicity (p < 0.001). Moreover, 2-MeNH was 
significantly less toxic to both cell lines than NH (p < 0.05). The metabolism of NH to 
2-MeNH may, therefore, be a detoxification mechanism. Accordingly, the 
expression of NNMT in PD may be a protective response in PD by increasing ATP 
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1.1.1. Parkinson’s disease prevalence and global impact 
Parkinson’s disease (PD) is a progressive neurological movement disorder 
characterised by a number of motor and non-motor symptoms including 
bradykinesia, rigidity, depression and fatigue. PD prevalence increases with age and 
is expected to rise sharply in the near future as life expectancy increases, 
particularly in industrialised countries (de Lau & Breteler 2006, Dorsey et al. 2007, 
Lesage & Brice 2009, Kowal et al. 2013). Currently, estimates suggest that 1 in 100 
people over 60 years of age have PD (de Lau & Breteler 2006, Kowal et al. 2013). As 
a consequence of the progressive increase in the proportion of elderly people 
within the populations of the world, this number is expected to more than double 
by 2030 (Dorsey et al. 2007).  
The rising incidence of PD is expected to have profound economic consequences. 
Although there are difficulties associated with determining the economic burden of 
PD (Dodel et al. 2014), a recent, conservative, estimate of PD burden in the USA 
suggested that medical costs amounted to $14 billion in 2010 (Kowal et al. 2013). 
Furthermore, the non-medical costs of PD (for example, lost workforce 
productivity, disability benefit payments, professional care) were estimated to 
amount to an additional $6.3 billion.  
In addition to the economic costs of PD, the disease also adds a large societal and 
emotional burden to PD patients and their friends and family. Consequently, PD is 
becoming an increasingly significant feature of many peoples’ lives. As a result, 
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there is a growing need for more research into its mechanisms and potential 
treatment options as we progress through the 21st century.  
 
1.1.2. PD patients have an impaired ability to regulate 
movement 
Aside from a range of often difficult to distinguish non-motor symptoms 
(Chaudhuri, Healy & Schapira 2006), the defining, outwardly recognisable, features 
of PD include bradykinesia, rigidity, tremor and postural instability (Hirsch, Jenner & 
Przedborski 2013). These symptoms arise as a consequence of the main 
pathological hallmark of PD: the degeneration of the dopaminergic neurons in the 
brain’s substantia nigra pars compacta (SNpc), a part of the basal ganglia in the 





Figure 1.1. Dopaminergic neurons of the midbrain following tyrosine hydroxylase 
staining. Image kindly provided by Cindy Escobar (July 2014). 
 
The degree of SNpc dopamine neuron loss varies with disease duration but is 
typically 80% at time of death with a 50% loss of dopamine in the striatum (Cheng, 
Ulane & Burke 2010). An illustration of the SNpc’s role in movement-generation is 


















The cerebral cortex sends and receives signals from 
the basal ganglia
Figure 1.2. The movement-signalling pathways of the brain’s basal ganglia. 
Signals are grouped into 2 pathways: the movement-generating direct pathway 
(solid lines) and the movement-inhibiting indirect pathway (dotted lines). Where 
pathways overlap (for example in the efferent signals from the SNpr and internal 
globus pallidus), a solid line is used. Signals in green are excitatory, while 
inhibitory signals are red. SNpc: substantia nigra pars compacta, SNpr: 
substantia nigra pars reticulata. D1 and D2 refer to the type of dopamine 
receptors located at the putamen and caudate nucleus respectively.  
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Movement-influencing signals in the basal ganglia can be grouped into 2 pathways: 
the movement-generating direct pathway and the movement-inhibiting indirect 
pathway. The direct pathway promotes movement by increasing thalamic-motor 
cortex signalling via its putamen-mediated disinhibition. On the other hand the 
indirect pathway dampens thalamic signalling by strengthening the inhibitory 
signals of the substantia nigra pars reticulata (SNpr) and the internal globus 
pallidus.  
The SNpc plays a key role in modulating the strengths of these 2 pathways. 
Dopamine released by SNpc neurons at D1 receptors promotes activation of the 
direct pathway at the putamen. At the same time, dopamine also acts upon 
inhibitory D2 receptors at the caudate nucleus to inhibit the indirect pathway. The 
end result of dopamine’s dual action is a movement-promoting signal being sent 
from the thalamus to the motor cortex and onwards to the periphery (Kandel, 
Schwartz & Jessel 2000, Purves et al. 2001). 
Upon degeneration of the SNpc, the balance between these 2 pathways is 
disrupted, causing increased thalamic inhibition. In practice, this leads to a lowering 
of the body’s ability to change conscious thought into movement. In particular, 
subtle movements, which the SNpc is especially capable of facilitating, become 
harder to perform, leading to the characteristically rigid movement patterns 
common in PD patients (Purves et al. 2001). 
While degeneration of SNpc dopaminergic neurons is the most identifiable cause of 
PD and, indeed, the key factor of its movement-deteriorating pathology, there is 
growing evidence to suggest that PD is not simply a disorder affecting this single cell 
28 
 
population. Instead, there appear to be a number of additional cells, both neuronal 
and non-neuronal, and also beyond the SNpc, that appear to be subjected to their 
own pathologies. For example, it has been reported that α-synuclein deposition, a 
molecular hallmark of PD in dopaminergic neurons (discussed in more detail in 
section 1.2.1.1), can spread from cell to cell via the transcellular movement of α-
synuclein (Braak et al. 2003, Kordower et al. 2008, Hirsch, Jenner & Przedborski 
2013).  
Accordingly, PD’s pathological mechanisms can be categorised as “cell 
autonomous” or “non-cell autonomous”. Cell autonomous processes are those that 
are occurring within the dopaminergic neurons of the SNpc, while the non-cell 
autonomous mechanisms cover the pathology outside of these neurons and the 
SNpc (Foltynie & Kahan 2013, Hirsch, Jenner & Przedborski 2013).  
While the presence of non-cell autonomous mechanisms indicates that PD cannot 
be solely viewed as a disease of the SNpc, its degeneration remains the defining 




Figure 1.3. The pigmentation of the midbrain is indicative of the presence of 
neuromelanin (arrows) within the dopaminergic neurons of the SN (A). In PD, 
these neurons degenerate, resulting in a loss of pigmentation (B). Picture adapted 






Accordingly, further detailed discussion of non-cell autonomous mechanisms are 
beyond the scope of this review, which will initially focus on characterising the 
intracellular environment of degenerating dopaminergic neurons before discussing 
the factors that could be causing their pathology.  
 
1.2. The pathophysiology of PD 
1.2.1. Inherited vs non-inherited PD 
Broadly speaking, PD can be classified into 2 categories: familial and sporadic. 
Familial PD refers to inherited forms of the disease that cluster within families. Due 
to the inherited nature of familial PD, its cause is often identifiable by the discovery 
of one or more mutated genes. On the other hand, people with sporadic PD do not 
appear to have a family history of the disease and, while some monogenic forms of 
sporadic PD do exist (discussed in more detail below), about 90% of PD cases occur 
idiopathically without a definable cause (Lesage & Brice 2009). However, while the 
cause of sporadic PD tends to be poorly defined, there is a large degree of 
physiological overlap between the monogenic and apparently non-genetic forms of 
PD. This has led to a large amount of research being undertaken into the genetic 
forms of the disease in an effort to understand the mechanisms that could also be 




1.2.1.1. SNCA  
The SNCA gene encodes the protein α-synuclein and was the first gene to be 
directly associated with PD (Polymeropoulos et al. 1997). Mutations of SNCA 
include single point mutations and gene multiplications causing early onset 
autosomal-dominant PD (Lesage & Brice 2009, Puschmann 2013). SNCA mutations 
are characterised by α-synuclein accumulation into cellular structures known as 
Lewy bodies (LB, figure 1.4), a classical histological hallmark of both familial and 
sporadic PD (Ross et al. 2008).  
 
Figure 1.4. A histological image depicting a LB (arrowhead) in the SN of a PD 
patient. The single arrow is indicating a less well-defined feature known as a pale 




The role of α-synuclein in PD has not been fully established but it has recently been 
linked to lysosomal dysfunction leading to disrupted autophagy (Sidransky & Lopez 
2012). 
As mentioned in section 1.1.2, α-synuclein depositions in the form of LBs are able to 
spread across the brain via the physical movement of α-synuclein from cell to cell. 
The migration of LB pathology appears to occur in several stages. In fact, LB 
deposition has been found to begin in the medulla oblongata of the brainstem as 
well as in brain areas regulating olfaction, only later progressing to the midbrain 
and the SNpc. As the disease progresses, LB inclusions continue to progress beyond 
the SNpc, reaching the thalamus and parts of the cerebral cortex in late-stage PD 
(Braak et al. 2003). This phenomenon provides evidence of additional facets of PD 
occurring beyond the SNpc, often in a pre-clinical pathology. For example, patients 
who later go on to develop PD frequently complain of a reduced sense of smell 
(Doty 2012). Interestingly, while the extensive presence of LBs in PD justifies their 
status as disease hallmarks, LB pathology is not a PD-specific phenomenon. In fact, 
LBs also occur in Alzheimer’s disease and Lewy body dementia, suggesting some 
form of mechanistic overlap within these 3 distinct diseases (Bras et al. 2014). As a 
consequence of this, it has been difficult to define the exclusive mechanistic role 
that α-synuclein plays in PD. However, the discovery that certain SNCA mutations 
trigger the disease indicates that α-synuclein, particularly in overabundance, has a 




1.2.1.2. LRRK2  
Mutations in the LRRK2 gene, responsible for encoding the leucine-rich repeat 
kinase 2 (LRRK2), result in the development of late onset autosomal dominant PD 
(Lesage & Brice 2012), with the G2019S mutation of LRRK2 being the most common 
PD-causing mutation (Puschmann 2013). The determination of LRRK2’s role is still 
ongoing but it appears that, like α-synuclein, it is also involved in lysosome-
mediated autophagy and it may also influence protein sorting by the Golgi 
(MacLeod et al. 2013). Furthermore, wild-type LRRK2 may be involved in protection 
of mitochondria from damage, with the G2019S mutation conferring an increased 
cellular vulnerability to mitochondrial damage (Saha et al. 2009). 
 
1.2.1.3. Parkin and PINK-1  
Mutations in the parkin gene account for the largest proportion of autosomal 
recessive PD (Dawson & Dawson 2010). In contrast to SNCA and LRRK2, the role of 
parkin, which encodes a protein of the same name, is quite well established. Parkin 
acts as a ubiquitin E3 protein ligase, and is involved in the tagging of proteins and 
organelles for degradation by autophagy (Shimura et al. 2000). In healthy cells, 
parkin functions as a quality control mediator of bioenergetics by relocating to 
dysfunctional mitochondria. Once there, it ubiquitinates proteins on the outer 
mitochondrial membrane, tagging the organelle for lysosomal degradation. In 
addition, parkin has also been linked to mitochondrial biogenesis and thus appears 
to play a role in all facets of mitochondrial turnover in the cell (Scarffe et al. 2014).  
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Parkin recruitment to the mitochondria is dependent upon another PD-linked gene: 
phosphatase and tensin homolog-induced putative kinase-1 (PINK1) (Vives-Bauza et 
al. 2010), mutations of which are the 2nd most common form of autosomal 
recessive PD (Lesage & Brice 2012). Accordingly, loss-of-function mutations of 
either parkin or PINK1 are associated with an accumulation of defective 
mitochondria and impaired cellular bioenergetics (Park et al. 2006, Hirsch, Jenner & 
Przedborski 2013, Scarffe et al. 2014).  
 
1.2.1.4. Homologous mechanisms of familial and sporadic PD  
Mutations of the above-mentioned genes constitute the bulk of the causative 
agents in familial PD. The intense study of these genes and their involvement in PD 
has not only led to a greater understanding of the genetic cases of PD but has also 
shed light on the potential mechanisms of sporadic cases. For example, α-synuclein 
accumulation into LBs is also a prevalent feature of sporadic PD, despite a lack of 
SNCA mutations (Ross et al. 2008). In addition, the LRRK2, parkin and PINK1 
mutation phenotypes all show great similarity to sporadic PD (Yao et al. 2004, 
Lesage & Brice 2009, Lesage & Brice 2012). In particular, the mitochondrial defects 
caused by mutations in these genes have resulted in a significant amount of 
research being carried out to investigate the relationship between the 




1.2.2. The role of mitochondria in PD 
Whether as a consequence of specific gene mutations or arising sporadically, the 
organelle most centrally involved in PD is the mitochondria. The following section 
will highlight the key characteristics of the mitochondria that are affected in PD.  
 
1.2.2.1. Complex I deficiency  
ATP production by oxidative phosphorylation occurs via the sequential trafficking of 
electrons across the inner mitochondrial membrane. This process occurs in several 
stages, with electrons passing through multiple protein complexes associated with 
the mitochondrial inner membrane. The initial protein complex, complex I (CxI), 
catalyses the oxidation of nicotinamide adenine dinucleotide (NADH) to NAD+. This 
reaction releases 2 electrons which are transferred to flavin mononucleotide (FMN) 
before being passed down the respiratory chain to other complexes (figure 1.5) 




Figure 1.5. A Schematic representation of the 5 complexes of the mitochondrial 
electron transport chain. Beginning with CxI, the complexes pass electrons from 
NADH to molecular oxygen in a series of stages, providing the energy required to 
move protons from the mitochondrial matrix to the intermembrane space. The 
proton electrochemical gradient, established by this movement, is used by 
complex V to generate ATP. The numbers in the figure represent each stage of the 
process from the transfer of electrons onto NADH to the generation of ATP from 




The first association between a disrupted mitochondrial function and PD arose from 
the report of mitochondrial CxI deficiency in the SNpc of patients that had died of 
sporadic PD (Schapira et al. 1989, Schapira et al. 1990). This deficiency does not 
appear to occur in all patients but amounts to an approximately 35% reduction in 
those affected (Schapira 2008). CxI deficiency has also been reported in familial PD 
(Palacino et al. 2004).  
CxI inhibition reduces the flow of electrons through the respiratory chain and, thus, 
the amount of ATP that can be produced by oxidative phosphorylation (Exner et al. 
2012). A reduction in cellular ATP has been shown to be a precursor to cell death 
(Eguchi, Shimizu & Tsujimoto 1997). Furthermore, dysfunctional CxI is associated 
with the increased production of reactive oxygen species (ROS), particularly the 
oxygen radical superoxide (O2•-), which occurs following electron leakage from 
reduced FMN and the iron-sulphur centres of CxI (figure 1.6). This occurs as a result 
of a bottleneck effect that arises from the reduction in CxI’s ability to pass on the 




Figure 1.6. Schematic representation of ROS generation by CxI. The superoxide 
radical is generated primarily by electron leakage from reduced FMN but also 
occurs to a lesser extent from iron-sulphur centres (red circles). This form of ROS 
generation occurs following a reduction in CxI’s ability to shuttle electrons 
onwards to coenzyme Q (CoQ) and the other complexes, a pathophysiological 
facet of PD. Electron leakage at CxI can also occur at the site of CoQ’s reduction 
and arise when electrons begin to move back towards CxI. However, this type of 





ROS can trigger the activation of cell death signals and also react with, and damage, 
DNA. This is particularly true for mitochondrial DNA (mtDNA) which is located in the 
mitochondrial matrix, close to the site of ROS generation (Ott et al. 2007). The fact 
that mtDNA encodes many proteins of the respiratory chain, including 7 of CxI 
(Exner et al. 2012), implies that damage-induced mutations of CxI subunits could 
further impair their ability to efficiently transport electrons. This is supported by the 
finding that transfection of mtDNA from patients with reduced CxI activity into rho-
zero A549 cells was able to transfer CxI deficiency (Gu et al. 1998). Accordingly, a 
vicious cycle can be established in which CxI deficiency and ROS production 
exacerbate each other, eventually leading to neuronal cell death via ATP depletion.  
 
1.2.2.2. Iron accumulation 
SNpc neurons are known to accumulate larger amounts of iron than other cells in 
the surrounding tissue (Dexter et al. 1987, Sofic et al. 1988, Dexter et al. 1989). In 
these neurons, iron accumulates and is sequestered into neuromelanin, a highly 
pigmented material which gives the SNpc a characteristically dark structure when 
viewed histologically (figure 1.3) (Gerlach et al. 2003). Under normal circumstances, 
iron accumulation and binding to neuromelanin is cytoprotective, preventing the 
release of free iron which can act as a catalyst for the production of highly reactive 
hydroxyl radicals (Zecca et al. 2008, Mochizuki & Yasuda 2012). However, in the 
presence of increased oxidative stress, for example caused by excessive 
mitochondrial ROS-generation, the binding of iron to neuromelanin is weakened, 
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facilitating its release and enhancing iron-mediated ROS production and damage 
(Zecca et al. 2008).  
 
1.2.2.3. Impaired mitochondrial turnover  
In order to maintain an efficient energy production within the cell, defective 
mitochondria, including those with CxI deficiency, require routine replacement. This 
typically occurs via a specialised form of autophagy, known as mitophagy (de Vries 
& Przedborski 2013). As mentioned above, loss of parkin and PINK1 results in a 
reduction in the neuron’s ability to recycle defective mitochondria.  
The precise consequences of impaired mitophagy in PD are difficult to fully 
elucidate due to the fact that a lot of the studies investigating mitophagy in PD 
were conducted in non-mammalian (Poole et al. 2008, Liu & Lu 2010) and non-
neuronal (Exner et al. 2007, Michiorri et al. 2010) cells. However, impaired 
mitophagy in PD is thought to result in the accumulation of defective mitochondria. 
Consequently, this would be expected to result in sub-optimal ATP synthesis, a 
failure to remove mtDNA mutations and increased ROS production, eventually 
leading to cell death (Chen & Chan 2009, de Vries & Przedborski 2013).  
 
1.2.2.4. Mitochondria and ROS in PD: the chicken or the egg?  
The mitochondria-associated deficiencies discussed above all result in the increased 
production of ROS. However, they can also arise as a result of ROS activity. 
Therefore, it is difficult to conclusively determine which factor, whether 
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mitochondrial dysfunction or a highly-oxidative environment, initiates this vicious 
cycle. However, as discussed in the following section, dopaminergic neurons 
possess a distinct intracellular environment that may hold the clues to what is 
occurring during the early stages of PD development.  
 
1.2.3. The susceptibility of dopaminergic neurons to damage 
Dopaminergic neurons in the brain are not created equal. In particular, there are 2 
features that set SNpc dopaminergic neurons apart from the dopaminergic neurons 
of the nearby ventral tegmental area (VTA).  
The first of these is the fact that SNpc neurons have a uniquely large axonal arbor 






Figure 1.7. A computer-reconstructed axonal arbor of a single dopaminergic 
neuron from the SNpc of a rat brain. Red and blue lines represent axon fibres 
projecting to different sub-compartments of the striatum. The arrow indicates the 




Calculations by Bolam and Pissadaki (2012) have estimated that dopaminergic 
neurons of the rat SNpc use their uncharacteristically large axons to innervate 
between 102,000 and 245,000 synapses per neuron. These figures are similar to the 
one proposed in another study (Andén et al. 1966). In contrast, Bolam and Pissadaki 
estimate that VTA neurons in the rat brain only contain up to 30,000 synapses per 
neuron. The relative bioenergetic cost of maintaining this huge number of synapses 
and an axon up to 78 cm long (Matsuda et al. 2009) will be substantial. ATP will be 
required to provide the energy for a large number of cellular factors including 
additional protein synthesis, organelle maintenance and intracellular signalling. 
More significantly, maintaining the membrane potential and axonal transport (all 
dependent upon ATP) across such a huge axon will lead to an extremely large 
energy demand. This, when scaled up to human SNpc axons, which are estimated to 
be in the region of 4.5 m long and innervate 10 times the number of synapses 
compared to rats (Bolam & Pissadaki 2012), is expected to result in a substantial 
energy burden that is unique to SNpc neurons. Furthermore, the dopaminergic 
neurons of the SNpc are non-myelinated (Pissadaki & Bolam 2013), further adding 
to additional ATP cost during action potential propagation (Attwell & Laughlin 
2001).  
Taken together, the morphological features of SNpc neurons create a phenomenal 
demand for ATP in order to maintain the successful innervation of their huge 
number of synapses. This large and sustained energy burden is likely to render SNpc 
dopaminergic neurons acutely susceptible to any form of insult or dysfunction that 
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reduces ATP production. Thus, it is possible that the unique morphological structure 
of these neurons contributes to their vulnerability towards degeneration in PD.  
The second distinguishing feature of the dopaminergic neurons of the SNpc is 
related to their unique Ca2+-conducting environment. Nigral dopaminergic neurons, 
unlike the dopaminergic neurons in the VTA, express a large amount of Cav1.3 L-
type calcium channels, a relatively rare form of Ca2+-channel found only in 10% of 
neurons in the brain (Surmeier et al. 2011). It appears that they use these channels 
to stimulate pacemaking Ca2+ oscillations in the absence of direct synaptic input. 
The pacemaking of the Cav1.3 L-type channels ensures that a slow but constant 
release of dopamine into the striatum occurs (Guzman et al. 2009). Another use for 
the Ca2+ oscillations could be the enhancement of dopamine synthesis which is 
thought to be linked to increased Ca2+ conductance (Mosharov et al. 2009). 
However, the physiological role of Cav1.3 in relation to the synthesis of dopamine is 
not thought to be that significant (Surmeier et al. 2011).  
The increased Ca2+ conductance that is required to maintain neuronal pacemaking 
further enhances the already existent ATP-dependent burden on the neuron, as 
Ca2+ needs to be tightly regulated in order to prevent unwanted cell death 
(Orrenius, Zhivotovsky & Nicotera 2003). This requires the use of ATP-dependent 
active transport to move Ca2+ against its electrochemical gradient from the cytosol 
either out of the cell or into intracellular Ca2+ stores in the endoplasmic reticulum 
(Surmeier et al. 2011).  
The increased ATP demand arising from the maintenance of cytosolic Ca2+ 
concentration will synergistically add to the ATP burden presented by Bolam and 
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Pissadaki (2012), as this will all take place across uncharacteristically large axons, 
further supporting the notion of dopaminergic neurons in the SNpc operating very 
close to the limit of their energy budget. In addition, the increased oxidative 
phosphorylation and mitochondrial shuttling of electrons required by these 
neurons to stay energetically viable will contribute to enhanced ROS production 
(Surmeier et al. 2012). Furthermore, increased Ca2+ conductance through Cav1.3 L-
type channels has also been directly linked to ROS production (Guzman et al. 2010).  
In addition to the points discussed above, the metabolism and oxidation of 
dopamine itself is thought to be toxic and, thus, contribute to the burden placed on 
SNpc neurons (Chen et al. 2008). Principally, dopamine-derived toxicity is mediated 
by its metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) which is produced 
following the deamination of dopamine by monoamine oxidases A and B (Goldstein 
et al. 2013). DOPAL exerts toxicity in multiple ways including via its oxidation to a 
semiquinone radical (Anderson et al. 2011), DOPAL-mediated generation of highly 
reactive hydroxyl radicals (Li et al. 2001) and protein modification via the formation 
of adducts at lysine (DOPAL) and cysteine (DOPAL-quinone) residues (Rees et al. 
2009).  
DOPAL appears to be produced more readily in PD brains compared with non-PD 
controls. This is appears occur via 2 mechanisms. Firstly, vesicular uptake of 
dopamine in PD is estimated to be reduced by 89% at the putamen, the principal 
site of dopamine’s action on the direct movement pathway (figure 1.2) (Goldstein 
et al. 2013). This will lead to less dopamine being packaged into synaptic vesicles 
and consequently less dopamine leaving the neurons via vesicle-mediated 
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exocytosis. The additional dopamine that remains in the cell is consequently 
metabolised to DOPAL. Secondly, activity of aldehyde dehydrogenase, the principal 
detoxifying enzyme of DOPAL, was estimated to be decreased by 70% in the PD 
putamen (Goldstein et al. 2013). This would prevent the removal of DOPAL from 
the cytosol, further prolonging and exacerbating DOPAL-mediated toxicity. 
From the evidence discussed above, it appears that the increased energy demand, 
oxidative environment and toxic metabolite of dopamine inherently put SNpc 
neurons under a large degree of stress. Through time and in the presence of any 
additional stress factors, it appears that the SNpc cells are more likely than others 
to exceed their cytotoxic threshold. This could explain why SNpc neurons appear to 
show the most prominent toxicity in PD even when the mutations in PD-associated 
genes occur across the whole body. Accordingly, given the hypersusceptibility of 
these neurons, research into determining what is causing idiopathic PD should 
focus on identifying mechanisms that could contribute towards pushing SNpc 
neurons past their cytotoxic threshold. As discussed below, there are likely 
multiple, sometimes minor, overlapping factors that contribute to this as opposed 
to 1 underlying cause. Accordingly, this multiple-hit hypothesis could explain why 
defining a cause of PD has historically been difficult, as the diverse nature of these 
insults suggest that PD may in fact be an amalgamation of defects that only through 




1.3. The cause(s) of PD 
1.3.1. Aging 
The largest known risk factor for developing PD is age (Dexter & Jenner 2013). 
However, whether the aging process is itself causative of PD or whether PD-specific 
factors unrelated to general aging simply accumulate as people get older has been 
debated for some time. Some studies posit that aging and PD development occur 
via separate and distinct mechanisms, citing differences in the regional loss of 
dopamine within the striatum between PD and normal aging (Hornykiewicz 1989, 
Kish et al. 1992). However, Collier, Kanaan & Kordower (2011) argue that the use of 
more modern immunohistochemical techniques has enabled more accurate 
identification and quantification of dopaminergic neuron subpopulations (for 
example, SNpc versus VTA neurons), allowing the relationship between aging and 
PD to be revisited.  
In a series of studies involving non-human primates, Collier and colleagues tested 
whether certain processes that occurred during normal aging overlapped with the 
development of PD (Collier, Kanaan & Kordower 2011). They discovered that the 
intensity of α-synuclein staining in SNpc tissue showed a significant positive 
correlation with age in normally aging primates. Furthermore, the distribution of α-
synuclein staining amongst all dopaminergic neurons of the midbrain matched the 
distribution of immunoreactivity in PD, with the highest intensity being seen in 
SNpc neurons and negligible staining in the neurons of the VTA (Chu & Kordower 
2007). Positive staining for α-synuclien was also associated with a loss of the 
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dopaminergic phenotype in those cells but, unlike in PD, was not found to correlate 
with dopaminergic neuron cell death (Chu & Kordower 2007). 
Markers for oxidative stress were also found to increase with age and were highest 
in SNpc neurons of naturally aging primates compared with neurons of the VTA 
(Kanaan, Kordower & Collier 2008). These findings support the evidence presented 
in section 1.2.3 for an innate SNpc-specific vulnerability to oxidative stress. Based 
on these and additional data showing SNpc-specific increases in lysosomal 
dysfunction, inflammation and accumulation of misfolded proteins, Collier, Kanaan 
& Kordower (2011) hypothesised that the aging process lays the foundation for the 
development of PD, with the addition of multiple causative factors accelerating 
what is essentially a natural progression towards the disease.  
This seems plausible, considering the overlapping mechanisms in both aging and 
PD. The histological differences between aging and PD SNpc neurons could 
therefore be made up by additional contributing factors to the aging process. 
However, the process of aging does not begin before the innately high energy 
demands in the SNpc neurons are established (see section 1.2.3). Thus, a more 
accurate hypothesis may be that the combination of innate SNpc neuronal 
susceptibility and the natural aging process combine to lay the foundation for PD 




1.3.2. Environmental factors in PD development 
The first discovery, in the 1980s, that PD-like symptoms and SNpc degeneration can 
be caused by compounds originating outside of the body triggered a substantial 
paradigm shift, as scientists became aware of the fact that PD development can be 
influenced by environmental factors. 1-methyl-4-phenyl-tetrahydropyridine (MPTP) 
was discovered after illicit drug users injected themselves with a 1-methyl-4-
propionoxypyridine solution that had become contaminated with MPTP during 
synthesis (Langston et al. 1983). The drug users rapidly developed parkinsonian 
symptoms which were later attributed to MPTP’s active metabolite MPP+ (Langston 
et al. 1984). 
Since then, pesticides in particular have been investigated as potentially causative 
agents in PD (Wirdefeldt et al. 2011). While it has been difficult to fully determine 
which pesticides are involved in PD or indeed the disease-specific role of pesticides 
in general, they are generally considered to contribute to PD development 
(Wirdefeldt et al. 2011, Kamel 2013). A recent meta-analysis concluded that 
exposure to pesticides was, indeed, a risk factor for PD but that a dearth of high-
quality studies prevented a cause-and-effect relationship from being confirmed 
(Pezzoli & Cereda 2013). Furthermore, future studies should focus on specific 
pesticides, rather than pesticide use in general, to elucidate which individual 
compounds are involved. The meta-analysis specifically implicated paraquat and 
maneb as pesticides directly associated with PD. In addition to paraquat and 
maneb, rotenone, a pesticide often used experimentally in both in vitro and in vivo 
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models of PD, has recently been associated with PD in a study of agricultural 
workers (Tanner et al. 2011). 
While all have been implicated in PD, the 3 pesticides mentioned above have 
different mechanisms of action. Rotenone, like MPP+, is an inhibitor of 
mitochondrial CxI and causes a reduction in ATP and also increases the production 
of ROS (Tanner et al. 2011). When used experimentally rotenone has been shown 
to cause PD-like symptoms in vivo (Martins et al. 2013). Paraquat, which also causes 
PD-like toxicity in vivo (Martins et al. 2013) is another mediator of ROS production 
but exerts its toxicity by facilitating the movement of electrons towards molecular 
oxygen, producing O2•- (Bus & Gibson 1984). The precise mechanism of maneb 
toxicity is unclear although it appears to disrupt the activity of proteins containing 
thiol groups (Roede & Jones 2014) and was found to inhibit aldehyde 
dehydrogenase (Fitzmaurice et al. 2014) suggesting that it may increase the 
presence of DOPAL in dopaminergic neurons. It too has been found to induce PD-
like pathology in vivo, particularly in combination with paraquat (Thiruchelvam et 
al. 2000). 
In addition to epidemiological evidence for the role of pesticides in PD, some 
studies have discovered potential associations between traumatic head injuries 
(Dick et al. 2007), organic solvents (Seidler et al. 1996), metals (Seidler et al. 1996) 
and magnetic fields (Noonan et al. 2002) and PD. However, the evidence in favour 
of these associations is currently thought to be inadequate (Wirdefeldt et al. 2011). 
Overall, more research is required with potentially larger, better-quality studies to 
fully establish any association with PD. However, based on the evidence in favour of 
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pesticides, it is likely that exposure to certain chemicals could play a role as part of 
the multiple-hit hypothesis in PD. 
 
1.3.3. The genetics of an un-genetic disease 
Despite initially appearing to show almost no involvement, genetics in PD are 
becoming an increasingly attributable causative factor. As discussed in section 
1.2.1, in a small number of cases, PD is identifiable by a specific genetic mutation 
that, in combination with the enhanced susceptibility of SNpc neurons (section 
1.2.3), is capable of mediating dopaminergic neuron cell death. In spite of this, the 
majority of people develop PD pathology without a clearly definable genetic cause. 
This had led PD being considered a predominantly un-genetic disease (Lesage & 
Brice 2009). However, recent advances in the ability to screen large numbers of 
patients and identify common genetic traits have indicated that genetics in PD may 
play a greater role than previously assumed.  
 
1.3.3.1. Monogenic causes of sporadic PD  
Traditionally, monogenic PD has been identified via an association of the disease 
within a particular family. However, an increased frequency of studies involving the 
genetic screening of non-familial PD patients has led to a number of people with 
sporadic PD being found to possess PD-causing mutations (table 1.1) (Gilks et al. 
2005, Klein et al. 2007, Lesage & Brice 2009, Lesage et al. 2011, Nalls et al. 2011, 




Table 1.1. Known PD-causing genes that occur in sporadic PD. Adapted from 
Lesage and Brice 2012. 
Gene Inheritance Type of PD 
SNCA Autosomal dominant Early onset PD 
parkin Autosomal recessive Early onset PD 
LRRK2  Autosomal dominant Late onset PD 
VPS35 (Vacuolar protein 
sorting 35) 
Autosomal dominant Late onset PD 
 
 
There are a number of explanations for this phenomenon. Firstly, de novo 
mutations, particularly in the autosomal-dominant LRRK2 and SNCA genes, could 
account for the seemingly spontaneous occurrence of PD (Gilks et al. 2005, 
Puschmann 2013). Secondly, cases in which PD appears to have occurred 
sporadically may yet be due to the inheritance of PD-causing genes. This could arise 
due to the late onset of some PD mutation phenotypes such as the G2019S 
mutation of LRRK2 (Lesage & Brice 2012). Accordingly, family members with this 
LRRK2 mutation may die before the diagnosis of PD and/or identification of the 
mutation via genetic testing. In addition, penetrance of LRRK2 mutations has been 
reported to be both incomplete and age-dependent, with penetrance even at 79 
years of age not exceeding 75% (Healy et al. 2008). Both of the above-mentioned 
factors could lead to a misrepresentation of familial PD as sporadic, as a lack of 
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penetrance or death prior to PD development could lead to LRRK2-mediated PD 
appearing to skip generations despite its autosomal dominant nature.  
Finally, a similar situation could arise with the autosomal-recessive forms of PD. 
While mutations in parkin, when inherited as homozygotes or compound 
heterozygotes (two different mutations of the same gene), show complete 
penetrance, the fact that they are only inherited 25% of the time from unaffected 
parents (due to the requirement for both recessive copies to be present) could lead 
to further cases of familial PD skipping multiple generations. This is particularly 
likely in smaller families where any Mendelian inheritance of PD-causing genes may 
be less obvious (Lesage & Brice 2012).  
Interestingly, transgenic mouse models of these mutations often do not result in 
neuronal cell death (Blandini & Armentero 2012). Consequently, while these 
mutations are considered causative for PD in humans, they may do so by vastly 
increasing the susceptibility of SNpc neurons to additional stress as part of the 
multiple-hit hypothesis rather than by directly causing the toxicity themselves. 
 
1.3.3.2. Genetic risk-factors for the development of sporadic PD  
In addition to the identification of monogenic causes of PD, the use of genome-
wide association studies (GWAS) has identified a number of genetic polymorphisms 
which have been found to enhance the probability of developing PD. GWAS allow 
associations to be made between specific genetic variants and PD, as they provide 
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the necessary, large sample size to find correlations between relatively infrequent 
mutations and disease prevalence.  
Some of the genes considered risk factors for sporadic PD are the same genes 
responsible for the development of monogenic PD. For example, mutations in the 
SNCA promoter have been shown to increase the risk of developing PD but are not 
directly causative (Pals et al. 2004, Maraganore et al. 2006). Furthermore, a single 
nucleotide polymorphism (SNP) of the SNCA gene has also been linked to increased 
PD susceptibility (Goris et al. 2007). This SNP, called rs356219, has also been found 
to synergise with particular haplotype of mictrotubule-associated protein tau 
(MAPT), a gene normally associated with Alzheimer’s disease (Myers et al. 2005). 
When these 2 polymorphisms are found together, Goris et al. (2007) determined 
that they approximately doubled the chance of developing PD. 
LRRK2 has also been implicated as a susceptibility factor in idiopathic PD via SNPs 
known as rs1491942 and rs11564273 (Nalls et al. 2011). In addition, 2 other risk-
enhancing polymorphisms (G2385R and R1628P), which are particularly prevalent 
in Asian populations, appear to confer up to 3-fold increased susceptibility to PD 
(Lesage & Brice 2009).  
Despite the association of various established PD-genes with an increased 
susceptibility to the disease, mutations in the glucocerebrosidase (GBA) gene are 
thought to be the most common risk factors for the development of PD (Lesage et 
al. 2011). Homozygous mutations of GBA are responsible for the development of 
the autosomal-recessive Gaucher’s disease (GD), a disorder characterised by 
abnormal storage and accumulation of glycolipids within lysosomes that most 
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commonly occurs outside of the CNS (Zimran 2011). Some homozygous GD patients 
have been shown to go on to develop early-onset PD (Tayebi et al. 2003). 
Interestingly, heterozygotes for GBA mutations don’t develop GD but have, 
nevertheless, been found to have approximately a 5-fold greater chance of 
developing PD compared with people with wild type GBA (Sidransky et al. 2009), 
strongly suggesting that the GBA enzyme could be involved in the pathogenesis of 
the disease. This is thought to be manifest via some form of synergy with α-
synuclein and its aggregation into Lewy bodies, but the precise mechanism is 
unclear (Sidransky & Lopez 2012). 
The discovery of multiple genetic risk factors with overlapping physiological 
pathways in addition to the already established causative mutations suggests that 
genetics in PD could play a much larger role in PD than previously assumed. The 
role of genetics in PD is likely to grow in the near future as more powerful GWAS 
and meta-analyses are performed and more and more novel genes, some of which 
have not yet been characterised, are identified as potential mediators of PD 
susceptibility (Nalls et al. 2011). Together with additional, non-genetic, factors a 
picture is emerging of a disease that, in the majority of cases, has not one but 
multiple underlying causes. 
 
1.3.4. Nicotinamide N-methyltransferase is upregulated in PD 
Another factor found at significantly higher levels in PD patients is nicotinamide N-
methyltransferase (NNMT). NNMT protein is expressed at higher levels in PD brains 
compared with controls (Parsons et al. 2002, Parsons et al. 2003) and in PD-
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patients’ cerebrospinal fluid (CSF) compared with controls (Aoyama et al. 2001). 
This increased expression occurs concomitantly with a shift towards higher NNMT 
activity in PD patients (Parsons et al. 2002), something which appears to be solely 
related to levels of mRNA as opposed to the presence of any gain-of-function 
mutations (Smith et al. 1998).  
NNMT is an S-adenosylmethionine (SAM) dependent enzyme with a molecular 
weight of 29 kDa. It belongs to a family of 3 closely-related N-methyltransferases 
(Thompson & Weinshilboum 1998) and is most highly expressed in the cytosol of 
hepatocytes (Parsons et al. 2002). Its principal role in the body is the conversion of 
nicotinamide to 1-methylnicotinamide (MeN, Parsons et al. 2011, figure 1.8). 
 
 
Figure 1.8. NNMT catalyses the N-methylation of nicotinamide to MeN. SAH = S-
adenosylhomocysteine  
 
The role of NNMT, which is also expressed in the dopaminergic neurons of the SNpc 
(Parsons et al. 2002), in PD is not yet fully established. However, it has been studied 
in diseases such as cirrhosis (Cuomo et al. 1994), hepatitis (Sternak et al. 2010), 
chronic obstructive pulmonary disease (Kim et al. 2010) and atherosclerosis 






inflammation, oxidative damage and cell death. NNMT is also upregulated in 
cancer, where it promotes cell survival (Zhang et al. 2014) and tumourigenesis 
(Tang et al. 2011). The cytoprotection and cell survival effects seen in these 
diseases may occur as a result of NNMT-mediated activation of Akt signalling 
(Thomas et al. 2013). Akt signalling is anti-apoptotic and has been reported to be 
neuroprotective against experimental PD-causing toxins in vivo (Burke 2007). 
Furthermore, NNMT expression has been reported to protect mitochondria from 
toxic insult by MPP+ and rotenone amongst others (Parsons et al. 2011, Milani, 
Ramsden & Parsons 2013). Consequently, NNMT in PD could be upregulated as a 
protective response to the underlying pathophysiology. However, this has not yet 
been verified and there are a number of hypotheses that suggest that NNMT may, 
in fact, play the opposite role in PD. 
Firstly, an enhanced NNMT activity would be expected to increase the production 
of MeN and, thus, reduce the concentration of nicotinamide in the cytosol. 
Consequently, this would reduce the amount of nicotinamide that can be 
incorporated into NADH (Parsons et al. 2002, Parsons et al. 2003). A reduction in 
NADH availability would conceivably reduce the supply of electrons to the electron 
transport chain and, therefore, lower the eventual production of ATP. This could be 
particularly toxic to SNpc neurons due to their increased energy requirements 
described above.  
Secondly, some studies suggest that MeN may, in fact, be toxic to cells. Fukushima 
et al. (1995) reported that MeN exposed to isolated mitochondrial CxI from bovine 
brains was toxic to the NDUFS3 subunit. It was speculated that MeN accepts 
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electrons from NADH and, thus, become a highly reactive free radical at the site of 
CxI. In support of this, the same group found that MeN injected stereotaxically into 
rat SN tissue significantly reduced striatal dopamine content compared with sham 
controls (Fukushima et al. 2002) and that MeN was significantly toxic to cultured 
mouse striatal neurons (Mori et al. 2012). However, it is important to note that the 
concentrations used in the Fukushima group’s studies were extremely high, with 
toxic effects only reported at concentrations in excess of 10 mM, far higher than 
the tens of µM physiological range that was reported in rat brains (Erb et al. 1999). 
Another study using a high concentration (25 mM) of MeN did not report any 
toxicity towards rat cerebellar granule cells; in fact, the study reported that 
administration of 25 mM MeN was able to protect the cells against glutamate-
induced excitotoxicity (Slomka et al. 2008). Moreover, MeN has been shown to be 
protective towards SH-SY5Y neuroblastoma cells at a concentration of 1 mM 
(Parsons et al. 2011), and concentrations below 1 mM were protective against liver 
damage (Sternak et al. 2010) and reduced inflammation in vivo (Chlopicki et al. 
2007). Accordingly, conclusions regarding the toxicity of MeN should be viewed 
with reference to the experimental concentrations used.  
Finally, and perhaps most intriguingly with regard to PD, NNMT has been found to 
have a wide substrate profile, being capable of catalysing the N-methylation of a 
number of compounds with pyridine moieties (Alston & Abeles 1988). This is of 
particular interest given that, as discussed in the following section, N-methylation 




1.3.5. The activation of endogenous neurotoxins 
1.3.5.1. The biosynthesis and environmental acquisition of βCs  
A remarkable structural similarity exists between norharman (NH), the prototypical 
molecule of a group of compounds called β-carbolines (βC), and the neurotoxin 




Figure 1.9. The structural similarity between NH and MPP+ following NH’s N-
methylation at the 2N position 
 
βCs are found endogenously in the human brain (Matsubara et al. 1993) where they 
are derived from the Pictet-Spengler condensation of tryptamine with acetaldehyde 
or pyruvic acid (Susilo et al. 1987, Susilo & Rommelspacher 1987, Stöckigt et al. 
2011). They are also found in well-cooked food and drink such as meat, fish and 
roasted coffee, and also in tobacco smoke as high temperatures permit the 
pyrolysis of tryptophan and its condensation with aldehydes (Herraiz 2004). βCs 
acquired from environmental sources are able to cross the blood brain barrier 
(Fekkes & Bode 1993) a fact attributed to their hydrophobic structure (Matsubara 
et al. 1995). Due to their structural similarity to MPP+, they are considered to be 
possible mediators of SNpc degeneration (Neafsey et al. 1989, Collins et al. 1992, 
Norharman 2-methylnorharman 1-methyl-4-phenylpyridine 
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Bonnet et al. 2004, Hamann et al. 2006, Pavlovic et al. 2006, Wernicke et al. 2007) 
and have been shown to be elevated in the CSF of patients with PD compared to 
controls (Kuhn et al. 1996).  
 
1.3.5.2. βCs are potential pro-toxins in PD 
In order for NH to more accurately resemble MPP+ it must be 2N-methylated and, 
thus, ionised, a process which has been shown to occur in the human brain 
(Matsubara, Collins & Neafsey 1992, Matsubara, Neafsey & Collins 1992, Gearhart 
et al. 2000). The conversion of NH to 2-methylNH (2-MeNH) facilitates entry into 
the cell via the dopamine transporter (DAT), the MPP+ ion’s primary point of entry 
into dopaminergic neurons (Wernicke et al. 2007). In contrast, NH is thought to 
enter the cell via passive diffusion. 2N-methylated βCs have been found at higher 
concentrations in PD CSF compared to healthy controls (Matsubara et al. 1995). As 
well as a 2N-methylation of βCs, a further 9N-methylation exclusive to 2-MeNH has 
been observed in the brain (Matsubara, Neafsey & Collins 1992, Matsubara et al. 









Figure 1.10 The methylation pathway of NH and 1,2,3,4-tetrahydroNH in the human 
brain. Image adapted from Matsubara, Collins & Neafsey 1992 
 
 
In addition to NH, tetrahydroNH (THNH) is also of interest in PD. THNH is produced 
via the removal of a methyl group from 1-methylTHNH, which is the direct product 
of the Pictet-Spengler reaction of tryptamine in the brain (Susilo et al. 1987, Susilo 
& Rommelspacher 1987, Stöckigt et al. 2011). It is principally of interest in PD due 
to its status as a precursor for the biosynthesis of NH (Susilo et al. 1987) and also 2-
MeNH via its own N-methylated intermediate (Matsubara, Collins & Neafsey 1992, 
Herraiz, Guillén & Galisteo 2007). 
While the 2N-methylated form of NH and the di-methylated 2,9-dimethyl-NH (2,9-
diMeNH) have been discovered in vivo, no evidence exists to support the existence 
of a 9N-monomethylated βC under physiological conditions (Matsubara, Collins & 
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Neafsey 1992, Gearhart et al. 2000). Instead, 9N-methylation has been found to 
occur only after 2N-methylation has taken place. It has been suggested that N-
methylation at the 2N position confers sufficient nucleophilicity for further N-
methylation at the 9N position to occur (Collins et al. 1992, Matsubara, Neafsey & 
Collins 1992). 
 
1.3.5.3. The toxicity of N-methylated βCs  
The toxicity of the N-methylated βCs has been studied extensively (Neafsey et al. 
1989, Matsubara et al. 1998, Bonnet et al. 2004, Hamann et al. 2006, Pavlovic et al. 
2006, Wernicke et al. 2007). While 2N-methylation has been shown to confer toxic 
properties and dopaminergic neuron specificity to most βCs, 9N-methylation of 2-
MeNH appears to be a crucial step in toxicity potentiation as 2,9-diMeNH has been 
shown to be markedly more toxic than 2-MeNH in Neuro 2A cells (Bonnet et al. 
2004), DAT-transfected and wild type human embryonic kidney (HEK) cells 
(Wernicke et al. 2007) and primary dopaminergic neurons (Hamann et al. 2006). In 
fact, 2,9-diMeNH has shown comparable toxicity to MPP+ with a reduced reliance 
on DAT (Bonnet et al. 2004, Hamann et al. 2006, Wernicke et al. 2007). Despite a 
lowered DAT dependency relative to MPP+, 2,9-diMeNH has been shown to be 
selective for dopaminergic neurons compared with other neurons and non-
neuronal cells (Pavlovic et al. 2006).  
N-methylated βCs, like MPP+, are principally thought to act via inhibition of CxI of 
the mitochondrial respiratory chain, although weaker inhibition at complexes II and 
III have also been reported (Albores et al. 1990, Collins et al. 1992, Fields et al. 
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1992). The most recent support for this comes from Hamann et al. (2006) who 
exposed isolated mouse mesencephalic dopaminergic neurons to 2,9-diMeNH. 
Within 24 hours, a significant (30%) reduction in ATP was recorded alongside a 
significant rise in ROS to 250% of control. This occurred concomitantly with an 
increased production of lactate, suggesting that compensatory glycolysis had been 
initiated to account for the reduced aerobic ATP yield. Following these initial 
events, markers of both apoptotic (coordinated and mostly ATP-dependent) cell 
death and, later, necrotic (largely uncontrolled, often mediated by ATP depletion) 
cell death were present (Hamann et al. 2006). In addition to these in vitro findings, 
2-MeNH and 2,9-diMeNH been shown to have in vivo toxicity to SNpc neurons 
(Neafsey et al. 1989, Neafsey et al. 1995, Pavlovic et al. 2006). Thus, N-methylated 
βCs are a PD-relevant neurotoxin that is produced in the brain from endogenously-
occurring precursors. 
 
1.3.5.4. The identity of enzyme responsible for NH’s N-
methylations  
While many elements of 2,9-diMeNH’s toxicity and biosynthesis have been 
confirmed, it is not fully established which enzyme or group of enzymes are capable 
of catalysing either of the N-methylations required for its production.  
While studies investigating 9N-methyltransferase activity towards 2-MeNH have 
been performed (Gearhart et al. 2000), the enzyme responsible for producing 2,9-
diMeNH has not been characterised and there are currently no suggested 
candidates for this reaction amongst known enzymes. It is also unclear whether one 
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or multiple enzymes are required for the initial 2N-methylation of NH followed by 
the 9N-methylation of 2-MeNH.  
Gearhart, Neafsey & Collins (2002) discovered that purified phenylethanolamine N-
methyltransferase (PNMT), an enzyme normally associated with adrenaline 
synthesis (Ziegler et al. 2002), has βC 2N-methyltransferase activity via its 
conversion of synthetic 9-methylNH (9-MeNH) to 2,9-diMeNH. However, the 
physiological relevance of this finding is unclear as 9-MeNH may not occur naturally 
in the brain (Matsubara, Neafsey & Collins 1992). While this finding suggests that 
PNMT may also convert NH to 2-MeNH, there was no evidence provided to support 
this. PNMT, which is found at its highest levels in the adrenal glands, has been 
detected in various parts of the brain including the SN (Kopp et al. 1979). In 
addition, it has been reported that PNMT-positive neurons in the brain are also lost 
during PD (Gai et al. 1993, Nagatsu & Sawada 2007). Taken together, these reports 
suggest that PNMT, in theory, could play role in PD progression by catalysing the 
primary step in the activation of NH toxicity. 
In addition to PNMT, it has been speculated that NNMT may possess βC 2N-
metyhyltransferase activity (Matsubara et al. 2002, Parsons et al. 2002, Parsons et 
al. 2003). As mentioned above, NNMT has been found to be upregulated in PD 
(Aoyama et al. 2001, Parsons et al. 2002, Parsons et al. 2003) and has been found to 
be capable of catalysing the N-methylation of numerous pyridine moieties in 
addition to nicotinamide (Alston & Abeles 1988). Furthermore, the expression of 
NNMT has been shown to be inversely proportional to disease duration (Parsons et 
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al. 2002). As such it is hypothesised that higher NNMT activity may result in the 
greater production of N-methylated βCs, particularly NH.  
 
1.4. The aims of the project 
The principal aim of the project was to determine the role of NNMT in PD. This was 
done in 3 primary studies. Firstly, the effects of NNMT expression on SH-SY5Y cells, 
a neuroblastoma cell line frequently used in in vitro PD studies (Xie, Hu & Li 2010), 
were determined in order to assess any inherent toxicity mediated by NNMT. 
Secondly, the susceptibility of NNMT-V5-expressing S.NNMT.LP cells versus non-
expressing cells to NH, THNH and 2-MeNH toxicity was investigated. Finally, the 
ability of NNMT to catalyse NH 2N-methylation was investigated.
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The most commonly used methods and techniques are described in this chapter. 
Methods that were used less frequently will be described in detail in their relevant 
chapters. 
2.1. Cell Culture 
Unless otherwise stated, solutions referred to in the text were made according to 





Table 2.1. Commonly used solutions during cell culture. 




PBS 1 Tablet (Invitrogen, Paisley, UK) in 500 mL of 
deionised H2O and then autoclaved 
Media for SH-
SY5Y cells 
SH media 90 mL of solution was removed from a 500 
mL bottle containing a premixed formula of 
1:1 Dulbecco’s Modified Eagle Medium:F12 
with phenol red (Sigma-Aldrich, Dorset, UK). 
Seventy five mL of fetal bovine serum (FBS, 
15%, Sigma-Aldrich, Dorset, UK), 5 mL non-
essential amino acids (1X), 5 mL L-glutamine 
(2mM), 5 mL of Penicillin/Streptomycin 
solution (100 Units/mL Penicillin, 100 µg/mL 
streptomycin, all Invitrogen, Paisley, UK) 
were added to the bottle and mixed. 
Media for 
S.NNMT.LP cells 
LP media 92.5 mL of liquid was removed from a 500 mL 
bottle containing a premixed formula of 1:1 
Dulbecco’s Modified Eagle Medium:F12 with 
phenol red (Sigma-Aldrich, Dorset, UK). 
Seventy five mL of fetal bovine serum (FBS, 
15%, Sigma-Aldrich, Dorset, UK), 5 mL non-
essential amino acids (1X), 5 mL L-glutamine 
(2mM) and 5 mL of Penicillin/Streptomycin 
solution (100 Units/mL Penicillin, 100 µg/mL 
streptomycin) and 2.5 mL of geneticin 
selection antibiotic (0.25 mg/mL, all 
Invitrogen, Paisley, UK) were added to the 
bottle and mixed. 
Serum-free SH 
media 
N/A 15 mL of liquid was removed from a 500 mL 
bottle containing a premixed formula of 1:1 
Dulbecco’s Modified Eagle Medium:F12 with 
phenol red (Sigma-Aldrich, Dorset, UK). Five 
mL non-essential amino acids (1X), 5 mL L-
glutamine (2 mM) and 5 mL of 
Penicillin/Streptomycin solution (100 
Units/mL Penicillin, 100 µg/mL streptomycin, 
all Invitrogen, Paisley, UK) were added to the 




2.1.1. Maintenance and culture of cell lines 
Unless otherwise stated, all cells were incubated with 10 mL of cell line-appropriate 
media in 75 cm2 flasks at 37°C and 5% CO2 in an incubator (Panasonic Biomedical, 
Loughborough, UK). All cell manipulations were undertaken within a Class II MSC 
and all solutions were pre-warmed to 37oC in a waterbath. Media was removed 
from the flasks every other day via aspiration, followed by the careful addition of 10 
mL fresh media using a serological pipette.  
 
2.1.2. Cell trypsinisation, centrifugation and counting 
In order to prepare cells for experimentation, the following method was used. Once 
cells had reached approximately 85% confluence, the media was aspirated and the 
cells were washed gently by adding 5 mL of PBS. The PBS was aspirated followed by 
the addition of 2 mL of 0.25% trypsin (Invitrogen, Paisley, UK) to each flask. After 
incubating at room temperature for approximately 2 minutes, flasks were struck 
with the palm of the hand repeatedly to dislodge the cells from the growing 
surface. Trypsin was neutralised by adding 8 mL of media to the flask and pipetting 
up and down over the growing surface multiple times. The entire volume of the 
flask was then added to a 25 mL centrifuge tube and centrifuged for 5 minutes at 
433 x g (Allegra X-22R centrifuge, Beckman Coulter, California, USA). The 
supernatant was aspirated and the pellet was resuspended by adding 10 mL of 
media directly onto the pellet and pipetting up and down repeatedly.   
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Viable cell number was determined via trypan blue exclusion. A 1:1 trypan blue 
(Sigma-Aldrich, Dorset, UK):cell suspension was made by adding 100 µL of the cell 
suspension to 100 µL trypan blue. The new suspension was mixed thoroughly 
before it was pipetted onto a haemocytometer. Under these conditions, viable cells 
are able to exocytose trypan blue and maintain a white appearance under a light 
microscope. This is not the case for dead or dying cells, which are unable to remove 
the dye and are, thus, stained blue. As a result, it was possible to identify and count 
only viable cells within 8 pre-determined grids of the haemocytometer under a 
microscope at 10x magnification. In order to remove bias, the same 8 grids were 
used each time and the initial grids were selected prior to viewing the slide under 
the microscope. The cell density (number of viable cells per mL) was then calculated 




 × 20,000  
The cell suspension was then diluted as necessary using media (desired cell 
densities are described in the individual assay descriptions) and added to the wells 
of the appropriate plate or flask for the assay using a repeat dispensing pipette. 
 
2.1.3. Preparation of cell pellets for snap freezing 
In order to prepare cells for RNA or protein extraction, cells were trypsinised and 
centrifuged as described above. After removal of the supernatant, pellets were 
resuspended in 10 mL of PBS before they were centrifuged again. This was done to 
ensure the removal of any excess protein or mRNA that may have been present in 
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any media residue. The supernatant was removed from the pellet and the cells 
were snap-frozen by immersion in liquid nitrogen. Frozen pellets were then 
transferred to a -80oC freezer and stored until required. 
 
2.2. Western Blotting 




Table 2.2. Components and abbreviations of the common reagents used during 
Western blotting. 
Name Abbreviation Contents 
Tris Buffered 
Saline 
TBS 6 g Trizma HCl (50 mM Tris, Sigma-Aldrich, 
Dorset, UK), 12 g Sodium Chloride (200 mM, 
Fisher Scientific, Loughborough, UK) dissolved 
in 500 mL, adjusted to pH 7.4. and made up to 




TBST 1 L of TBS with 500 µL (0.05%) Triton X-100 




MTBST 1 L of TBST with 50 g (5%) milk powder 
(Premier Foods, Hertforshire, UK) 
Anode Buffer 1 AB1 18.15 g Tris base (0.3 M), 50 mL methanol 
(10%, both Fisher Scientific, Loughborough, 
UK) in 400 mL using deionised H2O and 
adjusted to pH 10.4 and made up to 500 mL  
Anode Buffer 2 AB2 1.51 g Tris base (25 mM), 50 mL methanol 
(10%) in 400 mL using deionised H2O, adjusted 
to pH 10.4 and made up to 500 mL using 
deionised H2O 
Cathode Buffer CB 1.51g Tris base (25 mM), 50 mL methanol 
(10%), 1.5g glycine (40 mM, Fisher Scientific, 
Loughborough, UK) in 400 mL using deionised 





RIPA buffer 5 ml of 1 M (157.6 g/L in water) Trizma HCL (50 
mM, pH 7.4), 1 mL of 1% (v/v) Nonidet P40 
(0.1%), 0.5 g 0.5% sodium deoxycholate 
(0.0025%), 15 mL of 1 M (58.4 g/L in water) 
sodium chloride (150 mM), 0.15 g 
ethylenediamine-tetraacetic acid (EDTA, 5 
mM), 0.1 g 0.1% (w/v) Sodium 
dodecylsulphate (SDS, 0.0001%) made up to 
100 mL with deionised water. This was the 
separated into 7 mL aliquots before a single 
tablet each of cOmplete Protease Inhbitor 
Cocktail (Roche, Burgess Hill, UK) and 




2.2.1. Preparation of protein samples 
Snap-frozen cell pellets were lysed by resuspension in 100 µL of either 1% Triton X-
100 in PBS or RIPA buffer (Parsons et al. 2006, see table 2.2) as appropriate for the 
procedure. Samples were transferred into labelled 1.5 mL Eppendorf tubes and 
vortexed to further assist lysis. The samples were centrifuged at 16,160 x g for 10 
minutes using a microcentrifuge (1-14 Microfuge, Sigma Centrifuges, Wem, UK) 
before the supernatants were transferred to clean 1.5 mL Eppendorf tubes. Two 
dilutions of each sample (1:10 and 1:20) were prepared (20 µL of each), using 1% 
Triton X-100 in PBS or RIPA buffer, for protein analysis. The remaining samples were 
kept on ice until further processing as described in section 2.2.3. 
 
2.2.2. Protein assay using the Lowry method  
Protein standards of 0 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.6 mg/mL, 0.8 mg/mL, and 
1.0 mg/mL bovine serum albumin (BSA) in 1% triton-X in PBS or RIPA buffer were 
prepared from a 10 mg/mL stock of BSA prepared in appropriate lysis buffer (1% 
triton-X in PBS or RIPA buffer) as follows: 
 1.0 mg/mL (90 µL lysis buffer + 10 µL stock) 
 0.8 mg/mL (92 µL lysis buffer + 8 µL stock) 
 0.6 mg/mL (94 µL lysis buffer + 6 µL stock) 
 0.4 mg/mL (96 µL lysis buffer + 4 µL stock) 
 0.2 mg/mL (98 µL lysis buffer + 2 µL stock) 
 0 mg/mL (100 µL lysis buffer) 
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A protein assay (Bio–Rad, Hemel Hempstead, UK), based on the method of Lowry 
(Lowry et al. 1951), was performed as per manufacturer’s instructions. The assay 
measures a concentration-dependent colour change based upon the presence of a 
reduced Folin–Ciocalteu reagent which is produced following the copper-mediated 
oxidation of peptide bonds under alkaline conditions. 
Solution A’ was made by mixing 20 µL Solution S for every 1 mL of Solution A 
required. Five µL of each of the standard and diluted samples were transferred in 
triplicate to a 96-well plate (Thermo Scientific, Loughborough, UK). A typical 
example of the resulting plate layout is shown in figure 2.1. 
 
  
Figure 2.1. A typical plate layout used for protein assays. SH = SH-SY5Y, LP = 
S.NNMT.LP, 1:10 and 1:20 refer to the dilution factor of the samples in either 
RIPA buffer or 1% Triton X-100 in TBS. Numbers 0.0-1.0 are indicative of protein 
standard concentrations (in mg/mL) of BSA in RIPA buffer or 1% Triton X-100 in 
TBS. 
1 2 3 4 5 6 7 8 9 10 11 12
A SH 1:10 SH 1:10 SH 1:10 0.0 0.0 0.0
B SH 1:20 SH 1:20 SH 1:20 0.2 0.2 0.2
C LP 1:10 LP 1:10 LP 1:10 0.4 0.4 0.4
D LP 1:20 LP 1:20 LP 1:20 0.6 0.6 0.6
E 0.8 0.8 0.8





 Twenty five µL of solution A’ were added to both sample and standard-containing 
wells using a multichannel pipette. The wells were then mixed thoroughly by 
placing the plate onto a vortexer. Two hundred µL of Solution B were then added to 
the wells using a multichannel pipette followed by additional mixing. The assay was 
incubated for 15 minutes at room temperature before absorbance was measured at 
750 nm using a spectrophotometer (Perkin Elmer, Waltham, Massachusetts, USA). 
The absorbance values of the protein standards were then used to construct a 
calibration curve from which the protein content of the samples was calculated as 
µg/µL.  
 
2.2.3. Preparation of samples for Western blotting 
All samples were diluted to 3 µg of protein/µL using RIPA buffer before one volume 
of Laemmli sample buffer (Sigma-Aldrich, Missouri, USA) was added (final protein 
concentration 1.5 µg/µL), mixed and heated to 100oC for 5 minutes using an 
Eppendorf heater (Grant Instruments, Shepreth, UK). This process denatures 
proteins and dissociates quaternary subunits by disrupting disulphide bridges and 
intramolecular bonds such as electrostatic interactions. As a consequence, protein 
separation during electrophoresis occurs primarily as function of protein size and 




2.2.4. SDS – polyacrylamide gel electrophoresis (PAGE)  
A pre-cast 4-12% NuPage Bis-Tris SDS-PAGE gel was assembled and submerged in 1 
L of 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (both Invitrogen, Paisley, 
UK). Thirty µg of protein samples were loaded into the wells of the gel, along with 5 
µL of Strep-tagged Precision Plus Protein markers (Bio–Rad, Hemel Hempstead, UK) 
which were added to the furthest well on the left hand side of the gel. Proteins 
were electrophoresed at 200V for 50 minutes. 
 
 2.2.5. Semi-dry transfer of proteins to nitrocellulose 
membrane 
Samples were transferred onto a Hybond-ECL nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK) using a semi-dry transfer method (Thomas et al. 
2013) as described below.  
Cathode buffer, anode buffer 1 and anode buffer 2 were poured into separate 
incubation trays before the gel was removed from the assembly and the gel plate 
opened. All wells were removed and the top left corner of the gel was cut off to 
assist the determination of the gel’s orientation. The gel was carefully submerged 
into the cathode buffer and placed onto a rocking platform (Labnet International, 
New Jersey, USA) for at least 10 minutes to equilibrate the gel with the buffer. 
HybondECl nitrocellulose (GE Healthcare Life Sciences, Buckinghamshire, UK) was 
cut to the size of the filter paper, and was then rehydrated by submerging into 
deionised water for 2 minutes before being submerged in anode buffer 2 and 
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placed on a rocking platform for 5 minutes. A gel/membrane “sandwich” was then 
made on the anode of the transfer tank (Bio–Rad, Hemel Hempstead, UK) by 
submerging filter paper in buffers as detailed in figure 2.2. Once each piece filter 
paper had been placed, the sandwich was roller-pinned to remove air bubbles. The 
cathode plate was assembled, and proteins were transferred to the membrane at 





Figure 2.2 An illustration of the gel "sandwich" used during the semi-dry transfer 
of protein bands from a 4-12% NuPage Bis-Tris SDS-PAGE gel to a nitrocellulose 
membrane. The coloured layers represent Western blotting filter paper that had 
been submerged in appropriate buffer before being added onto the sandwich. 
From bottom to top: 2x anode buffer 1 (dark blue), 1x anode buffer 2 (light blue), 




The gel-membrane layer was removed and the nitrocellulose membrane was cut to 
the size of the gel. Immunoblotting was performed using electrochemiluminescence 
(ECL)-based detection, as follows. Nitrocellulose membranes were transferred into 
sealed containers and blocked in MTBST for 2 hours on a rocking platform. This 
process allows proteins from the milk to attach themselves to any free binding sites 
on the nitrocellulose membrane, thus preventing any antibodies from later 
attaching themselves to the membrane non-specifically and reducing background 
staining. Membranes were incubated with primary antibody (diluted in MTBST) 
overnight at 4°C in a sealed 50 mL tube under constant rocking and rotation using a 
tube roller (Spiramix, Thermo Scientific, Loughborough, UK). The specific primary 
and secondary antibodies used for each Western blot are described in the relevant 
experimental chapters. 
Following a 1 minute wash by submerging the blot in MTBST at room temperature 
under rocking conditions, the membranes were incubated for 2 hours in MTBST, 
while rocking at room temperature. This was followed by a co-incubation with a 
relevant secondary antibody-horseradish peroxidase (HRP) conjugate and a 
StrepTactin-HRP conjugate (1:4000, Bio–Rad, Hemel Hempstead, UK) in MTBST for 
1 hour under the same conditions. The StrepTactin-HRP conjugate was added to 
bind to - and later visualise - the Strep-tagged protein markers. The secondary 
antibody solution was removed and the blot was washed with MTBST for 5 minutes 
by rocking at room temperature before the solution was removed again and the 
blot was washed twice with TBST for 5 minutes under the same conditions. The blot 
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was submerged in TBS while the ECL Select solution (GE Healthcare Life Sciences, 
Buckinghamshire, UK) was prepared by mixing equal volumes of solutions A and B 
as per manufacturer’s instructions. The blot was removed from the TBS and any 
excess liquid was removed from the surface by applying the corner of the 
membrane to tissue paper. The membrane was covered with ECL solution and 
incubated at room temperature for 5 minutes, after which excess ECL reagent was 
removed as described above. Visualisation was performed using a ChemiDoc MP 
transilluminator (Bio–Rad, Hemel Hempstead, UK). In the event that membranes 
were to be re-used for reprobing with β-actin or β-tubulin loading control 
antibodies, stripping was performed by submerging membranes in Restore western 
blot stripping buffer (Thermo Scientific, Loughborough, UK) and rocking for 1 hour 
at 37oC before rinsing and re-blocking for another hour prior to repeating the 
immunoblotting process.  
Analysis of the blots was performed using ImageLab software (Bio–Rad, Hemel 
Hempstead, UK). Specifically, identification of band size was performed cross-
referencing imaged bands with those of known size in the molecular weight marker 
lane. Quantification of band intensity was performed by dividing the integrated 
peak area of the desired band by the integrated peak area of the housekeeping 





2.3.1. Isolation of cellular RNA 
Extraction of RNA from snap-frozen cell pellets was performed using the Isolate 
RNA Mini Kit (Bioline, London, UK) as per manufacturer’s instructions, with all steps 
undertaken within the confines of a PCR hood (SLEE, Mainz, Germany). Briefly, the 
pellet was resuspended via the addition of 400 µL Lysis Buffer R onto the pellet and 
pipetting up and down 10 times. The lysate was incubated at room temperature for 
3 minutes. Spin Column R1 was placed into a collection tube and the lysate was 
pipetted into it. The Spin Column was centrifuged for 2 minutes at 10,000 x g, after 
which 400 µL of 70% ethanol was added to the filtrate and thoroughly mixed by 
pipetting up and down 10 times. The entire volume was then transferred into Spin 
Column R2, placed inside a new collection tube, and centrifuged at 10,000 x g for 2 
minutes to bind RNA. Five hundred µL of Wash Buffer AR was added to the Spin 
Column which was then centrifuged at 10,000 x g for 1 minute. Seven hundred µL 
of Wash Buffer BR was added to the Spin Column which was again centrifuged at 
10,000 x g for 1 minute. Using a fresh collection tube, the Spin Column was spun at 
10,000 x g for 3 minutes to remove all traces of wash buffer. Finally, Spin Column 
R2 was placed in an Elution Tube, and 30 µL of RNase-free water was applied 
directly to the Spin Column membrane and incubated for 1 minute at room 




2.3.2. Reverse transcription of mRNA 
mRNA was reverse-transcribed into complimentary DNA (cDNA) using the High 
Capacity RNA-to-cDNA kit (Life Technologies, Paisley, UK) as per manufacturer’s 
instructions. Briefly, the extracted RNA (5 µL) was added to a mixture of nuclease-
free water (4 µL, Roche, Burgess Hill, UK), reverse transcriptase buffer containing 
poly-dT primers (10 µL) and reverse transcriptase (1 µL) in a 0.2 mL thin-walled, 
dome-capped polymerase chain reaction (PCR) tube (Alpha Laboratories, Eastleigh, 
UK). The inclusion of poly-dT primers, as opposed to random hexamers, in the 
reaction buffer ensured that only full length mRNA was converted to cDNA. The 
solution was vortexed and briefly centrifuged to collect all the liquid at the bottom, 
before it was transferred to a thermal cycler (PCR Sprint, Thermo Scientific, 
Loughborough, UK) and incubated at 37 °C for 1 hour, after which the reaction was 
terminated by incubation for 5 minutes at 94 °C.  
 
2.3.3. PCR amplification of target cDNA 
cDNA samples were amplified using primer pairs designed using the Roche on-line 
universal probe library qPCR design tool (http://www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.htmL). Details of the specific primers pairs used 
for each target gene are described in the relevant experimental chapter.  
PCR permits amplification of cDNA using DNA polymerase and primers for specific 
gene sequences to produce multiple copies of the desired gene. This is done in a 
temperature-controlled environment which permits melting of double stranded 
DNA, annealing of primers and DNA polymerase to the 2 single strands and 
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propagation of polymerase activity in both directions. The various temperature 
requirements for each stage are repeatedly cycled, allowing a large amount of 
specific cDNA replication from an initially small sample. 
Following reverse transcription, cDNA samples were diluted 10-fold prior to 
amplification of target cDNA using the PlatinumTaq PCR kit (Invitrogen, Paisley, UK). 
The PCR reaction mixture was made by adding, into a 0.2 mL thin-walled dome-
capped PCR tube: 2.5 µL of 10x reaction buffer, 0.5 µL of 10 mM 
deoxuribonucleotide triphosphate bases (0.2 mM final concentration), 0.75 µL of 50 
mM MgCl2 (1.5 mM final concentration), 0.625 µL of 10 µM forward primer (250 nM 
final concentration), 0.625 µL of 10 µM reverse primer (250 nM final concentration), 
0.1 µL of 5 U/µL platinum Taq polymerase (0.02 U/µL final concentration) and 1 µL 
of cDNA sample, and made up to 25 µL using 18.9 µL of PCR-grade water (Roche, 
Burgess Hill, UK). A control reaction was performed using 1 µL of PCR-grade water, 
which had also undergone the procedures described in sections 2.3.1 and 2.3.2, in 
place of cDNA. PCR was then performed in a thermal cycler (PCR Sprint, Thermo 
Scientific, Loughborough, UK) using the cycling conditions as described in each 
experimental chapter. All samples were held at 4oC once the reaction had been 
completed. 
 
2.3.4. DNA gel electrophoresis 
Confirmation of PCR success was performed using agarose gel electrophoresis. A 
1.5% agarose gel was made by adding 50 mL of Tris-acetate-EDTA (TAE) buffer 
(Invitrogen, Paisley, UK) to 0.75 g of agarose (Sigma-Aldrich, Dorset, UK) inside a 
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conical flask and microwaving (Category E, Panasonic, Bracknell, UK) on maximum 
for 1 minute. The microwave was stopped every 20 seconds to allow the solution to 
be gently mixed. While the solution was cooling, the gel tray and electrophoresis 
equipment were assembled. An 8-well gel comb was placed into the gel tray, and 
once the solution was cool enough to hold, 2.5 µL of 10,000 x GelRed (Biotium, 
Cambridge, UK) were added and the flask was mixed gently. The solution was then 
poured into a gel tray and left to set for 30-40 minutes. The gel comb was removed 
and the gel was submerged in TAE buffer. Five µL PCR product was mixed, by 
pipetting, with 1 µL of 5x loading buffer (Thermo Scientific, Loughborough, UK) and 
was carefully loaded into a well on the gel. One µL of a 100bp ladder (Invitrogen, 
Paisley, UK) was diluted using 4 µL of TAE and 1 µL of loading buffer before 2 µL 
were added to the leftmost well of the gel. Samples were electrophoresed at 50V 
for 40 minutes and visualised, and digital images taken, using a uv-transilluminator 
(U:GENIUS, Syngene, Cambridge, UK). Band size was determined by comparison 
with the 100 bp ladder. 
 
2.4. Toxicity Assays 
Two measures of cell viability were used; (i) the ability of cells to reduce 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan, and (ii) 
their intracellular ATP concentration. A more detailed explanation of the assays and 
their rationale can be found in section 3.1.1. A similar experimental procedure was 
followed for assays measuring cell viability via MTT reduction and ATP 
concentration. Unless otherwise stated, both assays followed the same procedure. 
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2.4.1. Preparation of cultured cells for toxicity assays 
For MTT assays, clear, flat-bottomed 96-well plates were used (Thermo Scientific, 
Loughborough, UK). For ATP assays, white, flat bottomed 96-well plates (Greiner 
Bio-One Ltd, Stonehouse, UK), pre-treated with 100 µL of 0.01% poly-L-Lysine 
(Sigma-Aldrich, Poole, UK), were used which were prepared as follows. Following 
sterilisation of the white plate with 70% ethanol, poly-L-Lysine was pipetted into 
each well and incubated for 1 hour, after which it was removed and the plate was 
allowed to dry.  
SH-SY5Y and S.NNMT.LP cells were trypsinised, pelleted and counted as described 
in Section 2.1.3. In order to minimise the time either cell line spent outside the 
incubator, all flasks were prepared one after the other rather than in parallel. This 
ensured that in studies comparing cell lines, both SH-SY5Y and S.NNMT.LP cells 
spent approximately equal time outside of the incubator prior to being seeded onto 
a plate. 
Following the cell count, cells were diluted to an appropriate density as described in 
each experimental chapter. One hundred µL of diluted cell suspension was then 
added to a number of wells on a 96-well plate. In assays comparing SH-SY5Y and 
S.NNMT.LP cells, this process was then repeated for the remaining cell line, 

















One hundred mM solutions of NH, 2-MeNH iodide, THNH, and 4-phenylpyridine 
(4PP) (table 2.3) were diluted in media to 2000 µM for 2-MeNH iodide (20 µL of 
solution in 1 mL of media), 800 µM (8 µL of solution in 1 mL of media) for NH and 
1600 µM (16 µL of solution in 1 mL of media) for THNH and 4PP. Each dilution was 
pipetted directly into the top well of a v-bottomed, 96 deep-well block (Starlab, 
Milton Keynes, UK) as shown in figure 2.4.  
  
1 2 3 4 5 6 7 8 9 10 11 12
A SH SH SH SH LP LP LP LP SH* SH*
B SH SH SH SH LP LP LP LP LP* LP*
C SH SH SH SH LP LP LP LP
D SH SH SH SH LP LP LP LP SH SH SH SH
E SH SH SH SH LP LP LP LP LP LP LP LP
F SH SH SH SH LP LP LP LP
G SH SH SH SH LP LP LP LP
H SH SH SH SH LP LP LP LP
1 2 3 4 5 6 7 8 9 10 11 12
A SH SH SH LP LP LP SH# SH#
B SH SH SH LP LP LP LP# LP#
C SH SH SH LP LP LP
D SH SH SH LP LP LP SH SH SH
E SH SH SH LP LP LP LP LP LP
F SH SH SH LP LP LP
G SH SH SH LP LP LP
H SH SH SH LP LP LP
Figure 2.3. 96-well plate layout used for MTT assays (top panel) and ATP 
assays (bottom panel). SH = SH-SY5Y cells, LP = S.NNMT.LP cells. All wells in 
columns 1-8 were incubated with test compounds as described in section 2.4.2. 
Wells in rows D and E, columns 9-12 were used as untreated controls. * 
indicates control wells that did not receive MTT solution. # indicates cell-free 




Table 2.3. The compositions of various solutions used in toxicity assays. 
Compound Concentration Composition 
NH 100 mM 16.8 mg (Sigma-Aldrich, Dorset, UK) in 1 mL 
of DMSO (Sigma-Aldrich, Dorset, UK) 
2-MeNH iodide 100 mM 31.0 mg (equivalent to 18.3 mg free base, 
synthesised according to chapter 6) in 1 mL 
of DMSO  
THNH 100 mM 17.2 mg (Sigma-Aldrich, Dorset, UK) in 1 mL 
of DMSO 
4-PP 100 mM 15.5 mg (Sigma-Aldrich, Dorset, UK) in 1 mL 
of DMSO 
MTT 6 mg/mL 60 mg of MTT (Invitrogen, Paisley, UK) in 10 
mL of PBS 
MTT lysis buffer N/A 25 g of SDS (10% w/v) dissolved in 125 mL 
of N,N-dimethylformamide (DMF, 50% v/v, 
both Sigma-Aldrich, Dorset, UK) and made 





   1 2 3 4 5 6 7 8 9 10 11 12
A
800 µM 800 µM 1600 µM 1600 µM 1600 µM 1600 µM 2000 µM 2000 µM 
B
400 µM 400 µM 800 µM 800 µM 800 µM 800 µM 1000 µM 1000 µM 
C
200 µM 200 µM 400 µM 400 µM 400 µM 400 µM 500 µM 500 µM 
D
100 µM 100 µM 200 µM 200 µM 200 µM 200 µM 250 µM 250 µM 
E
50 µM 50 µM 100 µM 100 µM 100 µM 100 µM 125 µM 125 µM 
F
25 µM 25 µM 50 µM 50 µM 50 µM 50 µM 62.5 µM 62.5 µM 
G
12.5 µM 12.5 µM 25 µM 25 µM 25 µM 25 µM 31.125 µM 31.125 µM 
H
6.25 µM 6.25 µM 12.5 µM 12.5 µM 12.5 µM 12.5 µM 15.563 µM 15.563 µM 
Figure 2.4. A schematic example of NH (columns 1-2), THNH (columns 3-4), 4-PP 
(columns 5-6) and 2-meNH (columns 7-8) serial dilutions into a deep-well block. 
The highest concentration for each compound was made by diluting a 100 mM 
solution into 1 ml of media. Serial dilutions were then performed by removing 500 
µl of solution and adding it to the subsequent well containing 500 µl of media 




Five hundred µL of appropriate media was added to rows B-H. Five hundred µL of 
each solution within row A was then removed and mixed by pipetting 10 times up 
and down into the wells of the row immediately below. This was then repeated 
with each subsequent row to produce 7 1:1 serial dilutions.  
Media covering the cells in the plate was aspirated using a filterless 10 µL tip 
attached to the aspirator in order to minimise the contact between the aspirator 
and the growing surface. A multichannel pipette was used to add 100 µL of each 
individual concentration to all cells within plate row (n = 4 for the MTT assay, n = 3 
for ATP assay, figure 2.3). Untreated (n = 4 for the MTT assay, n = 3 for ATP assay) 
and control wells were incubated with 100 µL media. Once cells had been dosed 
they were incubated for the required amount of time as detailed in the relevant 
experimental chapters.  
 
2.4.3. End-point analyses 
2.4.3.1. MTT assay 
Following incubation as described in Section 2.4.2, the ability of the cells to reduce 
MTT to formazan was assessed as a measure of cell viability (Matharu et al. 2009). 
Ten µL of MTT solution (table 2.3) was added to each well, with the exception of 
the 2 no MTT control wells, using a repeat pipettor. The plate was then placed in 
the incubator for 4 hours.  
Media was carefully aspirated from all the wells and 100 µL of lysis buffer (table 
2.3) was added. The plate was then placed inside an Orbital Incubator SI50 (Stuart 
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Scientific, Stone, UK) at 150 rpm for 1 hour at 37oC, after which absorbance was 
measured at 570nm using a spectrophotometer (Perkin Elmer, Massachusetts, 
USA). Results were calculated and expressed as described in section 2.5.4. 
 
2.4.3.2. ATP assay 
ATP content was assessed using the ATP-Glo kit (Biotium, California, USA) as 
previously described (Parsons et al. 2011). Briefly, ATP-Glo cocktail mix was made 
by dissolving 10 mg of D-luciferin in 1 mL of deionised water (final concentration 10 
mg/mL). Eight hundred µL of D-luciferin solution was then added to 20 mL ATP 
assay buffer (final concentration 0.4 mg/mL D-luciferin). Two hundred µL of firefly 
luciferase was added to complete the cocktail.  
After dosing as described in Section 2.4.2, plates were transferred without removal 
of media to a spectrophotometer equipped with an injector (Fluostar Omega, BMG 
Labtech, Buckinghamshire, UK). The spectrophotometer was programmed with the 
following protocol: injection of 100 µL of ATP-Glo cocktail, shake for 3 seconds, 
delay for 10 seconds and then measure luminescence for 10 seconds using a gain of 
2000. All wells were sequentially injected and measured individually. Results were 
calculated and expressed as described in section 2.4.4. 
In the event that absolute ATP values were to be determined via a calibration 
curve, a set of standards were made as follows: 
 10,000 pmol ATP: 5 µL of a 2 mM ATP solution was added to 995 µL of PBS 
 1000 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
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 100 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
 10 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
 1 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
 0.1 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
 0.01 pmol ATP: 100 µL of the above solution was added to 900 µL of PBS 
One hundred µL of each standard were then loaded in triplicate onto the same 
white 96-well plate as the relevant experimental samples before the assay was 
performed as described above. Taking into account the addition of 1/10th of the 
stock solution of the standards into each well, the final amounts of ATP in each 
triplicate set of wells were 1000 pmol, 100 pmol, 10 pmol, 1 pmol, 0.1 pmol, 0.01 
pmol, and 0.001 pmol. The calibration curve was constructed by creating a double 
log plot of luminescence against concentration of ATP. A line of best fit was then 
determined via linear regression.  
 
2.4.4. Statistical analysis 
All statistical analysis was performed using Graphpad Prism software (Graphpad, 
California, USA). In all cases p < 0.05 was taken as significant. 
 
2.4.4.1. Determination of individual dose toxicity 
In order to determine the overall effect of each, individual, compound dose on the 
viability (MTT reduction) and ATP content (ATP assay) of a single cell line, a 1-way 
repeated-measures ANOVA using blocked, mean data for each experimental repeat, 
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was performed with concentration as the independent variable and absorbance 
minus background (control wells with no MTT solution) or luminescence minus 
background (control wells with media only) as the dependent variable for the MTT 
and ATP assays respectively. Raw absorbance and luminescence values were used 
due to the requirement for ANOVA data to show an equal distribution of variability 
in the groups. Normalisation of data by expressing them as percentage of untreated 
(control) cells would, provided the control data were included, violate this 
assumption due to the fact that the untreated control would exist as 100% ± 0% 
(Lew 2007). Therefore, given that the aim of the test was to compare the effect of a 
particular dose versus untreated, raw data were used.  
 
2.4.4.2. Determination of individual dose toxicity between cell 
lines 
In order to determine whether SH-SY5Y and S.NNMT.LP cells exhibited significant 
differences in viability or ATP content at individual concentrations, a 2-way 
repeated-measures ANOVA using blocked, mean data for each experiment was 
performed with concentration and cell line as the two independent variables and 
data normalised as percentage of untreated (control) cells as the dependent 
variable. Data were normalised in order to take into account differences in baseline 
between both cell lines. Control data were not included in the analysis as, due to 
the normalisation process, these would violate the assumption of the ANOVA of an 
equal distribution of variability amongst the data. Data were blocked for individual 
experiments to take into account the week-to-week variation. 
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2.4.4.3. Determination and comparison of EC50s  
In order to investigate the overall effect of a compound on a particular cell line, 
EC50s for each experiment were determined from dose-response curves as follows. 
Data were normalised as percentage of untreated (control) cells before 
concentration (in M) was log-transformed. These were then plotted using an XY 
scatter graph with log concentration as the independent variable and percentage of 
untreated (control) cells as the dependent variable. A non-linear regression analysis 
was then carried out using a log inhibitor vs response – variable slope model to the 
following equation:  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(𝐿𝑜𝑔𝐸𝐶50−𝑋) ∗ 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒
 
A constraint at Y = 0 was used due to the subtraction of background readings from 
all toxicity data. Two different EC50s can be calculated from this data. The first one, 
the relative EC50, is the point halfway between the top and the bottom of the 
plotted curve. The relative EC50 takes into account instances where the lowest 
concentrations of a compound achieve lower viability than untreated cells or 
instances where the lowest concentrations actually enhance the viability of the cells 
beyond 100%. While it can be of interest to take into account these effects at lower 
concentrations when determining general toxicity, the comparison of 2 separate 
relative EC50s is difficult, due to the fact that they could be derived from largely 
different areas of the y-axis. However, this is not the case for the absolute EC50. 
The absolute EC50 is determined by calculating the point on the x-axis (the log 
concentration), at which the curve intersects 50% viability (relative to untreated 
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cells) on the Y axis. Due to the desire to compare toxicity between cell lines using a 
fixed point of reference during our studies, only the absolute EC50s were 
determined. As a consequence, any further mention of EC50 will be in reference 
only to the absolute EC50. Furthermore, in order to differentiate between EC50s 
calculated following the MTT or ATP assays, the nomenclature EC50MTT and EC50ATP 
will be used in future chapters. 
During statistical analysis, EC50s were generated and maintained in their log format 
due to the requirement for concentration to be log-transformed when constructing 
a dose-response curve. It was not considered to be statistically sound to perform 
statistics with the antilog of the logEC50s, due to the uneven symmetry that exists 
when a log standard error is anti-logged. For example, an EC50 of 1 µM +/- a 
standard error of 1 on the log scale, when anti-logged, will produce an EC50 with a 
negative error of 0.1 µM but a positive error of 10 µM. To avoid this skew, 
statistical analysis was performed using logEC50s, given that EC50s expressed this 
way show a normal distribution (Hancock et al. 1988). For ease of presentation and 
interpretation, where applicable, mean LogEC50 data were anti-logged to show the 
corresponding natural number. However, any statistical analysis concerning EC50s 
was exclusively carried out using log-transformed data. 
In order to assess whether the overall toxicity of the tested compounds varied 
between cell lines, logEC50s were compared using a Student’s t-test. In addition, 
EC50MTTs generated for each compound/cell line were compared with their 
respective EC50ATPs via a Student’s t-test. This was done to determine whether a 
compound’s toxicity varied depending on the assay. Finally, the relative order of 
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toxicity for all compounds used in a particular chapter was determined by 
comparing the EC50MTTs and the EC50ATPs in each cell line via either a Student’s t-








In order to provide the most definitive answers to the research questions, a number 
of optimisation studies were performed. These were designed to determine the 
most appropriate toxicity assays for the cell lines used in the project, to determine 
the ideal conditions for maximising the production of relevant data in these assays 
and to develop a relevant and reliable positive control for Western blotting of 
neuronal markers. Therefore, this chapter has been presented as a collection of 
individual studies containing related optimisation experiments. 
 
3.1. Determination of appropriate cell viability assays 
3.1.1. Introduction 
In vitro cytotoxicity can be determined in a number of ways. Some commonly used 
methods include the lactate dehydrogenase (LDH) assay, the MTT assay and the 
ATP assay.  
 
3.1.1.1. The LDH assay 
In healthy cells, LDH is located exclusively within the cytosol. However, during cell 
death, plasma membrane rupture leads to LDH leakage into the surrounding media. 
By measuring the amount of LDH that has been released from cells, the LDH assay 
reveals the extent of plasma membrane rupture and as such a measure of late-
stage toxicity and cell death (Koh & Choi 1987). In practice, LDH presence in the 
media is determined via the measurement of the downstream production of a red 




LDH catalyses the conversion of lactate to pyruvate, producing 1 NADH molecule as 
a result. NADH is then used by diaphorase, supplied with the assay kit, to convert 
colourless iodonitrotetrazolium to red formazan. The conversion is quantified via 
the measurement of absorbance at 490 nm. Thus, the production of formazan is 
directly dependent on LDH activity and, therefore, gives a quantitative measure of 
end-stage cytotoxicity.  
 
3.1.1.2. The MTT assay 
The MTT assay correlates cell viability with metabolic activity, via the reduction of 
the MTT dye into purple formazan (figure 3.2).  
  
Figure 3.1. Schematic representation of the relationship between LDH activity and 
formazan production in the LDH assay. NADH produced via LDH activity is used by 















The production of purple formazan is proportional to the cells’ metabolic activity 
and is quantified by measuring absorbance at 570 nm. Contrary to popular belief, 
which states that this reduction is carried out by succinate dehydrogenase in the 
mitochondria and as such is an indicator of mitochondrial function (Kaneko et al. 
1995, Satoh et al. 1996, van Meerloo, Kaspers & Cloos 2011), various reports 
suggest that the MTT assay is an indicator of the overall metabolic activity of the 
cell, as many additional cytosolic enzymes are able to catalyse MTT reduction 
(Berridge & Tan 1993, Liu et al. 1997, Bernas & Dobrucki 2002, Takahashi et al. 
2002, Berridge, Herst & Tan 2005). In contrast to the LDH assay, the MTT assay can 
give an indication of an early-stage toxicity, as reduced metabolic activity will occur 
upstream of cell death (Fotakis & Timbrell 2006). However, the MTT assay can still 
demonstrate that cell death has occurred, as the lack of any detectable conversion 







Figure 3.2. Schematic representation of the conversion of MTT into purple 
formazan by various enzymes in the mitochondria and cytosol. 
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3.1.1.3. The ATP assay 
The measurement of intracellular ATP concentration, given its role as the principal 
energy store within the cell, is another commonly-used method for assessing cell 
viability (figure 3.3).  
 
  
D-luciferin + O2 + ATP
Firefly luciferase
Oxyluciferin + CO2 + PPi + AMP +
Light
Figure 3.3. Schematic representation of the ATP luciferase assay. Intracellular 
ATP is directly proportional to the amount of light produced during the 
conversion of D-luciferin to oxyluciferin. 
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The assay involves the addition of a D-luciferin and firefly luciferase-containing 
solution to cells. This lyses the cells and provides firefly luciferase with intracellular 
ATP to drive the light-producing oxidation of D-luciferin. Thus, the amount of light 
produced is directly proportional to the amount of ATP contained within the cells. 
Viability studies involving the ATP assay can, therefore, give an indication of toxicity 
occurring via the depletion of ATP stores. In addition and similar to its MTT-based 
counterpart, the ATP assay can give an indication of toxicity prior to cell death, as 
the assay’s high sensitivity allows it to rapidly detect changes in ATP content 
(Mueller, Kassack & Wiese 2004). The high sensitivity of the assay also allows the 
measurement of ATP levels in low numbers of cells, and is thus ideal for use with, 
for example, primary cultures where cell numbers may be low, or for high-
throughput screening of 96-well based assays. The measurement of ATP as an 
indicator of cell viability/toxicity has been shown to correlate well with both cell 
proliferation and cytotoxicity of a number of different cell types (Crouch et al. 
1993). 
 
3.1.1.4. The balance between assay number and practicality 
While each individual assay reveals different subtleties about what is causing 
cytotoxicity, performing multiple different assays for the same set of experiments is 
both time-consuming and expensive. However, solely relying on one method will 
only provide limited mechanistic information when cells undergo a toxic event. 
Also, it is possible that, in an assay assessing the effects of a compound on cell 
viability, the compound itself is interfering with the mechanism of the assay, for 
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example by inhibiting LDH or succinate dehydrogenase directly. Therefore, it was 
concluded that performing two cytotoxicity assays would provide a compromise: 
preventing excessive repetition, while also providing both confirmation of toxicity 
and additional mechanistic information about the stage of toxicity, whether very 
early (measured in the ATP assay), early to moderate (measured in the MTT assay) 
or late (measured in the LDH assay). Thus, the aim of this study was to determine 
which 2 of the above mentioned assays would be most suitable for assessing the 





3.1.2.1. LDH assay optimisation 
3.1.2.1.1. The effect of media supplements on the LDH assay  
In order to accurately quantify toxicity in vitro, it is important to ensure that there 
are no interfering factors in the cells’ culture media. The possible interference of 
media components in the LDH assay was determined as follows. A 50 µL sample (in 
triplicate) of SH-SY5Y media was taken following each step of the media 
supplementation process (section 2.1, table 2.1) and added to a clear, flat-
bottomed 96-well plate (Thermo Scientific, Loughborough, UK). Phenol red free 
Dulbecco’s Modified Eagle Medium:F12 media (Sigma-Aldrich, Dorset, UK) was used 
for this process. In order to assess the effect of phenol red supplementation to the 
media, commercially-available Dulbecco’s Modified Eagle Medium:F12 media 
containing phenol red (section 2.1, table 2.1) was used.  
Cytoscan assay mix (G-Biosciences, St Louis, Missouri, USA) was made by dissolving 
the substrate mix in 11.4 mL of deionised water before adding 600 µL of assay 
buffer. Fifty µL of assay mix were then added to each well before incubating for 20 
minutes at 37oC. Absorbance at 490 nm was then measured using a 




3.1.2.1.2. The dose-response effect of FBS-supplemented cell 
culture media on the LDH assay  
Quantification of FBS-mediated interference in the LDH assay was determined by 
adding triplicate 50 µL samples of SH-SY5Y media containing 0%, 5%, 10%, and 15% 
FBS to a clear, flat-bottomed 96-well plate. Triplicate 50 µL samples of LDH enzyme 
(diluted 1:10,000 in PBS containing 1% bovine serum albumin) were also added to 
the plate as a positive control. The LDH assay was then carried out as described in 
section 3.1.2.1.1. 
 
3.1.2.2. MTT assay optimisation 
3.1.2.2.1. The effect of FBS supplementation on cell viability via 
MTT reduction 
In order to determine the consequences of varying the FBS content in media upon 
cell viability, the following experiment was performed. SH-SY5Y and S.NNMT.LP 
cells in 15% FBS media were trypsinised, counted and seeded onto a 96-well plate 
at a density of 10,000 cells per well. Following an overnight incubation, all wells 
were washed with PBS before quadruplicate wells were given either serum-free 
media, media supplemented with 15% FBS, or media supplemented with 15% heat-
inactivated (HI) FBS. The cells were then incubated for 48 hours before the MTT 




3.1.2.3. ATP assay optimisation 
3.1.2.3.1. Determination of the relationship between 
luminescence values, ATP concentration and cell viability 
In order to confirm the proportional relationship between ATP content - as 
measured in the ATP assay - and cell viability, the following 2-part experiment was 
performed. Firstly, a set of ATP standards were made and luminescence was 
determined as described in section 2.4.3.2. Luminescence values and ATP content 
(in pmol) were expressed as a double-log plot. Secondly, SH-SY5Y and S.NNMT.LP 
cells were prepared for ATP assay as described in section 2.4.1. Cells were seeded 
at densities of 20,000, 40,000, and 80,000 cells per well. The plate was incubated 
overnight to allow the cells to settle before the ATP assay was performed as 
described in section 2.4.2.2. Cell number and luminescence values were plotted 
using a double-log plot.  
 
3.1.3. Statistical Analysis 
All statistical analyses were performed using Graphpad Prism software (Graphpad, 
California, USA). Effects of media components and FBS supplementation on the LDH 
assay were analysed using a 1-way ANOVA followed by a Dunnet post-test, 
comparing all columns against unsupplemented media. The effect of FBS 
supplementation on cell viability in the MTT assay was determined using a repeated 
measures 1-way ANOVA for each cell line followed by a Dunnet post-test comparing 
all columns against serum-free media. Data were matched by experimental repeat. 
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Finally, linearity of luminescence vs ATP concentration, and luminescence vs cell 





3.1.4.1. LDH assay optimisation 
3.1.4.1.1. Media supplementation with phenol red and FBS 
increased absorbance in the LDH assay  
The effect of media supplementation on absorbance at 490 nm is shown in figure 
3.4. Supplementation of non-essential amino acids, L-glutamine or 
penicillin/streptomycin to phenol red-free media had no significant effect upon 
absorbance. However, addition of phenol red significantly increased absorbance 
(0.039 vs 0.067 ± 0.001, p < 0.01, n = 3). Addition of 15% FBS also significantly 
increased the absorbance of cell-free, media-only solutions (0.039 vs 0.53 ± 0.01, p 










Figure 3.4. The effect of cell culture media supplements on the LDH cytotoxicity 
assay. All data are triplicate mean ± SEM. NEAA = non-essential amino acids, Glut 
= L-Glutamine, Pen/Strep = Penicillin/streptomycin, FBS = Fetal bovine serum. ** 































































3.1.4.1.2. Media supplementation with FBS increased LDH assay 
absorbance in a dose-dependent manner 
Figure 3.5 shows the dose-dependent increase in absorbance following FBS 
supplementation. Absorbance was significantly increased following each 
subsequent addition of 5% FBS (serum free: 0.037 ± 0.001; 5% FBS: 0.20 ± 0.003; 









































Figure 3.5. The effect of FBS-supplementation on the LDH-cytotoxicity assay. All 
data are triplicate mean ± SEM. Control consisted of diluted LDH enzyme solution 
only. *** p < 0.001, n = 3 
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3.1.4.2. MTT assay optimisation 
3.1.4.2.1. FBS supplementation significantly affected cell viability 
Cells cultured in 15% FBS for 48 hours showed significantly enhanced viability, as 
measured by the MTT assay, compared with cells grown in serum-free media (0.12 
± 0.05 vs 0.46 ± 0.16, 3.7-fold increase in absorbance, p < 0.05, n = 4 for SH-SY5Y 
cells; 0.06 ± 0.02 vs 0.18 ± 0.07, 3.9-fold increase in absorbance, p < 0.05, n = 4 for 
S.NNMT.LP cells, figure 3.6). No significant difference was seen between serum-free 
media and HI FBS-supplemented media for either cell line. 
 
  
Figure 3.6. The effect FBS on SH-SY5Y (dark green, n = 4) and S.NNMT.LP (dark 
red, n = 4) cell viability as measured by the MTT assay. All data are mean ± SEM. 
– FBS = serum-free media, HI = media supplemented with 15% heat inactivated 
FBS, FBS = media supplemented with 15% FBS. * = p < 0.05 vs – FBS in the same 







































3.1.4.3. ATP assay optimisation 
3.1.4.3.1. Luminescence values were proportional to ATP content 
and cell density in the ATP assay 
The effect of cell number on ATP content is shown in figure 3.7. A strong linear 
relationship was observed between ATP content and luminescence (r2 = 0.998, 
figure 3.7A). A strong linear relationship was observed between SH-SY5Y (r2 = 
0.9998, figure 3.7B) and S.NNMT.LP (r2 = 0.92, figure 3.7B) cell density compared 




   
Figure 3.7. The linear relationship between ATP and luminescence (A) and cell 
density and luminescence (B) in the ATP assay. All data are mean ± SEM. Green 
circles = SH-SY5Y, red circles = S.NNMT.LP, n = 3 






































Summary of key findings 
 Absorbance in the LDH assay was significantly increased following the 
addition of FBS and phenol red 
 FBS increased the LDH assay absorbance in a dose-dependent manner 
 Cells cultured in media supplemented with 15% FBS, but not 15% HI FBS, 
showed significantly enhanced viability compared to cells with serum-free 
media 
 Luminescence in the ATP assay was directly proportional to ATP content 
and cell density 
 
The significant increase in absorbance observed following the addition of phenol 
red and FBS to the cell culture media suggested that these supplements had the 
potential to interfere with the LDH assay by increasing background absorbance, 
thus unfavourably decreasing the signal:noise ratio and the sensitivity of the assay. 
In the case of phenol red, this was most likely due to phenol red having an 
absorbance spectrum encompassing 490 nm (Baylor & Hollingworth 1990). On the 
other hand FBS, which showed dose-dependent interference, likely increased 
absorbance due to the presence of LDH within the serum (Van Der Helm 1962). The 
large response seen following FBS supplementation, particularly considering that 
both cell lines were routinely maintained in media supplemented with 15% FBS, 
was deemed to result in too great a background absorbance in the LDH assay.  
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One solution to this problem was to reduce the percentage of FBS or remove the 
FBS from the media in order to lower the background absorbance of the assay. 
However, given that the MTT assay demonstrated that there was a significant 
decrease in cell viability when FBS was removed from the media, doing so would 
have had physiological consequences for both cell lines due to the removal of 
growth factors (Honegger & Humbel 1986). This was also true of HI FBS which did 
not show significantly enhanced viability when compared with serum-free media. 
However, due to its alternate mechanism, the MTT assay would not be affected by 
the presence of LDH in FBS. This coupled with the finding that cell viability was at its 
highest when cells were cultured in 15% FBS media and the fact the MTT assay 
provides a more subtle, early indicator of toxicity than the LDH assay strongly 
suggested that the MTT assay was the more appropriate assay of the two for the 
purpose of the project. 
The strong linearity between the ATP content of the standards and the measured 
luminescence confirmed the relationship between the two variables. Thus, the 
proportional increase in luminescence – and therefore ATP content – seen when 
luminescence was plotted against cell density also confirmed that the ATP content 
measured by the assay provided an accurate indicator of cell viability. Therefore, it 
appeared that both the MTT and ATP assays were suitable tools for the 
measurement of toxicity in both cell lines and could be used in later toxicity studies 




3.2. Determination of the appropriate cell density for toxicity 
assays 
3.2.1. Introduction 
When establishing a toxicity profile, it is important to maximise the dynamic range 
between the upper and lower limits of toxicity in order to generate a well-described 
sigmoidal curve. Maximum toxicity can be achieved by increasing the compound’s 
dose beyond the point at which all cells die. Achieving the highest possible viability - 
and thus the greatest dynamic range between upper and lower limits of the curve - 
can be achieved via the determination of the optimal cell density.  
While signal intensity (in an assay that measures live cells) should increase in 
proportion with cell number, there will be a point at which this becomes saturated, 
i.e. the absorbance curve starts to plateau and no longer follows the Beer-Lambert 
law. Absorbance can be expressed by the following equation: 
𝐴 = 2 − 𝑙𝑜𝑔 % 𝑇  
where A is absorbance and log % T is the percentage of light that is transmitted 
through the sample logged to the base of 10. Accordingly, increasing the 
absorbance from 1 to 2 represents a reduction in transmittance from 10% to 1%. In 
many microplate readers, and indeed in the microplate readers utilised during the 
project, absorbance is only linear up to A = 2 due to the lack of accuracy in 
determining transmittances below 1%. Consequently, it is imperative for any assays 
involving absorbance measurements as endpoints to avoid over-seeding cells, as 
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the larger signal generated during the subsequent viability assay may lead to 
absorbances that exceed A = 2. 
In addition to the instrumental issues with absorbance saturation, an excessively 
high cell density can lead to cells overgrowing, causing the rate at which the assay 
signal (e.g. MTT reduction) is produced to become saturated due to substrate 
depletion or difficulties in cell uptake due to the spatial interference from other 
cells. Overgrown cells could also lead to the masking of toxic effects via a similar 
mechanism, as cells that have been grown on top of by others may be spatially 
shielded from toxins. Finally, if the population is too dense, auto-toxicity may occur 
due to depletion of nutrients.  
In order to determine the ideal cell seeding density for subsequent toxicity assays, a 
number of cell densities for incubations of 2 days and 5 days were tested for their 





SH-SY5Y and S.NNMT.LP cells were trypsinised and counted as described in section 
2.1.2. Cell suspensions were then seeded onto clear, flat-bottomed 96-well plates 
(Thermo Scientific, Loughborough, UK) at the following densities: for 2-day 
incubations cells were seeded at 5,000, 10,000, 20,000, 30,000, 40,000 and 50,000 
cells per well, and for 5-day incubations cells were seeded at 5,000, 10,000, 20,000 
and 40,000 cells per well. Following incubation, an MTT assay was performed as 





Following the 2 day incubation, absorbance at 570 nm increased in proportion with 
initial cell density (figure 3.8A). The peak absorbances of 1.30 ± 0.03 and 1.28 ± 0.03 
for SH-SY5Y and S.NNMT.LP respectively were measured in the wells seeded with 
50,000 cells but were only 6.6% and 2.7% respectively higher than the absorbances 
measured in wells seeded with 40,000 cells (1.22 ± 0.03 and 1.24 ± 0.03 for SH-SY5Y 
and S.NNMT.LP respectively). 
Absorbance increased proportionally with cell density after 5 days in wells 
containing SH-SY5Y cells but not S.NNMT.LP cells (figure 3.8B). Absorbance in 
S.NNMT.LP cells increased proportionally from 5,000 cells/well to 20,000 cells/well 
but significantly decreased at 40,000 cells/well compared with 20,000 cells/well 




Figure 3.8. The relationship between cell density and absorbance after 2 days (A) 
and 5 days (B) incubation as measured by the MTT assay. All data are triplicate 
mean ± SEM. Green circles = SH-SY5Y, red circles = S.NNMT.LP 





























Summary of key findings 
 Absorbance increased in proportion with cell density for both cell lines 
after a 2-day incubation but showed only a marginal increase at the 
highest densities 
 Absorbance increased in proportion with cell density after a 5-day 
incubation for SH-SY5Y cells but not for S.NNMT.LP cells 
 
While the maximum absorbance after 2 days of incubation was achieved at 50,000 
cells/well, the relatively small increase from 40,000 cells/well suggested that the 
absorbance may have been close to the saturation point. Thus, increasing the cell 
density beyond 40,000 cells/well for toxicity studies would have not only produced 
relatively trivial increases in absorbance, it could also have led to a masking of toxic 
effects as milder forms of toxicity may have remained undetected due to excess 
metabolic activity. Also, any potential detection of increased cell viability may also 
be compromised. As a consequence, 40,000 cells/well was the density chosen for 2 
day assays. 
For 5 day incubations, SH-SY5Y cells produced a peak absorbance at 40,000 
cells/well. However, the fact that absorbance decreased when S.NNMT.LP density 
was increased to 40,000 cells/well suggested that using the higher density could 
cause S.NNMT.LP cells to become autotoxic. In addition, the longer incubation time 
and, thus, higher rates of cell division increased the possibility of overcrowding 
and/or instrumental absorbance saturation occurring during the incubation period. 
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Therefore, a lower density was considered. While 20,000 cells/well corresponded to 
the peak absorbance for S.NNMT.LP cells, it was not clear whether this density 
represented a point shortly after which absorbance was saturated. Fifteen 
thousand cells/well was considered to be an appropriate density, due to the 
combination of its close proximity to the peak absorbance of S.NNMT.LP cells and 
its presence within the linear, non-saturated portion of the curve for SH-SY5Y cells. 
In accordance with this, 15,000 cells/well was the density used in later 5-day 




3.3. Determination of the optimal incubation time for toxicity 
assays 
3.3.1. Introduction 
Due to the fact that age is the greatest risk factor in PD-development (Kieburtz & 
Wunderle 2013) it is important to model toxicity studies relevant to PD with as 
much of a long-term approach as possible. However, it is impractical to maintain 
proliferating cell lines in a constant environment for an extended period of time 
without introducing factors such as overcrowding and senescence. Nevertheless, it 
is important to expose cells to potential PD-causing compounds for as long as 
possible, given the likelihood that PD-relevant toxicity emerges over time. Thus, the 
applicability of 5-day in vitro toxicity assays was tested by comparing the results 





SH-SY5Y and S.NNMT.LP cells were trypsinised and counted as described in section 
2.4.1. Cell suspensions were then seeded into clear, flat-bottomed 96-well plates 
(Thermo Scientific, Loughborough, UK) at densities of 40,000 cells/well and 15,000 
cells/well for 2-day and 5-day assays respectively. The plate layout described in 
section 2.4.1 was followed. 
Following an overnight incubation, serial dilutions of THNH were made and 
transferred to cells in the plates according to the method described in section 2.4.2. 
Plates designated for 2-day assays were incubated for 48 hours before an MTT 
assay was performed (section 2.4.3.1). For the 5-day assays, the dosing procedure 
was repeated after an initial 48-hour incubation in order to replenish spent media. 
Plates were then incubated for an additional 72 hours before an MTT assay was 
performed.  






3.3.3.1. Extending the incubation time to 5 days improved the 
dose-response curve in SH-SY5Y cells 
The dose-response curves for the 2-day and 5-day THNH incubations are shown in 
figure 3.9. Increasing the incubation time from 2 to 5 days increased the gradient of 
the linear portion of both dose-response curves. This occurred alongside an 
improvement in the r2 of the SH-SY5Y curve (0.88 after 2 days vs 0.94 after 5 days) 







   
Figure 3.9. Dose response curves of THNH following its incubation with SH-SY5Y 
cells (A) and S.NNMT.LP cells (B). The duration of exposure was either 2 days 
(blue) or 5 days (brown). Cell viability was determined via MTT assay. All data are 

























































3.3.3.2. The EC50MTT in S.NNMT.LP cells was significantly lower 
when the incubation time was extended to 5 days 
Increasing the incubation length from 2 to 5 days lowered the THNH log EC50MTT in 
each cell line. This difference was significant for S.NNMT.LP cells (2 day: -3.42 ± 0.02 
(573 µM) vs µM 5 day: -3.39 ± 0.02 (410 µM), p = 0.003) but not for SH-SY5Y cells (2 





Summary of key findings 
 The EC50MTT of THNH was reduced in S.NNMT.LP cells after extending the 
incubation time 
 Extending the incubation time improved the r2 of the SH-SY5Y dose-
response curve 
 
Lengthening the incubation time resulted in a lowering of the THNH EC50MTT. 
However, this change was only significant in S.NNMT.LP cells. This suggested that 
increasing the exposure time allowed more toxicity to manifest itself. While the 
EC50MTT was not significantly reduced in SH-SY5Y cells, the EC50 was reduced by 
28% which matched the significant 28% reduction seen in S.NNMT.LP cells. 
Furthermore, the relatively low number of experimental repeats (n = 3) in this study 
may have contributed to the lack of statistical significance seen in the SH-SY5Y cells.  
Whilst extending the incubation time did not have a significant effect on the THNH 
EC50MTT in SH-SY5Y cells, the overall toxicity profile of THNH in SH-SY5Y cells, with 
reference to the r2, was improved. Accordingly, given both sets of data showing 
more pronounced toxicity at longer incubations, the incubation time for all future 
toxicity assays was increased to 5 days. In addition, in order to provide a more 
robust indication of toxicity, both in terms of the curve fit and EC50, the number of 




While it is clear that an incubation time of 5 days may appear trivial in comparison 
to the 50 years over which neurotoxicity in idiopathic PD can develop, there are a 
number of reasons why this approach is justified.  
Firstly, the overall life cycle of cells in culture is significantly shorter than that of 
neurons in the human brain. While a direct comparison (which itself will vary 
between cell lines and environmental conditions) between SH-SY5Y and S.NNMT.LP 
cells and neurons in the brain has not been reported, the relatively rapid decline in 
cell proliferation and viability seen from personal observations in these cells and as 
reported for other cell lines over successive passages (Hayflick 1965, Simons & Van 
den Broek 1970), is an indicator of an accelerated “aging” process of cells in culture 
compared to in vivo. Thus, in relative terms, incubating the cell lines with the 
compounds for 5 days in vitro was more physiologically relevant to the in vivo 
situation than incubating for only 2 days. 
Secondly, the proliferating nature of both cell lines placed a practical constraint on 
the amount of time that cells could be incubated with their compounds before 
untreated controls became confluent. All toxicity assays were performed in 96-well 
plates to allow an entire experiment to be contained in 1 plate. This limited any 
spatial or environmental variability that could occur arise from using multiple 
plates, along with limiting physical damage to cells due to the splitting and 
reseeding process, which may be exacerbated if already under cytotoxic challenge. 
While longer incubations would have been possible using multiple 24-well plates, 
the introduction of additional variability that this would have caused was not 
considered to be of statistical best practice. Accordingly, 96-well plates were 
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considered to provide the best compromise between incubation length, absorbance 
strength and the number of possible experimental compound concentrations. 
Finally, considering that these toxicity assays were principally designed to 
determine whether the expression of NNMT could alter cell toxicity in the presence 
βCs and 4PP, the incubation time was considered sufficient for any altered viability 
to become manifest. Should NNMT in fact be responsible for increased toxicity in 
the presence of these compounds, future studies would focus on maximising 




3.4. Characterisation of a positive control for the Western 
blotting of neuronal markers  
3.4.1. Introduction 
In order to characterise whether enhanced NNMT expression in SH-SY5Y cells 
produced a change in neuronal lineage or general neuronal characteristics, the 
S.NNMT.LP cells’ protein expression was investigated to determine whether they 
exhibited any altered expression of specific neuronal markers (chapter 4). For 
confirmatory purposes, this required a positive control against which bands on the 
Western blots could be compared. Mouse brain homogenate was considered to be 
the ideal candidate for this, given that this single control would express the entirety 
of the neuronal lineage spectrum required. Accordingly, a series of Western blots 
were performed to determine whether mouse brain homogenate could be used as 
a control for a variety of cell phenotype markers. These markers are, typically, 
enzymes involved in the biosynthetic pathway of the neurotransmitter of interest 
for a specific phenotype. Confirmation of expression of a particular enzyme is, thus, 
indicative of the phenotype in question. 
Tyrosine hydroxylase (TH) is a commonly used neuronal marker for the expression 
of dopamine (Lopes et al. 2010, Korecka et al. 2013, Thomas et al. 2013). TH 
catalyses the conversion of L-tyrosine to L-dopa, the precursor to dopamine 
(Nagatsu 1995) and is, thus, expressed in dopaminergic areas of the brain such as 




Phenylethanolamine N-methyltransferase (PNMT) is an enzyme involved in the 
downstream conversion of the dopamine metabolite noradrenaline/norepinephrine 
to adrenaline/epinephrine (Bülbring & Burn 1949). In the brain, PNMT is found 
mostly in the medulla oblongata, the arcuate nucleus of the hypothalamus and the 
SN (Kopp et al. 1979) and is indicative of an adrenergic phenotype. 
Tryptophan hydroxylase (TPH) catalyses the rate-limiting step of serotonin synthesis 
(Grahame-Smith 1967). TPH exists as 2 isoforms, TPH1 and TPH2, with the former 
being expressed in the pineal gland and also in the gut and the latter being 
expressed exclusively in the brain, particularly the forebrain, midbrain and the 
hippocampus (Sakowski et al. 2006). Its presence is indicative of a serotonergic 
phenotype. 
Choline acetyltransferase (ChAT) is responsible for catalysing the final step in the 
synthesis of acetylcholine (Nachmansohn & Berman 1946). ChAT expression in the 
human brain is principally located in the basal forebrain but it is also widely 
expressed in the basal ganglia and brainstem (Oda 1999) and is indicative of a 
cholinergic phenotype. 
In addition to determining the expression of the cell-type markers, mouse brain 
homogenate was also investigated for the expression of the post-mitotic marker 
NeuN, a protein that is specific for neuronal maturity and thus a marker for the 
differentiation state of neuronally-derived cell lines such as SH-SY5Y and S.NNMT.LP 





Mouse brains were obtained as snap-frozen hemispheres in liquid nitrogen from 
the Biological Services Unit, King’s College London, from animals which had been 
culled using a Schedule 1 method as outlined in the Animal (Scientific Procedures) 
Act 1986. Tissues were prepared as previously described (Parsons et al. 2001). 
Briefly, tissue was homogenised in 10x volume of ice-cold RIPA buffer or 1% triton 
X-100 (approximately 400 µL) using 20 strokes of a Dounce homogeniser. 
Supernatant was centrifuged at 600 x g for 10 mins at 4oC using a Sorval RT7 
centrifuge (Thermo Scientific, Loughborough, UK), after which supernatant was 
collected and stored at -20oC prior to protein concentration analysis as described in 
Section 2.2.2. Samples were subsequently prepared for Western blotting as 
described in section 2.2.3. Neuronal marker expression was assessed using primary 
antibodies against ChAT, TPH1, PNMT, TH and the post-mitotic neuronal marker 




Table 3.1. Antibodies and their dilutions used during Western blotting. Each 
primary antibody corresponded to a phenotypic cell marker: ChAT 
(acetylcholinergic); TPH1 (serotonergic); PNMT (adrenergic); TH (dopaminergic); 
NeuN (post-mitotic neurons). All secondary antibodies used were conjugated to 
horseradish peroxidase 








Goat anti-rabbit IgG 
(1:2000, Sigma-Aldrich, 
Dorset, UK, A8275) 
 
NeuN 
Rabbit anti-NeuN (1:100, 
Merck, Darmstadt, 
Germany, MAB377) 
Goat anti-rabbit IgG 
(1:2000, Sigma-Aldrich, 








Goat anti-rabbit IgG 
(1:2000, Sigma-Aldrich, 








Goat anti-rabbit IgG 
(1:2000, Sigma-Aldrich, 
Dorset, UK, A8275) 
Tyrosine hydroxylase 
(TH) 
Rabbit anti-TH (1:500, 
New England Biolabs, 
Hertfordshire, UK, #2792) 
Goat anti-rabbit IgG 
(1:2000, Sigma-Aldrich, 
Dorset, UK, A8275) 
 
 
In addition, a secondary antibody control, performed by blotting mouse brain 
protein along with SH-SY5Y and S.NNMT protein samples, with secondary antibody 
only was also performed to determine whether any non-specific binding of the 





The Western blots for the secondary antibody controls are shown in figure 3.10. 
The secondary antibody control revealed non-specific bands occurring in the mouse 
brain samples at approximately 140 kDa and at 75 kDa. Accordingly, subsequent 
















Figure 3.10. Secondary antibody controls of SH-SY5Y (lane 2), S.NNMT.LP (lane 3), 
mouse brain in RIPA buffer (lane 4) and mouse brain in 1% triton-X in PBS (lane 5). 
Blots were incubated with goat anti-rabbit IgG (A) or goat anti-mouse IgG (B) 
antibodies, diluted 1:2000 in MTBST, for 1 hour. Lane 1 comprises a series of 
Strep-tagged markers of known size (indicated) which were detected via the 
addition of Strep-Tactin-conjugated HRP. 
A
1       2        3        4        5
B
1       2        3        4        5
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The Western blots of the neuronal markers are shown in figure 3.11. NeuN was 
detected as a 45-50 kDa doublet which is in accord with its published size in the 
mouse brain (Dredge & Jensen 2011). This was also true for TH which was detected 
as a single band seen at approximately 58 kDa (Presgraves et al. 2004), ChAT which 
was detected as 2 bands at approximately 70 kDa (Misawa, Ishii & Deguchi 1992) 
and TPH which was detected as multiple bands just above 50 kDa (Sakowski et al. 
2006). Finally, PNMT was detected as a single band at approximately 33 kDa, also in 
accord with published data (White & Lawson 1997). No clear difference in banding 
pattern was seen between RIPA buffer and 1% triton-X in PBS-treated homogenate.   
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Figure 3.11 Western blots of homogenised mouse brain, prepared in RIPA 
buffer (lane 2) or 1% Triton X-100 in PBS (lane 3). Primary antibodies were 
anti-NeuN (1:100, A), TH (1:200, B), ChAT (1:500, C), TPH1 (1:500, D) and 
PNMT (1:500, E). The Secondary antibody for all cases was goat anti-rabbit 
IgG (1:2000). Lane 1 comprises a series of Strep-tagged markers of known size 
(indicated) which were detected via the addition of Strep-Tactin-conjugated 
HRP. Arrows indicate the identification of the relevant marker. 
A B C
D E
1        2        3 1        2        3 1        2        3











Summary of key findings 
 The secondary antibody controls revealed a subset of bands that occurred 
due to non-specific binding 
 Each primary antibody was capable of detecting the protein of interest 
 
The blots shown in figure 3.11 all contained multiple bands. Thus, it was necessary 
to cross-reference each blot with both the antibody manufacturers’ information 
and available literature in order to determine which bands corresponded to the 
desired neuronal markers. Furthermore after cross referencing with the goat anti-
rabbit IgG secondary antibody control (figure 3.10A), it appeared that the 
pronounced bands at approximately 140 kDa and 75 kDa appeared as a result of 
non-specific binding. Bands corresponding to this size in subsequent analyses were, 
thus, discounted. 
Although more defined bands of greater size were seen in figure 3.11A, the double 
bands slightly below 50 kDa likely corresponded to NeuN (Dredge & Jensen 2011). 
Similar to the data shown here, Dredge and Jensen reported bands of 
approximately 66 kDa and between 70-90 kDa using an identical antibody but 
confirmed, via immunoprecipitation and mass spectrometry, that the doublet 
between 45-50 kDa was NeuN. 
The single band seen at ~58 kDa in figure 3.11B matched the manufacturer’s data 
(predicted size 58 kDa) and a previous report for the detection of TH (Presgraves et 
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al. 2004). Thus, this strongly indicated a successful identification of TH in the mouse 
brain samples. This was also true for ChAT (figure 3.11C), where the predicted 
target size of 70 kDa matched the two bands seen below the 75 kDa marker. The 
presence of more than one band can be explained by the presence of multiple 
splice variants of mouse ChAT (Misawa, Ishii & Deguchi 1992).  
The multiple bands seen just above 50 kDa in figure 3.11D correspond to the TPH1 
antibody manufacturer’s predicted target size of 51 kDa. The additional bands seen 
at this size appear to be the result of cross-reactivity with the second isoform of 
tryptophan hydroxylase, TPH2 (Sakowski et al. 2006). Interestingly, it appears that 
TPH2 is the most predominant form of TPH in the brain, with TPH1 being expressed 
predominantly in the pineal gland which is not routinely considered to be part of 
the brain due to its localisation external to the blood brain barrier (Walther & Bader 
2003). However, the positive detection in the Western blot suggests that the brain 
tissue obtained contained at least part of the pineal gland, and thus allowed for the 
detection of TPH1. Finally, the faint bands seen at ~33 kDa in figure 3.11E 
corresponded to the manufacturer’s data and previously reported size for PNMT 
(White & Lawson 1997). Consequently, homogenised mouse brain provided a 
robust positive control for all of the phenotype markers under investigation. While 
no difference was seen between RIPA buffer and 1% Triton X-100 lysed samples, 
RIPA buffer was considered to be more desirable due to the presence of protease 
inhibitors minimising the likelihood of protein degradation. 
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NNMT, responsible for the N-methylation of nicotinamide to MeN, is expressed at 
higher concentrations in the CSF of PD-patients (Aoyama et al. 2001) and in the 
brains of patients who had died of PD (Parsons et al. 2002, Parsons et al. 2003) 
compared to non-disease controls. In addition, Parsons et al. (2002) discovered that 
the level of expression of NNMT was inversely proportional to disease duration. 
Thus, it was suggested that NNMT may play a causative role in PD pathogenesis by 
facilitating the death of SNpc neurons.  
There are three principal mechanisms by which NNMT is thought to increase 
toxicity (covered in detail in chapter 1). Firstly, NNMT may act as a catalyst for the 
N-methylation of βCs, a group of compounds found endogenously in the CNS 
(Deitrich & Erwin 1980, Susilo & Rommelspacher 1987, Matsubara et al. 1993, 
Matsubara et al. 1995, Kuhn et al. 1996) and in a variety of foods and tobacco 
smoke (Herraiz 2004, Crotti et al. 2010).  
Secondly, increased NNMT activity may lead to an energy deficiency in the cell, as 
the metabolism of nicotinamide into MeN will reduce the availability of NADH and, 
thus, potentially reduce the supply of electrons to the ATP-generating electron 
transport chain (Parsons et al. 2002, Parsons et al. 2003). However, even though 
the expression of NNMT in SH-SY5Y cells was shown to decrease pyridine 
nucleotide (NAD+ and NADH) concentrations, CxI activity was significantly increased 
(Parsons et al. 2011).  
The third mechanism by which NNMT may exert toxicity is via increased MeN 
production. Studies by Fukushima et al. suggested that MeN was destructive to the 
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CxI subunit NDUFS3 (1995) and also significantly reduced rat striatal dopamine 
content (2002). However, the MeN concentrations in both studies were very high, 
the lowest being 10 mM, and conflict with the more-recent Parsons et al. (2011) 
study which showed that MeN was in fact neuroprotective at concentrations below 
1 mM. Thus, more research is required to clarify the effects of NNMT on cell 
viability. 
In order to determine whether increased NNMT expression is inherently toxic, the 
effects of NNMT expression upon SH-SY5Y cells, a cell line that does not express the 
enzyme (Parsons et al. 2011), were examined. Prior to the commencement of this 
study, a cell line (S.NNMT.LP) was generated by the stable transfection of SH-SY5Y 
human neuroblastoma cells with a plasmid encoding a recombinant human NNMT 
(pNNMT.V5). Translated protein from this plasmid contained a C-terminally fused 
V5 tag to allow for easy detection of recombinant protein (NNMT-V5).  
In this chapter, recombinant NNMT-V5 expression was confirmed using Western 
blotting and RT-PCR and the absence of endogenous NNMT expression in SH-SY5Y 
cells was confirmed using RT-PCR. Subsequently, the effect of NNMT expression 
upon cellular ATP concentration, mitochondrial membrane potential and oxygen 
consumption were determined via a series of in vitro assays comparing SH-SY5Y 
cells with S.NNMT.LP cells. In addition, to identify whether any of the changes in 
mitochondrial function are mediated via increased MeN production, experiments 
were also performed in SH-SY5Y cells incubated with 1 mM MeN for 24 hours, a 
concentration shown in several studies to not be toxic and to have cytoprotective 
effects in this and other cell-types (Chlopicki et al. 2007, Sternak et al. 2010, 
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Parsons et al. 2011). Finally, the consequences of NNMT expression upon neuronal 





4.2.1. Confirmation of NNMT-V5 expression 
In order to confirm that SH-SY5Y cells were successfully transfected with the 
pNNMT.V5 plasmid and that, consequently, recombinant NNMT-V5 protein was 
being produced by S.NNMT.LP cells, Western blotting and RT-PCR were performed 
as described in sections 2.2 and 2.3 respectively. Mouse anti-V5 and mouse anti-β-
actin (table 4.1), were used for Western blotting, while primers for NNMT and β-
actin (table 4.2), were used for RT-PCR. The PCR temperature cycling conditions 
were as follows: 94°C for 5 minutes followed by 30 cycles of 94°C for 30 seconds, 
55°C for 30 seconds, and 72°C for 1 minute. The procedure was concluded with a 





Table 4.1. Antibodies and their dilutions used for Western blotting. All secondary 
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4.2.2. Validation of NNMT-V5 expression over time in 
S.NNMT.LP cells 
NNMT-V5 protein expression was assessed in S.NNMT.LP cells of varying passage 
numbers to determine whether the expression of NNMT-V5 remained stable with 
length of time in culture. Western blots were performed with proteins from 
S.NNMT.LP of passages 10 (twice), 12, 16, 19 and 21 along with SH-SY5Y of passage 
number 28, with β-tubulin used as loading control. Densitometry of detected bands 
was performed using Image Lab (Bio–Rad, Hemel Hempstead, UK), and the ratio of 
NNMT-V5:β-tubulin expression was calculated and expressed as absorbance units.  
 
4.2.3. Determination of cellular ATP concentration in 
S.NNMT.LP and SH-SY5Y incubated with 1 mM MeN 
In light of previous studies which demonstrated an increase in CxI activity in 
S.NNMT.LP cells (Parsons et al. 2011), it was decided to determine whether this 
translated into a corresponding increase in ATP synthesis. SH-SY5Y and S.NNMT.LP 
cells were trypsinised, counted and seeded as described in section 2.4.1 at a density 
of 7,500 cells per well. SH-SY5Y cells were seeded into 8 wells of the plate while 
S.NNMT.LP cells were seeded into 4 wells.  
Following an overnight incubation, the media from 4 SH-SY5Y- and 4 S.NNMT.LP-
containing wells was aspirated and replaced with 100 µL of fresh media. The 
remaining 4 SH-SY5Y-seeded wells were aspirated and replaced with media 
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supplemented with 1 mM MeN (table 4.3). Two wells containing media only were 
used as background controls.  
 
Table 4.3. The compositions of solutions used during the determination of the 
biochemical effects of NNMT. 
Compound Concentration Method 
MeN 1 mM 17.3 mg (Sigma-Aldrich, Dorset, UK) in 1 
mL of SH-SY5Y media, syringe-filtered 
and diluted 1:100 in SH-SY5Y media. 
2,4-dinitrophenol (2,4-
DNP) 
1mM 9 mg (Sigma-Aldrich, Dorset, UK) in 1 mL 
of DMSO, diluted 1:50 in media to 
produce the final solution. 
Oligomycins A, B, and C 250 µg/mL 2.5 mg (Sigma-Aldrich, Dorset, UK) in 10 
mL of DMSO. 
Mannitol  0.3 M 54.7 g mannitol (0.3 M,), 0.76 g 
potassium chloride (10 mM), 0.48 g 
magnesium chloride (5 mM) and 1.36 g 
potassium phosphate (10 mM, all Sigma-
Aldrich, Dorset, UK) in 900 mL deionised 
H2O adjusted to pH 7.4 before being 
made up to 1 L. 
 
 
Cells were incubated for 24 hours before intracellular ATP content was determined 
via ATP assay (section 2.4.3.2). In addition to the samples, a set of ATP standards 
(section 2.4.3.2) was also produced and assayed in order to construct a calibration 
curve which was used to determine the absolute ATP content within cells. Protein 
content was also measured in all samples as described in section 2.2.2. The protein 
and ATP content of the wells were then used to calculate ATP concentration, 




4.2.4. Measurement of oxygen consumption in S.NNMT.LP and 
SH-SY5Y incubated with 1 mM MeN 
4.2.4.1. Culture of cells prior to the measurement of oxygen 
consumption 
In order to determine whether the increase in CxI activity previously reported 
(Parsons et al. 2011), and whether any changes in cellular ATP concentration 
observed in this study, were due to changes in the rate of oxidative 
phosphorylation, the rate of cellular O2 consumption was measured. SH-SY5Y and 
S.NNMT.LP cells were cultured in 75 cm2 tissue culture flasks until they reached the 
log phase of growth (corresponding to 65-70% confluence). Media was aspirated, 
cells were washed with 5 mL PBS, and 10 mL of appropriate media were added to 1 
flask of SH-SY5Y and 1 flask of S.NNMT.LP cells (6 x 106 cells). An additional flask of 
SH-SY5Y cells was were incubated with 10mL of media supplemented with 1 mM 
MeN. All cells were subsequently incubated at 37oC and 5% CO2 for 24 hours.  
 
4.2.4.2. Measurement of oxygen consumption 
Oxygen concentration, using a method adapted from Kwok et al. (2010), was 
measured using a Clarke Electrode, with a waterjacket heated to 37oC and 
calibrated to 100% O2 content using cell line-appropriate culture media.  
Briefly, after 24 hours incubation, cells were trypsinised and pelleted (section 2.1.2) 
before being resuspended in 1 mL of a mannitol solution (table 4.3). One hundred 
µL of the cell suspension was taken as an aliquot in order to measure protein 
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concentration (section 2.2.2). Eight hundred µL of the remaining cell suspension 
was added to 200 µL of mannitol buffer, mixed by pipetting and then transferred to 
the calibrated electrode chamber, after which measurements were taken for 3 
minutes using a chart recorder. Twenty µL of oligomycin solution (final 
concentration 5 µg/mL, table 4.3) was added and oxygen concentration was 
measured for a further 3 minutes, after which 20 µL of 2,4-DNP solution (final 
concentration 1 mM, table 4.3) was added and measurements were taken for a 
final 3 minutes. Once the measurements were completed, the chamber was rinsed 
5 times with deionised water before the procedure was repeated for the next cell 
suspension. Following the experiment and the conclusion of the protein assay, the 
rate of oxygen consumption was calculated and expressed as percent oxygen 
consumption/min/mg protein ± SD. 
 
4.2.5. Determination of mitochondrial membrane potential 
(Δψm) in S.NNMT.LP and SH-SY5Y incubated with 1 mM MeN 
In order to determine whether the previously reported differences in CxI activity, 
and any differences in ATP production and oxygen consumption observed in this 
study, had any effect on the membrane potential of the cells’ mitochondria, Δψm 
was measured. Δψm is used as an indicator of mitochondrial function, with a 
depolarised Δψm indicating a disrupted ATP-producing capacity via a reduction in 
proton motive force (Beltran et al. 2000). Accordingly, a high Δψm can be indicative 
of increased ATP production via enhanced proton movement across into the 
mitochondrial intermembrane space (Chen 1988). However, an excessively 
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hyperpolarised Δψm can also lead to the production of ROS (Votyakova & Reynolds 
2001). Thus, it is imperative for cells to maintain Δψm at its most efficient ATP-
producing state. 
 The cationic dye JC-1 allows measurement of Δψm by forming aggregates with 
intense red fluorescence inside mitochondria with high Δψm. At lower Δψm, JC-1 
remains in its monomeric form and fluoresces green. Thus the ratio of red:green 
fluorescence can be used to determine Δψm. 
SH-SY5Y and S.NNMT.LP cells were trypsinised, counted and seeded into the wells 
of a black, poly-L-Lysine-coated flat bottomed 96-well plate (Greiner Bio-One Ltd, 
Stonehouse, UK) at a density of 7,500 cells per well. SH-SY5Y cells were seeded into 
12 wells per plate and S.NNMT.LP cells were seeded into 4 wells. The 4 additional 
wells seeded with SH-SY5Y cells were required for the use of a positive control 
(described below). 
Following overnight incubation, 4 of the wells containing SH-SY5Y cells and the 
S.NNMT.LP cells were given 100 µL of fresh media. Four of the remaining SH-SY5Y-
seeded wells were given media supplemented with 1 mM MeN. The final 4 SH-
SY5Y-seeded wells were given media containing 1 mM of 2,4-DNP, a mitochondrial 
uncoupler which depolarises Δψm, as a positive control. The plate was subsequently 
incubated for 24 hours, after which staining was performed as per manufacturer’s 
instructions (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, 10 µL of JC-1 
reagent (diluted 1:10 in media appropriate for the cell line) was added to each well. 
Cells were then incubated for 15 minutes before the plate was centrifuged at 400 x 
g for 5 minutes (Allegra X-22R centrifuge, Beckman Coulter, California, USA). The 
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media was then aspirated and the cells washed twice with 200 µL of Assay Buffer, 
with centrifugation each time. One hundred µL of Assay Buffer was added to each 
well and fluorescence was measured using a Fluostar Optima fluorescence plate 
reader (BMG Labtech, Offenburg, Germany) with an excitation wavelength of 544 
nm and an emission wavelength of 590 nm for the red JC-1 aggregates, and an 
excitation wavelength of 485 nm and an emission wavelength of 520 nm for the 
green JC-1 monomers. Two wells containing assay buffer only were used as 
background fluorescence controls. Fluorescence readings were corrected for 
background fluorescence and expressed as red:green ratio ± S.D. 
 
4.2.6. Determination of neuronal lineage 
In order to investigate whether NNMT expression influences neuronal lineage and 
neuronal differentiation, Western blots comparing a range of neuronal markers 
specific for neuronal cell-type plus the post-mitotic marker NeuN, were performed 
with SH-SY5Y and S.NNMT.LP cells as described in section 2.2. Mouse brain 
homogenate was used as a positive control for all neuronal lineage and post-mitotic 
markers. β-tubulin was used as a loading control (table 4.1).  
 
4.2.7. Statistical analysis 
Statistical analyses were performed using Prism (Graphpad, CA, USA). Differences 
between SH-SY5Y, SH-SY5Y supplemented with MeN and S.NNMT.LP cells were 
analysed using 1-way ANOVA followed by Dunnet or Tukey post-tests. The analysis 
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of whether NNMT-V5 expression varied with passage number was undertaken using 
a Spearman’s rank correlation of passage number against NNMT-V5 expression 





4.3.1. NNMT-V5 was expressed exclusively in S.NNMT.LP cells 
Confirmation of NNMT-V5 mRNA and protein expression exclusively in S.NNMT.LP 




Figure 4.1. RT-PCR detection of NNMT-V5 expression in SH-SY5Y and S.NNMT.LP 
cell lines. Samples used were RT blank (1), SH-SY5Y cDNA (2), and S.NNMT.LP 
cDNA (3), 100 base pair ladder (4). NNMT and actin labels correspond to the 
appropriate band sizes for their respective PCR products. The 500 bp label points 






Figure 4.2. Western blot detection of NNMT-V5 and β-actin expression in 
S.NNMT cells (1) and SH-SY5Y cells (2).  






NNMT mRNA was detected as a single ~490 bp PCR product in S.NNMT.LP cells 
only, with β-actin detected as a single ~200 bp PCR product in both S.NNMT.LP and 
SH-SY5Y, demonstrating the expression of recombinant NNMT mRNA in S.NNMT.LP 
only. Furthermore, the lack of NNMT mRNA in SH-SY5Y cells demonstrated the lack 
of endogenous expression of NNMT in SH-SY5Y cells, as the assay was designed to 
detect both endogenous and plasmid-derived NNMT mRNA. 
NNMT-V5 protein was detected as a  ~30 kDa band in S.NNMT.LP cells only, with β-
actin detected as ~40 kDa band in both S.NNMT.LP and SH-SY5Y, demonstrating the 
expression of recombinant NNMT-V5 protein in S.NNMT.LP only. 
 
4.3.2. NNMT-V5 expression did not vary with passage number 
Having demonstrated that NNMT-V5 was expressed solely in S.NNMT.LP, it was 
decided to determine whether NNMT-V5 expression varied with increasing passage 
number. Although NNMT-V5 expression showed minor variations between samples 
of differing passage numbers (figure 4.3), a Spearman’s rank correlation analysis 
demonstrated that there was no correlation between NNMT-V5 expression and 




1 2 3 4 5 6 7 
Figure 4.3. Western blots of recombinant NNMT expression (via anti-V5 
antibody, top) and β-tubulin (bottom) in SH-SY5Y cells (1, control) and 
S.NNMT.LP cells of passage 10A (2), passage 10B (3), passage 12 (4), passage 16 
(5), passage 19 (6) and passage 21 (7). 
NNMT-V5 
β-tubulin 
Figure 4.4. NNMT-V5 protein expression as a function of passage number in 
S.NNMT.LP cells. The relationship between passage number and NNMT-V5 
expression was analysed using a Spearman’s rank correlation. No correlation 
was found between the two variables (r = -0.1, P = 0.95). The line represents a 





















4.3.3. ATP concentration was significantly elevated in 
S.NNMT.LP cells and SH-SY5Y cells treated with 1 mM MeN 
compared to untreated SH-SY5Y 
As shown in figure 4.5, S.NNMT.LP cells and SH-SY5Y cells supplemented with 1 mM 
MeN contained a significantly higher (311.56 ± 53.19 pmols/mg protein and 310.95 
± 58.12 pmols/mg protein respectively; both p < 0.01, n = 4) concentration of ATP 
compared to untreated SH-SY5Y cells (150.81 ± 12.02 pmols/mg protein, n = 4). 
 
  
Figure 4.5. ATP concentrations within SH-SY5Y cells, SH-SY5Y cells 
supplemented with 1 mM MeN and S.NNMT.LP cells. All data are mean ± SD. 
** p < 0.01 vs SH-SY5Y. Statistical analysis was performed using a 1-way 


































4.3.4. Oxygen consumption was significantly elevated in 
S.NNMT.LP cells and SH-SY5Y cells treated with 1 mM MeN 
Oxygen consumption was significantly increased in both 1 mM MeN-supplemented 
SH-SY5Y cells (4.49 ± 0.45 % O2/min/mg protein, p < 0.05, n = 4) and in S.NNMT.LP 
cells (4.97 ± 0.50 % O2/min/mg protein, p < 0.01, n = 4) compared with untreated 
SH-SY5Y cells (3.00 ± 0.25 % O2/min/mg protein, n = 4, figure 4.6). Oxygen 
consumption decreased upon addition of oligomycin, and increased upon addition 
of 2,4-DNP (figure 4.7), in accord with their effects upon the mitochondrial 




Figure 4.6. The oxygen consumption of SH-SY5Y cells, SH-SY5Y cells incubated 
with 1 mM MeN, and S.NNMT.LP cells. All data are mean ± SD. * p < 0.05, ** p < 
0.01 vs SH-SY5Y. Statistical analysis was performed using a 1-way ANOVA 




























































Figure 4.7. Typical trace of the oxygen consumption over time of SH-SY5Y cells 
(green), SH-SY5Y cells supplemented with 1 mM MeN (blue) and S.NNMT.LP cells 
(red). 





4.3.5. Δψm was not significantly different in SH-SY5Y cells 
treated with 1 mM MeN and S.NNMT.LP cells compared to 
untreated SH-SY5Y 
Δψm was not significantly different in either 1 mM MeN-supplemented SH-SY5Y 
cells or in S.NNMT.LP cells, compared to untreated SH-SY5Y (Figure 4.8, n = 3). Δψm 
was significantly decreased in SH-SY5Y cells in the presence of 2,4-DNP (63.46 ± 
3.26 vs 31.66 ± 5.61, p < 0.01, n = 3), thus confirming that the assay had successfully 
measured cellular Δψm. 
 
  





















Figure 4.8. The mitochondrial membrane potential, as determined by JC-1 
staining, in SH-SY5Y cells, SH-SY5Y cells supplemented with 1 mM MeN and 
S.NNMT.LP cells. SH-SY5Y cells exposed to 2,4-DNP were used as a control. All 
data are mean ± SEM. ** p < 0.01 vs SH-SY5Y. Statistical analysis was performed 
using a 1-way ANOVA followed by a Dunnet post-test, n = 3 
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4.3.6. NNMT-V5 expression did not induce a change in neuronal 
lineage in SH-SY5Y cells 
Both SH-SY5Y and S.NNMT.LP samples were positive for the neuronal markers of 
acetylcholine (ChAT) and serotonin (TPH, figure 4.9). ChAT was detected in both cell 
lines as a protein of approximately 70 kDa while the 2 bands seen at approximately 
50 kDa corresponded to the presence of both TPH isoforms. The larger band of the 
45-50 kDa NeuN doublet was observed in SH-SY5Y and S.NNMT.LP cells. No gross 
change was seen in the expression of neuronal markers between SH-SY5Y and 
S.NNMT.LP cells. TH and PNMT were not detected in either SH-SY5Y or S.NNMT.LP 










SH-SY5Y S.NNMT.LP Control 
Figure 4.9. Western blots for various neuronal markers using protein 
samples derived from SH-SY5Y cells and S.NNMT.LP cells. Control 




Summary of key findings 
 NNMT-V5 expression was confirmed in S.NNMT.LP cells and did not vary 
with increasing passage number 
 ATP concentration and oxygen consumption were significantly higher in 
S.NNMT.LP cells and SH-SY5Y cells supplemented with 1 mM MeN, 
compared with SH-SY5Y cells alone 
 Both SH-SY5Y and S.NNMT.LP cells expressed markers for 
acetylcholinergic, serotonergic phenotypes and the post-mitotic marker 
NeuN but markers for dopamine and adrenaline were not detected 
 There was no change in the relative expressions of the markers between 
cell lines 
 
4.4.1. Confirmation and validation of NNMT-V5 expression 
The presence of NNMT mRNA and NNMT-V5 protein in S.NNMT.LP cells but not in 
SH-SY5Y cells demonstrated that the S.NNMT.LP cell line expressed NNMT-V5. 
Furthermore, the differences in NNMT expression provide a more effective knock-in 
(S.NNMT.LP) and knock-out (SH-SY5Y) model than would be possible using siRNA 
silencing, which is considered successful when gene expression is reduced by 70% 
(Hood 2004). This allowed an effective study of the effects of NNMT expression to 
be conducted. Furthermore, the level of NNMT activity shown in S.NNMT.LP cells 
was similar to that observed in the cerebellum of PD patients (Parsons et al. 2002, 
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Parsons et al. 2011). Thus, the S.NNMT.LP cell line represents a disease-relevant 
model of NNMT expression.  
While NNMT-V5 expression did not appear to vary with passage number, 
expression was lower in 2 samples (P12 and P16). This appeared to be related to 
the length of time between the thawing of liquid nitrogen-stored cells and the 
centrifugation and snap-freezing of cell pellets. The P12 and P16 samples were 
derived from cells which had been rejuvenated but had not undergone a 
subsequent passage, and as such were only a week or so in culture following their 
removal from storage. In contrast, other samples were obtained from cells which 
had been in culture for a number of passages. Accordingly, the 2 samples with the 
lowest NNMT-V5 expression were derived from cells which had spent the shortest 
amount of time in culture following thawing. Thus, it appears that it may take over 
a week for cellular NNMT expression to reach its peak after rejuvenation of cells 
from liquid nitrogen storage.  
There is currently no study in the literature investigating this phenomenon, and 
although it is considered good scientific practice to allow cells to undergo at least 
one passage prior to experimental use, this is the first, to the author’s knowledge, 
experimental demonstration of this phenomenon. Consequently, any further 
experiments conducted with S.NNMT.LP cells were performed only with cells that 




4.4.2. NNMT-V5-expression significantly enhanced cell viability, 
an effect mediated by MeN 
In order to assess the biochemical effects of NNMT-V5 expression, ATP production, 
oxygen consumption and Δψm were measured and compared in SH-SY5Y and 
S.NNMT.LP cells. ATP production was higher in S.NNMT.LP cells and SH-SY5Y cells 
incubated with 1mM MeN. The oxygen consumption of S.NNMT.LP cells and 1mM 
MeN-supplemented SH-SY5Y cells was also significantly increased and was likely 
elevated as a result of increased mitochondrial respiration as evidenced by the 
effect of oligomycin and 2,4-DNP controls. Oligomycin inhibits the synthesis of ATP 
at complex V and, thus, reduces the cellular requirement to consume oxygen (Kwok 
et al. 2010). Accordingly, the addition of oligomycin reduced the rate of oxygen 
consumption measured in the trace. On the other hand, 2,4-DNP, as a 
mitochondrial uncoupler, greatly enhances mitochondrial oxygen consumption as 
the cell must compensate for the loss in Δψm. It does so by increasing electron 
transport through complexes I-V a process which requires higher rates of oxygen 
consumption, which was replicated in the traces obtained. Thus, the data confirm 
that the oxygen consumption seen in the experiment was occurring due to 
mitochondrial respiration. As such, these results demonstrate that the increase in 
ATP production observed arose from an increase in mitochondrial respiratory chain 
activity. 
The increased ATP concentration and oxygen consumption in S.NNMT.LP cells and 
1mM MeN-supplemented SH-SY5Y cells was unexpected, considering the 
hypothesis that the presence of NNMT would lead to a lowering of the cellular ATP 
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supply via the removal of NADH from the cell. Instead, whilst NNMT-V5 expression 
has indeed been shown to reduce the synthesis of NADH in SH-SY5Y cells (Parsons 
et al. 2011), it is clear that this decrease in NADH was not detrimental to the 
function of the mitochondria in terms of ATP and oxygen consumption.  
The combination of an increased CxI activity, oxygen consumption and the resulting 
ATP synthesis are potentially indicative of an increased proton motive force and 
were, thus, expected to manifest as an increase in Δψm. However, this was 
surprisingly not the case. The lack of change in Δψm, despite the aforementioned 
increases, may be attributable to an elevated expression of mitochondrial 
uncoupling proteins (UCPs). The uncoupling process mediated by UCPs allows 
protons to pass down their electrochemical gradient without entering ATP 
synthase. This results in a lowering of Δψm but also limits the generation of ROS 
which readily occurs at high Δψm (Votyakova & Reynolds 2001). UCPs in the CNS are 
thought to counteract neuronal ROS production that occurs concomitantly with ATP 
synthesis (Andrews, Diano & Horvath 2005). In addition, overexpression of UCP5 in 
SH-SY5Y cells was shown to be protective upon MPP+ exposure via a reduction in 
ROS and maintenance of ATP levels (Ho et al. 2006, Kwok et al. 2010). Thus, it is 
speculated that the lack of altered Δψm may have arisen due to an induction of one 
or more UCPs in order to counteract the elevated ROS production that may occur as 
a consequence of enhanced ATP synthesis. Further studies are needed to confirm 
this hypothesis.  
In addition to these data, other studies using this knock-in/knock-out model have 
shown that S.NNMT.LP cells were significantly protected against the toxicity of a 
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variety of mitotoxins such as MPP+, rotenone, 2,4-DNP and 6-hydroxydopamine in 
comparison to SH-SY5Y cells, again mediated via an increase in MeN production 
(Parsons et al. 2011, Milani, Ramsden & Parsons 2013). These findings are 
supported by numerous other studies which have shown that increased NNMT 
expression, and MeN production, is cytoprotective in other cells (Cuomo et al. 
1994, Kim et al. 2010, Sternak et al. 2010, Ulanovskaya, Zuhl & Cravatt 2013, Zhang 
et al. 2014).  
Taken together, these data suggest that the expression of recombinant NNMT-V5 
increases the viability of SH-SY5Y cells, an effect mediated by increased MeN 
production. Thus, the hypotheses that NNMT causes toxicity via NADH depletion or 
the increased production of toxic MeN were rejected. Instead, these data and data 
published in other studies (Cuomo et al. 1994, Kim et al. 2010, Parsons et al. 2011, 
Milani, Ramsden & Parsons 2013, Ulanovskaya, Zuhl & Cravatt 2013) support the 
hypothesis that the induction of NNMT expression is, in fact, a cytoprotective 
response towards cells. In light of the discovery that NNMT is upregulated in PD 
(Aoyama et al. 2001, Parsons et al. 2002, Parsons et al. 2003), this may be, 
therefore, occurring as a neuroprotective response to the underlying pathogenic 
process rather than contributing towards disease pathogenesis. 
 
4.4.3. The consequence of NNMT-V5 expression on neuronal 
lineage 
NNMT expression did not appear to alter the neuronal lineage of SH-SY5Y cells. It 
also did not appear to alter the expression of NeuN and, thus, does not appear to 
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play a role in the neuronal differentiation of SH-SY5Y cells. Interestingly, neither SH-
SY5Y cells nor S.NNMT.LP cells appeared to express TH. While some groups report 
that SH-SY5Y cells do in fact express TH, whether undifferentiated (Constantinescu 
et al. 2007, Korecka et al. 2013) or following a differentiation protocol (Lopes et al. 
2010), a number of personal disclosures from colleagues report a lack of TH 
expression in SH-SY5Y cells. The reason for these divergent opinions may be the 
geographical origin of particular batches of SH-SY5Y cells, or selection pressures 
from divergent protocols for culturing SH-SY5Y cells. 
While the lack of TH expression in our cells will not correspond to ideal 
physiological relevance for PD, the production of this knock-in/knock-out model for 
NNMT expression allows the effective study of the biochemical consequences of 
NNMT. As such, subsequent investigations need to be undertaken in animal 
models, both transgenic and non-transgenic, to investigate the relevance of NNMT 
within an intact CNS. 
While NNMT-V5 expression did not appear to alter neuronal phenotype or 
differentiation state, a paper published using data from this study (Thomas et al. 
2013) reported that NNMT expression resulted in the induction of EFNB2 and AKt 
cell signalling pathways, leading to increased neurite and synapse formation. 
Coupled with increased ATP synthesis, which will be required for the maintenance 
of axonal transport down these nascent neurites, this suggests a role for NNMT in 





In conclusion, NNMT-V5 expression increased the ATP content of SH-SY5Y cells, a 
process mediated by increased MeN production. These data, and supporting data 
from other studies, suggest that NNMT may play a protective role in PD. However, 
while NNMT expression may have been protective in and of itself, the possibility of 
interaction with the proposed protoxic β-carbolines cannot be ruled out. The 
potential for NNMT to interact with these compounds will be discussed in 
subsequent chapters.  
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5. The toxicity of βCs and 4PP in SH-SY5Y and 





The previous chapter discussed how inducing NNMT expression in SH-SY5Y cells 
enhanced their viability and protected them from toxic insult. While this appears to 
suggest that NNMT expression may be beneficial to cell survivability, there is 
presently no data investigating NNMT’s potential bioactivation of βCs, which are 
also increased in PD (Kuhn et al. 1996).  
βCs, as discussed in chapter 1, are an endogenous group of compounds produced in 
the brain following the metabolism of tryptamine via the Pictet-Spengler reaction 
(Susilo et al. 1987, Susilo & Rommelspacher 1987, Stöckigt et al. 2011). They are 
also present in various foods such as cooked meat and fish and are a constituent of 
tobacco smoke. In both cases they are produced following the pyrolysis of 
tryptophan and its condensation with aldehydes (Herraiz 2004). They, particularly 
NH, are of particular interest in PD because of their structural similarity to MPP+ 
(section 1.3.5.1, figure 1.9). In fact, N-methylation of βCs to form toxic β-
carbolinium ions has been demonstrated in human brain homogenate (Matsubara, 
Collins & Neafsey 1992, Matsubara, Neafsey & Collins 1992, Gearhart et al. 2000) 
and this N-methylation appears to more readily occur in PD patients (Matsubara et 
al. 1995). However, the identity of an enzymatic catalyst for the reaction at either 
the 2N or 9N position is still unknown. Thus, it was hypothesised that, given 
NNMT’s elevation in PD (Parsons et al. 2002, Parsons et al. 2003) and its ability to 
N-methylate pyridine groups (Alston and Abeles 1988), NNMT may be a catalyst for 
this reaction. Even if this were not the case, the simultaneously increased presence 
of both NNMT and the βCs in PD warranted investigating. Indeed, the induction of 
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NNMT expression in PD may cause cells to interact differently with βCs, 
independently of whether or not NNMT can catalyse βC-N-methylation. For 
example, if the protective effects of NNMT expression seen in chapter 4 persist 
following βC exposure, this would add additional support to the theory that NNMT 
is protective in PD. Accordingly, the susceptibility of the NNMT-expressing 
S.NNMT.LP cells to 2 βCs (NH and THNH) was compared with that of the non-
NNMT-expressing SH-SY5Y cells via the MTT and ATP toxicity assays.  
In addition to βCs, another compound of interest is 4PP. Although apparently 
lacking in PD-specific toxicity itself (Irwin, Langston & DeLanney 1987, Perry et al. 
1987), 4PP is the closest non-methylated analogue to MPP+ (figure 5.1).  
 
  
Figure 5.1. The structural similarity between 4PP (left) and the MPP+ (right) 
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Unlike the βCs, 4PP is not produced endogenously. However it has been identified 
as a constituent of oranges (Thomas & Bassols 1992), mint (Snyder & D'Amato 
1985) and also cigarette smoke (Heckman & Best 1981) and should readily cross the 
blood brain barrier due to its small size and hydrophobic nature (predicted logP = 
2.59 ± 0.24 http://www.chemspider.com/Chemical-Structure.13062.html). Once 
inside the brain, 4PP may act as an extremely potent pro-toxin in patients with 
elevated levels of N-methylation activity, for example via the increased expression 
of NNMT. Thus, in addition to investigating S.NNMT.LP and SH-SY5Y cells for their 





5.2.1. MTT assay of SH-SY5Y cells and S.NNMT.LP cells 
incubated with NH, THNH and 4PP 
SH-SY5Y and S.NNMT.LP cells were prepared for MTT assays as described in section 
2.4.1. Cells were seeded at a density of 15,000 cells/well, following the plate layout 
described in figure 2.3.  
Solutions of NH, THNH and 4PP were made according to section 2.4.2, table 2.3. 
The dosing procedure (also in section 2.4.2) was followed, resulting in both cell lines 
being exposed to 8 different concentrations:  
 NH: 800 µM, 400 µM, 200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM 
 THNH: 1600 µM, 800 µM, 400 µM, 200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM 
 4PP 1600 µM, 800 µM, 400 µM, 200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM  
All plates were then placed into the incubator for 48 hours before the dosing 
process was repeated again and the plates were incubated for a further 72 hours, 
making a total of 120 hours incubation. 




5.2.2. ATP assay of SH-SY5Y cells and S.NNMT.LP cells incubated 
with NH, THNH and 4PP 
SH-SY5Y and S.NNMT.LP cells were prepared for ATP assay as described in section 
2.4.1. Cells were seeded and incubated with NH, THNH and 4PP as described in 
Section 5.2.1. 
Toxicity, via ATP assay, was assessed using the method described in section 2.4.3.2.  
 
5.2.3. Statistical analysis 





5.3.1. No difference in cell viability between SH-SY5Y and 
S.NNMT.LP cells in response to NH, THNH and 4PP 
Dose-response curves of the MTT assays, derived from the mean data of each 
experimental repeat (n = 5), are shown in figure 5.2. The dose-response curves for 
each experiment, which were used to generate 1 EC50MTT and 1 set of mean data 








Figure 5.2. Dose response curves of NH, THNH and 4PP following their incubation 
with SH-SY5Y cells (green circles) and S.NNMT.LP cells (red circles) for 5 days. Cell 
viability was determined via MTT assay. All data are mean ± SEM, n = 5. * = p < 
0.05 vs untreated SH-SY5Y, *** = p < 0.001 vs untreated SH-SY5Y, ### = p < 0.001 
































































































NH was toxic to SH-SY5Y cells at concentrations of 100 µM (p < 0.05) and 200 µM, 
400 µM and 800 µM (all p < 0.001). NH also caused significant toxicity to SH-SY5Y 
cells at the lowest dose, 6.25 µM (p < 0.05). In S.NNMT.LP cells, NH was toxic at 
concentrations of 200 µM, 400 µM and 800 µM (all p < 0.001). No significant 
difference in toxicity was seen between cell lines at any individual dose. The log 
EC50MTTs (in M) for SH-SY5Y and S.NNMT.LP cells exposed to NH were -3.79 ± 0.06 
(equivalent to 162 µM) and -3.81 ± 0.05 (equivalent to 155 µM) respectively. The 
difference between the 2 log EC50MTTs was not significant (p = 0.78). 
 
5.3.1.2. THNH 
THNH was toxic to SH-SY5Y cells at concentrations of 400 µM (p < 0.05), 800 µM 
and 1600 µM (both p < 0.001). In S.NNMT.LP cells, THNH was also toxic at 
concentrations of 400 µM, 800 µM and 1600 µM (all p < 0.001). No significant 
difference in toxicity was seen between cell lines at any individual dose. The log 
EC50MTTs (in M) for SH-SY5Y and S.NNMT.LP cells exposed to THNH were -3.37 ± 
0.02 (equivalent to 427 µM) and -3.44 ± 0.04 (equivalent to 363 µM) respectively. 
The difference between the two log EC50MTTs was not significant (p = 0.19). 
 
5.3.1.3. 4PP 
4PP was toxic to SH-SY5Y cells at concentrations of 400 µM, 800 µM and 1600 µM 
(all p < 0.001). In S.NNMT.LP cells, 4PP was also toxic at concentrations of 400 µM, 
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800 µM and 1600 µM (all p < 0.001). No significant difference in toxicity was seen 
between cell lines at any individual dose. The log EC50MTTs (in M) for SH-SY5Y and 
S.NNMT.LP cells exposed to 4PP were -3.47 ± 0.04 (equivalent to 339 µM) and -3.48 
± 0.03 (equivalent to 331 µM) respectively. The difference between the two log 
EC50MTTs was not significant (p = 0.85).  
 
5.3.1.4. Order of compound toxicity – MTT 
Overall, NH was most toxic to both cell lines, followed by 4PP and THNH as 
illustrated by the EC50MTTs (-3.79 ± 0.06 (162 µM), -3.47 ± 0.04 (339 µM) and -3.37 ± 
0.02 (427 µM) respectively for SH-SY5Y and -3.81 ± 0.05 (155 µM), -3.48 ± 0.03 (331 
µM) and -3.44 ± 0.04 (363 µM) respectively for S.NNMT.LP) and figure 5.3, which 
shows the comparative toxicity profiles of all 3 compounds within each cell line. NH 
log EC50MTT was significantly lower than both THNH and 4PP in both cell lines (p < 



























































Figure 5.3. Comparative toxicity curves of NH (turquoise), 4PP (blue) and THNH 
(orange) in SH-SY5Y cells (top) and S.NNMT.LP cells (bottom) following a 5-day 
incubation. Cell viability was determined via MTT assay. All data are mean ± 
SEM, n = 5. 
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5.3.2. S.NNMT.LP cells showed significantly greater decrease in 
ATP content and EC50ATP than SH-SY5Y cells in response to NH 
only  
Dose-response curves of the ATP assays, derived from the mean data of each 
experimental repeat (n = 5), are shown in figure 5.4. The dose-response curves for 
each experiment, which were used to generate 1 EC50ATP and 1 set of mean data 




Figure 5.4. Dose response curves of NH, THNH and 4PP following their incubation 
with SH-SY5Y cells (green circles) and S.NNMT.LP cells (red circles) for 5 days. 
Cell viability was determined via ATP assay. All data are mean ± SEM, n = 5. * = p 
< 0.05 vs untreated SH-SY5Y, ** = p < 0.01 vs untreated SH-SY5Y, *** = p < 0.001 



























































































NH was toxic to SH-SY5Y cells at concentrations of 400 µM and 800 µM (both p < 
0.001). In S.NNMT.LP cells, NH was toxic at concentrations of 200 µM, 400 µM and 
800 µM (all p < 0.001). ATP content was significantly lower in S.NNMT.LP cells 
compared to SH-SY5Y at 200 µM (-3.7 on the log scale, p <0.01) only. The log 
EC50ATPs (in M) for SH-SY5Y and S.NNMT.LP cells exposed to NH were -3.58 ± 0.05 
(equivalent to 263 µM) and -3.76 ± 0.04 (equivalent to 174 µM) respectively. The 
difference between the 2 log EC50ATPs was statistically significant (p = 0. 02). 
 
5.3.2.2. THNH 
THNH was toxic to SH-SY5Y cells at concentrations of 400 µM, 800 µM and 1600 µM 
(all p < 0.001). In S.NNMT.LP cells, THNH was also toxic at concentrations of 400 
µM, 800 µM and 1600 µM (all p < 0.001). No significant difference in toxicity was 
seen between cell lines at any individual dose. The log EC50ATPs (in M) for SH-SY5Y 
and S.NNMT.LP cells exposed to THNH were -3.36 ± 0.06 (equivalent to 437 µM) 
and -3.46 ± 0.03 (equivalent to 348 µM) respectively. The difference between the 
two log EC50ATPs was not significant (p = 0.21). 
 
5.3.2.3. 4PP 
4PP was toxic to SH-SY5Y cells at concentrations of 800 µM (p < 0.01) and 1600 µM 
(p < 0.001). In SH-SY5Y cells, 4PP also caused a significant increase in ATP content at 
200 µM (p < 0.01). In S.NNMT.LP cells, 4PP was also toxic at concentrations of 800 
181 
 
µM and 1600 µM (both p < 0.001). 4PP did not increase ATP content in S.NNMT.LP 
cells. Significant differences in toxicity were seen between cell lines at 200 µM (-3.7 
on the log scale, p < 0.01) and 400 µM (-3.4 on the log scale, p < 0.05). The log 
EC50ATPs (in M) for SH-SY5Y and S.NNMT.LP cells exposed to 4PP were -3.13 ± 0.02 
(equivalent to 741 µM) and -3.20 ± 0.04 (equivalent to 631 µM) respectively. The 
difference between the two log EC50ATPs was not significant (p = 0.12). It should be 
noted that, due to the increased ATP content above untreated cells seen at low 
concentrations of 4PP, the calculated error of the EC50ATP in SH-SY5Y cells is likely to 
have been underestimated. This is due to a reduced fit of the data to the top of a 
traditional sigmoid curve. 
 
5.3.1.4. Order of compound toxicity – ATP 
In accordance with the data from the MTT assays, NH was most toxic to both cell 
lines. However, contrary to what was seen in the MTT assays, the second most-toxic 
compound was THNH followed by 4PP as illustrated by the EC50ATPs (-3.58 ± 0.05 
(263 µM), -3.36 ± 0.06 (437 µM) and -3.13 ± 0.02 (741 µM) respectively for SH-SY5Y 
and -3.76 ± 0.04 (174 µM), -3.46 ± 0.03 (348 µM) and -3.20 ± 0.04 (631 µM) 
respectively for S.NNMT.LP) and in figure 5.5, which shows the comparative toxicity 
profiles of all 3 compounds within each cell line. NH log EC50ATP was significantly 
lower than both THNH and 4PP in both cell lines (p < 0.05 vs THNH and p < 0.001 vs 
4PP in SH-SY5Y, p < 0.001 for both in S.NNMT.LP). THNH EC50ATP was significantly 





























































Figure 5.5. Comparative toxicity curves of NH (turquoise), 4PP (blue) and THNH 
(orange) in SH-SY5Y cells (top) and S.NNMT.LP cells (bottom) following a 5-day 
incubation. Cell viability was determined via ATP assay. All data are mean ± 
SEM, n = 5. 
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5.3.3. Toxicity differences existed between the MTT and ATP 
assays  
A t-test analysing the differences in log EC50 from one assay to another revealed 
that the NH EC50MTT for SH-SY5Y cells was significantly lower than EC50ATP (-3.79 ± 
0.06 (162 µM) vs -3.58 ± 0.05 (263 µM), p = 0.03). This was not the case for 
S.NNMT.LP cells (-3.81 ± 0.05 (155 µM) vs -3.76 ± 0.04 (174 µM), p = 0.41). THNH 
EC50s showed no difference between assays (-3.37 ± 0.02 (427 µM) vs -3.36 ± 0.06 
(437 µM), p = 0.91 for SH-SY5Y and -3.44 ± 0.04 (363 µM) vs -3.46 ± 0.03 (348 µM), 
p = 0.68 for S.NNMT.LP). The EC50MTTs of 4PP-treated SH-SY5Y and S.NNMT.LP cells 
were significantly lower than the corresponding EC50ATPs (-3.47 ± 0.04 (339 µM) vs -
3.132 ± 0.02 (741 µM), p < 0.0001 and -3.48 ± 0.03 (331 µM) vs -3.20 ± 0.04 (631 




Summary of key findings 
 No difference in toxicity between cell lines was seen following MTT assays 
 Differences between SH-SY5Y and S.NNMT.LP in onset of toxicity, toxicity 
at specific doses and EC50 were seen in the ATP assay for NH 
 4PP had significantly greater protective effects in SH-SY5Y cells than 
S.NNMT.LP cells following the ATP assay 
 
5.4.1. βC-toxicity in SH-SY5Y and S.NNMT.LP cells 
When measured by MTT cell viability assay, all compounds exhibited similar toxicity 
responses in both cell lines, although NH showed significant toxicity towards SH-
SY5Y at 6.25 µM and 100 µM but not S.NNMT.LP cells. However, the fact that there 
was neither a difference in toxicity between cell lines at these concentrations, nor a 
difference in EC50MTT, indicated that the 2 cell lines did not possess meaningful 
differences in cell viability when incubated with NH. 
Furthermore, the toxicity seen in SH-SY5Y cells at the lowest dose may be due to 
experimental, rather than biochemical, factors. This is supported by the observation 
that in the MTT assays, the lowest dose of every compound, particularly in SH-SY5Y 
cells, showed a lower viability than doses thereafter (figure 5.2). This is likely due to 
the fact that the lowest dose given to the SH-SY5Y cells was consistently applied to 
the wells at the bottom left corner of the 96-well plate. A study investigating 
location-dependent biases in plate readers found that, in some cases, row H 
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columns 1-4 exhibit lower absorbances relative to the grand mean of the plate. This 
is in contrast to row D columns 9-12 which typically exhibited greater than average 
absorbances (Harrison & Hammock 1988). While the differences in absorbances 
observed in Harrison and Hammock’s study were generally low (5%-10% either side 
of the grand mean depending on the plate reader) this may have been sufficient to 
contribute to the unexpected difference seen between the lowest NH dose and 
untreated SH-SY5Y cells in this study. Why this difference was only significant to the 
SH-SY5Y cells incubated with NH is unclear and may be coincidental.  
Differences in toxicity between both cell lines were more apparent when measuring 
ATP content. While, again, no differences were seen when either cell line was 
exposed to THNH, the NNMT-V5-expressing S.NNMT.LP cells appeared to be 
significantly more susceptible to NH-mediated loss of ATP than the non-NNMT-
expressing SH-SY5Y cells. This was supported by the fact that significant reductions 
in ATP content began at a lower NH dose (200 µM) in S.NNMT.LP cells; S.NNMT.LP 
ATP content compared to SH-SY5Y cells was significantly lower at this dose and the 
overall EC50ATP for NH was significantly lower in the S.NNMT.LP cells. The significant 
difference in EC50ATP was paralleled by a significant increase in the NH EC50ATP 
compared with EC50MTT in the SH-SY5Y cells, but not S.NNMT.LP cells. This 
unilateral difference in inter-assay EC50 suggests that the SH-SY5Y cells may have 
been able to protect themselves against NH-mediated ATP depletion by a 
mechanism that was absent or overcome in S.NNMT.LP cells incubated with NH.  
The precise mechanism for this increased susceptibility of S.NNMT.LP cells to NH-
mediated ATP-dependent toxicity is unclear. It is also unclear whether this 
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difference in toxicity was due to the production of N-methylated NH in S.NNMT.LP 
cells or an alternative mechanism that simply renders NNMT-V5-expressing SH-SY5Y 
cells more susceptible to ATP-dependent NH toxicity. Regardless of the exact 
mechanism, the fact that this difference was only detected in the more sensitive of 
the 2 assays (ATP analysis) may suggest that NH toxicity was only marginally more 
severe to S.NNMT.LP cells over the time-course of the study. However, whilst 
during the 5-day timeframe of the MTT assay no toxicological differences were 
found, over a longer period of time differences in energy availability may manifest 
themselves into more pronounced toxicity. Accordingly, a situation could arise in 
the brain whereby cells with higher NNMT expression, exposed to NH over many 
years, are subjected to a slow yet increasing toxicity that may only become fully 
manifest at a later stage. This long-term build-up of toxicity is in line with the 
development of PD pathophysiology, as the gradual degeneration of SNpc neurons 
in the brain typically spans several years.  
It should be noted that the increased susceptibility of S.NNMT.LP cells to NH-
mediated ATP reduction is in contrast to the overall enhanced viability of 
S.NNMT.LP cells seen in the previous chapter. Given that NNMT is thought to be 
cytoprotective to many different cell-types, including SH-SY5Y (see chapter 4), it is 
possible that the upregulation of NNMT as a cytoprotective response in the brain 
could have long-term unwanted toxic consequences in the presence of sufficient 
quantities of NH. This raises the possibility that NNMT expression in PD could be a 
double-edged sword, resulting in a situation in which the initially protective effects 
of NNMT are counteracted by the effects of long-term exposure of NNMT-
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expressing cells to NH. Over time this balance of toxicity vs protection could shift 
towards greater harm due to the slow, but steady, accumulation of NNMT-
dependent NH toxicity, eventually surpassing the neuron’s cytotoxic threshold and 
initiating cell death.  
The lack of toxicological differences between SH-SY5Y and S.NNMT.LP cells as well 
as the significant differences in EC50 between THNH and NH suggest that THNH has 
no direct relevance as a toxin to either cell line. Furthermore studies involving the 
injection of 2N-methylated THNH into rat brains found no dopaminergic neuron-
specific toxicity (Perry et al. 1986). Thus, THNH is unlikely to play a direct role in 
either PD toxicity or toxicity derived from the expression of NNMT. However, due 
its place in the biosynthetic pathway for the production of 2,9-diMeNH, THNH may 
yet play an indirect role in the disease via its oxidation to NH (section 1.3.5.2, figure 
1.10). 
 
5.4.2. 4PP-exposure in SH-SY5Y and S.NNMT.LP cells 
While there was no apparent difference in cell viability following 4PP incubation at 
any dose, and the EC50MTTs and EC50ATPs of the 2 cell lines were not significantly 
different, the ATP content of SH-SY5Y cells was significantly higher at 200 µM and 
400 µM 4PP compared with that observed in S.NNMT.LP cells. In particular, 200 µM 
4PP significantly enhanced ATP content in SH-SY5Y cells above the level in 
untreated cells, an effect that was absent in the S.NNMT.LP. To the author’s 
knowledge, there are currently no other experimental reports of 4PP-mediated 
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enhancement of ATP. However, 4PP-mediated cytoprotection against MPP+ toxicity 
has previously been reported in vivo (Irwin, Langston & DeLanney 1987).  
The fact that this enhancement was only measured in the ATP assay suggests that 
4PP may initially exert its cytoprotective properties by acting as a mediator of 
increased ATP production. Over a longer period of time, this increased ATP content 
may manifest itself as greater overall cell viability and survival. Thus, increased cell 
viability mediated by 4PP may be detectable via MTT assay over an incubation time 
longer than 5 days. While exposure of NNMT-expressing cells to 4PP did not appear 
to be toxic, the lack of protective effect seen compared to non-expressing cells 
may, over time, result in lower cell viability due to comparatively lower ATP content 
in S.NNMT.LP. However, the mechanism for this is unclear, although it is unlikely 
that the lack of protection seen in the NNMT-expressing cells is due to the 
simultaneous production of MPP+. Had this been the case, MPP+ production would 
have occurred intracellularly and, thus, would have provided the neurotoxin with 
immediate access to its primary target, mitochondrial CxI (Nicklas, Vyas & Heikkila 
1985, Cleeter, Cooper & Schapira 1992). This would have resulted in a substantially 
increased - and more noticeable - toxicity towards S.NNMT.LP cells.  
Interestingly, 4PP exposure to both cell lines showed a significant increase in 
EC50ATP compared with EC50MTT. The precise reason for this in unclear but it may 
indicate that 4PP-mediated cell death at higher doses occurs principally via an ATP-
independent mechanism as approximately twice as much 4PP was required to 
reduce cellular ATP by half than to halve the cell viability. The significantly higher 
4PP EC50ATPs compared with EC50MTTs appear to explain the change in order of 
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toxicity that occurred, as THNH, which was less toxic than 4PP in the MTT assays, 
did not have a significantly increased EC50ATP. More studies are required in order to 
fully elucidate why 4PP shows such a strong variation in toxicity between assays. 
 
5.4.3. The physiological relevance of the compound 
concentrations used in the study 
Unfortunately, for comparative purposes, there are currently no published data 
that provide an indication of the concentration 4PP can reach in the mammalian 
brain. While data exist reporting THNH concentrations in rat brain (370 – 1510 pg/g 
of tissue, approximately 2.15 – 8.78 nM) (Faull et al. 1982, Peura et al. 1989), no 
human data have been published. On the other hand data does exist for NH which 
suggests that the NH concentrations used in this study were higher than those that 
have been reported in healthy human brains. Matsubara et al. (1993) reported a 
NH concentration of 16 +/- 8 nM in the SN of non-PD human brains (16.00 +/- 8 
pmol/g, equivalent to 16 +/- 8 nM, assuming 1 g = 1 ml). Currently, there are no 
data reporting the concentration of NH in the PD brain but it is assumed that its 
concentration would be substantially higher than the one reported in non-PD 
brains. This is supported by the finding that NH concentration showed a significant 
2.1-fold increase in the CSF of PD patients compared with controls (134 +/- 107 pM 
vs 64.1 +/- 57 pM) (Kuhn et al. 1996).  
Similar results to those reported in this study may be achievable using lower NH 
concentrations but with significantly longer incubation times. Should the 
S.NNMT.LP cells indeed be converting NH to its N-methylated forms, the slow but 
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gradual sequestration of any N-methylated products in mitochondria would lead to 
the cytotoxic threshold of the cell eventually being reached. This could occur even 
with low substrate concentrations and rates of N-methylation. This is due to the 
fact that that positively charged ions, like MPP+ or the 2N-methylated β-carbolinium 
ions, are known to sequester within mitochondria (Ramsay et al. 1989), with some 
cationic compounds reaching concentrations up to 1000-fold higher inside the 
mitochondria than outside (Hoppel et al. 1987). Indeed, with PD being associated 
primarily with age, this very slow but gradual accumulation could be occurring over 
several decades in human brains. 
However, due to the impracticalities of the long-term culture of immortalised cells, 
whether because of cost, overgrowing or the inability to keep conditions constant, 
it is often necessary to perform assays over a shorter space of time in vitro. Thus, 
the process can be accelerated by using supra-physiological concentrations in order 
to determine possible effects of exposure more rapidly. In this case, the higher NH 
concentration may also function to force the hypothetical N-methylation reaction 
to completion. While this may not be indicative of ideal physiological conditions for 
the reaction, should the toxicity seen in this study be confirmed to be due to the 
production of N-methylated NH, the data can be seen as a proof of concept rather 
than a direct indicator of the capability of NNMT-expressing neurons in the human 
brain to form N-methylated NH products. As such, in future, in vivo studies should 






In conclusion, S.NNMT.LP cells were significantly more susceptible to NH-mediated 
ATP reduction compared to SH-SY5Y cells. The precise mechanism for this increased 
susceptibility is unclear. The absence of this observation in the MTT assay 
suggested that the reduction in ATP content mediated by NH was insufficient to 
affect cell viability over the time course of the study. THNH showed no differences 
in toxicity to either cell line. 4PP was found to be significantly better at enhancing 
the ATP content of SH-SY5Y cells compared with S.NNMT.LP cells. The precise 
mechanism of this protection is not currently known. 
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6. The determination of the role of NNMT in 2-MeNH 





The previous chapter discussed the increased susceptibility of the NNMT-V5-
expressing S.NNMT.LP cells to NH toxicity compared with SH-SY5Y cells which do 
not express the enzyme. However, it was unclear whether this toxicity was due to 
the S.NNMT.LP’s inherent susceptibility to NH or to the possible conversion of NH 
into one of its more toxic, N-methylated forms. Figure 1.10 in Chapter 1 illustrated 
that there are 2 possible NH N-methylation products, 2-MeNH or 2,9-diMeNH. A 
study by Matsubara, Collins & Neafsey (1992) suggested that 2,9-diMeNH, the end 
product of NH di-N-methylation, arises from sequential NH N-methylation, initially 
at the 2N position followed by the 9N position. Thus, N-methylation of the pyridine 
moiety appears to be the first step towards the production of the endogenous 
neurotoxin, and it is this particular moiety in other compounds, such as 3-
acetylpyridine, that NNMT has been shown to N-methylate (Alston & Abeles 1988).  
While 2,9-diMeNH has been reported to be the most toxic of all the naturally-
occurring βC derivatives (Hamann et al. 2006, Pavlovic et al. 2006, Wernicke et al. 
2007), 2-MeNH has also been reported to be toxic, particularly to cells expressing 
DAT (Wernicke et al. 2007). Thus, given the concomitant elevation of both NNMT 
expression and the concentration of N-methylated βCs in PD, the toxicity of 2-
MeNH and 2,9-diMeNH to SH-SY5Y and S.NNMT.LP cells was determined via MTT 
and ATP assays. Due to the lack of commercially-available 2-MeNH and 2,9-
diMeNH, both compounds were synthesised using published methods (figure 6.1, 




Figure 6.1. The reaction conditions for the synthesis of 2-MeNH, as described by 
Thatcher et al. 2012 (A) and 2,9-diMeNH, as described by Cao et al. 2005 (B). 
CH3CN = acetonitrile, MeI = methyl iodide, DMF = N,N-dimethylformamide, NaH = 
sodium hydride 
 
In addition, the possibility of NNMT catalysing NH 2N-methylation was determined. 
This was achieved via a cell free NNMT enzyme activity assay in the presence of NH 
and SAM cofactor. The results were analysed via liquid chromatography-mass 
spectrometry (LC-MS) in order to definitively determine whether the enzyme is 
capable of catalysing the 2N-methylation of NH to 2-MeNH. In particular, the 
detection of 2-MeNH was performed using a triple quadrupole mass spectrometer, 
as this allowed improved identification of specific analytes via MS-MS selected 
reaction monitoring (SRM) and also provided a sufficient signal-to-noise ratio for 






6.2.1. Synthesis  
6.2.1.1. Synthesis of 2-MeNH  
The synthesis of 2-MeNH was based upon the method of Thatcher et al. (2012) and 
was carried out as follows within the confines of a fume cupboard. Five hundred mg 
of NH was added to a 50 mL round-bottomed flask. A magnetic flea was added to 
the flask which was then clamped above a magnetic stirrer (Nickel Electro Ltd, 
Weston-super-Mare, UK). Ten mL of acetonitrile (ACN, Fisher Scientific, 
Loughborough, UK) were added to the flask and gently stirred for 30 minutes at 
room temperature, before 0.5 mL methyl iodide (MI) were added using a needle 
and syringe. The flask was firmly stoppered and the reaction was left to stir at room 
temperature for 16 hours, during which time a light yellow precipitate was formed. 
The stopper was removed and the solution was left to stir for an additional 30 
minutes to allow any residual MI to evaporate.  
The reaction solution was then poured into a sintered funnel and was filtered under 
vacuum, resulting in the collection of a yellow powder. The filtrate was collected 
into a conical flask. The precipitate was washed with 5 ml of diethyl ether followed 
by filtration under vacuum for 1 minute to ensure as much solvent as possible was 
drawn off. The remaining solid was scraped off the funnel and collected into a 
beaker. The filtrate was then added to the top of the sintered funnel and filtered 
once more under vacuum for 1 minute, with any additional precipitate pooled with 
the previously collected precipitate. The pooled precipitate was then added back 
onto the filter and washed with diethyl ether a further three times. The remaining 
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precipitate was then scraped off and dried under reduced pressure in a desiccator 
overnight.  
 
6.2.1.2. Synthesis of 2,9-diMeNH  
The synthesis of 2,9-diMeNH was based upon the method by Cao et al. (2005) and 
was carried out as follows within the confines of a fume cupboard. Four hundred 
and twenty mg of NH was added to a 100 mL round-bottomed flask inside a fume 
hood. A magnetic flea was added to the flask which was then clamped above a 
magnetic stirrer (Nickel Electro Ltd, Weston-super-Mare, UK). Fifteen ml of 
anhydrous DMF was added to the flask which was then stoppered and gently 
stirred until the NH dissolved. An oil bath upon a temperature-controlled stirring 
plate was pre-heated to 60oC before 0.3 g of sodium hydride (NaH) was added to 
the NH-DMF solution. One mL of MI was then added via needle and syringe and the 
flask was submerged in the oil bath. A condenser was attached to the top of the 
flask and the water supply was switched on. The reaction was then left for 1 hour. 
The condenser was disassembled and the flask was removed from the oilbath and 
clamped over a stirring plate. The flask was then stirred un-stoppered for 30 
minutes to allow it to cool and to allow any excess, un-reacted MI to evaporate. Ten 
mL of deionised water was added before the solution was poured into a 500 mL 
separating funnel. Thirty mL of ethyl acetate (EA) were added to the separating 
funnel which was then stoppered and shaken vigorously. The separating funnel was 
inverted and the tap opened periodically to relieve the pressure during shaking. The 
funnel was then left to rest for 30 seconds to allow the solvents to partition. The 
197 
 
lower (aqueous) and upper (EA) layers were then collected into separate conical 
flasks. The EA-containing flask was set aside and the flask containing the aqueous 
layer was poured back into the separating funnel. Thirty mL of fresh EA was added 
to the funnel and the shaking and draining process was repeated a total of 3 times 
as described above, pooling the aqueous and EA layers into their respective flasks 
each time. 
The conical flask containing the aqueous partition was set aside. The entire volume 
of the EA-containing conical flask was then added to the separating funnel before 
10 mL of deionised water was added. The funnel was then shaken and drained as 
described above and the process was repeated once more. Both the aqueous layer 
and EA layer were drained into clean conical flasks. The aqueous-layer flask was 
again set aside. The EA layer was then added back into the separating funnel a final 
time in order to wash and shake with 15 mL of brine. The brine layer was drained 
and set aside before the EA layer was collected into a clean conical flask. 
Excess water was removed from the EA solution by adding several heaped spatula 
measures of anhydrous magnesium sulphate and swirling the flask. The contents 
were then filtered using a sintered funnel attached to the vacuum supply. No wash 
was performed after filtration. The filtrate was then evaporated using a Rotavapor 




6.2.1.3. Confirmation of the identities of the synthetic products  
The identification of synthetic products was performed using nuclear magnetic 
resonance (NMR), mass spectrometry and melting point analysis. 
 
6.2.1.3.1. NMR 
Analysis of synthetic products was performed using proton (1H-NMR) and carbon 
(13C-NMR) NMR. Samples were prepared for NMR by dissolving 10 mg of product in 
700 µL of deuterated DMSO (Santa Cruz Biotechnology, Heidelberg, Germany). 
1H-NMR spectra were recorded at 400 MHz and 13C-NMR spectra were recorded at 
100.6 MHz using an Ultrashield 400 NMR spectrometer (Bruker, Coventry, UK). 
NMR spectra were then compared with spectra reported in the literature (Thatcher 
et al. 2012, Cao et al. 2005). 
 
6.2.1.3.2. Melting point analysis 
Melting point was determined by placing a small amount of product into a capillary 
tube. This was then inserted into a digital melting point apparatus (Electrothermal, 
Stone, UK) with the temperature initially set to 180oC, increasing by 0.2oC every 10 
seconds. The temperatures at the commencement of melting and the completion 
of melting were recorded and compared with those reported in the literature (Rook 




6.2.1.3.3. Mass spectrometry 
Confirmation of synthesis was performed via infusion of 1 ng/mL product in 
methanol into a TSQ Quantum Access triple quadrupole (Thermo Scientific, 
Loughborough, UK) followed by full scan analysis to provide confirmation of 
product size and purity. 
 
6.2.2. MTT assay of SH-SY5Y cells and S.NNMT.LP cells 
incubated with 2-MeNH 
SH-SY5Y and S.NNMT.LP cells were prepared for MTT assay as described in section 
2.4.1. Cell solutions were seeded at a density of 15,000 cells/well as per the plate 
layout described in figure 2.3. 
A 100 mM solution of 2-MeNH was made according to section 2.4.2, table 2.3. The 
dosing procedure (section 2.4.2) was followed, resulting in both cell lines being 
exposed to 8 different concentrations of 2-MeNH: 2000 µM, 1000 µM, 500 µM, 250 
µM, 125 µM, 62.5 µM, 31.25 µM, 15.625 µM. Control wells were given media only. 
All plates were then incubated with 2-MeNH for a total of 120 hours as described in 




6.2.3. ATP assay of SH-SY5Y cells and S.NNMT.LP cells incubated 
with 2-MeNH 
SH-SY5Y and S.NNMT.LP cells were prepared for ATP assay as described in section 
2.4.1. Cell solutions were seeded at a density of 15,000 cells/well as per the plate 
layout described in figure 2.3. 
The dosing procedure was identical to that used in section 6.2.2. Toxicity, via ATP 
assay, was assessed using the method described in section 2.4.3.1. 
 
6.2.4. Determination of NNMT NH N-methyltransferase activity 
6.2.4.1. Proof-of-concept study  
It has been hypothesised that NNMT may catalyse the first stage of NH’s N-
methylation pathway (section 1.3.5.2, figure 1.10); as such, the elevated expression 
of NNMT observed in the PD patient brain (Parsons et al. 2002, Parsons et al. 2003) 
may facilitate local increases in the levels of N-methylated βCs. Accordingly, an 
enzyme assay (Patel et al. 2013) in which NH was substituted for nicotinamide as 
substrate, using purified, active, recombinant NNMT protein (a kind gift from Prof. 
M. Emanuelli, Università Politecnica delle Marche, Ancona, Italy) was carried out in 
order to assess whether NNMT can catalyse the formation of 2-MeNH. 
Prior to beginning the reaction, 5 750 µL aliquots of ACN were prepared in 1.5 mL 
Eppendorf tubes and placed on ice. A reaction mix was prepared in a 1.5 mL 
Eppendorf tube containing the following components (table 6.1): 694 µL deionised 
water, 8 µL of 100 mM NH (section 2.4.2, table 2.3, 1 mM final concentration), 40 
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µL of 1 M, pH 8.6 Tris (50 mM final concentration), 8 µL of 100 mM dithiothreitol 
(DTT, 1 mM final concentration) and 10 µL of 1.7 µg/µL NNMT protein in DMSO 
(21.25 ng/µL final concentration).  
 
Table 6.1. The compositions of solutions used in the NNMT enzyme assay. 
Compound Concentration Composition 
Tris 
 
1 M 12.1 g Trizma HCL in 90 mL deionised H2O, 












The reaction mix was vortexed and inserted into a pre-heated Eppendorf heater 
(Grant Instruments, Shepreth, Cambridgeshire) set to 37oC. The reaction mix was 
incubated for 5 minutes to reach temperature prior to the addition of 40 µL 10 mM 
SAM cofactor (0.5 mM final concentration) to start the reaction. The reaction tube 
was vortexed immediately following the addition of SAM and a 150 µL aliquot was 
transferred to one of the ACN aliquots, vortexed and placed on ice in order to 
terminate the enzyme reaction and precipitate the protein. The reaction tube was 
placed back onto the heater and the time was noted. One hundred and fifty µL 
reaction aliquots were transferred to ACN every 15 minutes for 1 hour.  
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In order to quantify the production of 2-MeNH, a range of 2-MeNH standards were 
produced from a 5 mg/mL DMSO stock of synthesised 2-MeNH (equivalent to 8.5 
mg/ml of 2-MeNH iodide). The standards were made as outlined in table 6.2.  
 
Table 6.2. The composition of 2-MeNH standards made from a 5 mg/mL stock of 









Volume of DMSO 
added 
A 5 µg/mL Stock, 5 µL 4995 µL 
B 2 µg/mL Solution A, 400 µL 600 µL 
C 1 µg/mL Solution B, 500 µL 500 µL 
D 500 ng/mL Solution C, 500 µL 500 µL 
E 200 ng/mL Solution D, 400 µL 600 µL 
F 100 ng/mL Solution E, 500 µL 500 µL 
G 20 ng/mL Solution F, 200 µL 800 µL 
 
 
Eight µL of each standard were transferred into an Eppendorf containing 744 µL 
deionised water, 40 µL Tris and 8 µL DTT. Accordingly, the final concentrations of 
the standards were 50 ng/mL, 20 ng/mL, 10 ng/mL, 5 ng/mL, 2 ng/mL, 1 ng/mL and 
0.2 ng/mL. Once each solution had been prepared and vortexed, a 150 µL aliquot of 
each sample was transferred into 750 µL ACN as described above. 
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Upon collection of all samples and standards, the Eppendorf tubes were centrifuged 
(1-14 Microfuge, Sigma Centrifuges, Wem, UK) for 10 minutes at 16,000 x g. Eight 
hundred µL of supernatant were then carefully transferred into a fresh Eppendorf, 
taking care not to disturb the protein pellet.  
 
6.2.4.2. Detection of 2-MeNH 
6.2.4.2.1. Determination of 2-MeNH and THNH parent → product 
ion transitions  
Prior to beginning LC-MS analysis of the enzyme assay samples, parent and product 
ion transitions for selected reaction monitoring (SRM) were determined for 2-
MeNH and THNH (internal standard) following their infusion into a TSQ Quantum 
Access triple quadrupole mass spectrometer (Thermo Scientific, Loughborough, 
UK). Determination of ions fragments was performed by analysing the full scan MS-
MS spectrum of 1 µg/mL (in a 0.1% FA, 50% methanol solution) infusions of 2-
MeNH and THNH. Collision energies for the MS-MS were 33 V and 12 V for 2-MeNH 
and THNH respectively.  
 
6.2.4.2.2. Sample preparation and LC-MS  
One hundred µL of each enzyme assay sample were transferred into an extraction 
tube. A 1 mg/mL stock solution of THNH in methanol was made to be used as an 
internal standard. The solution was diluted to 1 µg/mL in a 0.1% formic acid (FA), 
50% methanol solution before 20 µL was added to each extraction tube (final 
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concentration 166 ng/mL). The tubes were evaporated to dryness under N2 at 40oC 
for 30 minutes before being reconstituted in 200 µL of 0.1% FA, 50% methanol 
solution.  
Ten µL of each solution was injected into a Thermo Accela Pump and Autosampler 
(Thermo Scientific, Loughborough, UK) coupled to a Thermo TSQ Quantum Access 
and separated using a C4 Thermo Hypersil Gold 50x2.1mm 1.9µ column (Thermo 
Scientific, Loughborough, UK) at a flow rate of 200 µL/min using the mobile phase 
gradient outlined in table 6.3. The total run time was 12 minutes.  
 
Table 6.3. The gradient conditions of the LC analysis of 2-MeNH following the 
NNMT enzyme assay. 
Time (min) % Solvent A (0.1% FA in H2O) % Solvent B (0.1% FA in ACN) 
0.00 95 5 
0.50 95 5 
5.00 50 50 
6.00 50 50 
6.20 95 5 
12.00 95 5 
 
Eluted reaction components were analysed using triple quadrupole, positive 
electrospray ionisation, with a spray voltage of 3000 kV and a capillary temperature 
of 350oC. Identification of 2-MeNH and THNH were performed via the detection of 




6.2.4.2.3. Analysis of LC-MS data  
A 2-MeNH calibration curve was generated by plotting the normalised peak area 
(NPA), determined by dividing the peak area for 2-MeNH by the corresponding peak 
area for the THNH internal standard, against the amount of 2-MeNH injected. NPA 
was calculated for each sample before NNMT activity was calculated and expressed 
as nmoles 2-MeNH produced/mg protein. Linearity of the reaction over time was 
determined using linear regression analysis. 
 
6.2.4.3. Calculation of Michaelis-Menten kinetic parameters of 
NNMT NH 2-N-methylation  
In order to calculate the Michaelis-Menten kinetic constants Km and Vmax for the 
conversion of NH to 2-MeNH by NNMT, the assay was repeated as described above 
using NH in the concentration range of 0.05 mM, 0.1 mM, 0.25 mM, 0.5 mM and 1 
mM. Each dilution into the reaction mix was made directly from a 100 mM NH stock 
(section 2.4.2, table 2.3) and 150µL aliquots were taken at 30 seconds, 1 minute, 2 
minutes, 4 minutes and 8 minutes. In addition, a no-enzyme control was prepared, 
replacing protein with 10 µL deionised water to control for non-enzymatic 
conversion of NH to 2-MeNH. Samples were taken at 0 minutes and 8 minutes and 
prepared for LC-MS as described above. 
Initial velocity (expressed as NPA/min) was determined for each substrate 
concentration, corrected for no-enzyme control and then expressed as specific 
activity (nmoles 2-MeNH produced/hour/mg NNMT protein). Km (expressed as mM) 
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and Vmax (nmoles 2-MeNH produced/hour/mg protein) were calculated using (1) 
non-linear regression analysis using a Michaelis-Menten plot (v vs [S]), (2) linear 
regression analysis of a Eadie-Hofstee plot (v vs. v/[S]), which also allows for the 
determination of the presence of substrate inhibition, a property demonstrated by 
NNMT when using nicotinamide as a substrate (Patel et al. 2013), and (3) linear 
regression analysis of a Hanes-Woolf plot ([S]/v vs. [S]), each using GraphPad Prism. 
 
6.2.5. Statistical Analysis 
Enzyme kinetic data were analysed via non-linear and linear regression as described 





6.3.1. Analysis of syntheses: 2-MeNH 
6.3.1.1. Characteristics of the synthetic product 
The synthesis of 2-MeNH produced a light yellow powder with a yield of 90% which 
was close to the 97% yield reported by Thatcher et al. 2012. The melting point of 2-
MeNH powder was 236 - 238oC, which matched the previously reported melting 
point of 236 - 238oC (Rook et al. 2010). 
 
6.3.1.2. NMR spectra for 2-MeNH matched those previously 
reported 
The 1H-NMR spectrum for the 2-MeNH synthesis was as follows:  
400 MHz (DMSO d6): δ 12.78 (1H, s, NH), 9.36 (1H, s, aromatic), 8.81 (1H, s (br), 
aromatic), 8.65 (1H, s (br), aromatic), 8.50 (1H, s (br), aromatic), 7.80 (2H, s (br), 
aromatic, aromatic), 7.46 (1H, s (br), aromatic), 4.49 (3H, s, N+CH3).  
Chemical shifts (δ) are quoted in parts per million (ppm) and are referenced to the 
residual protonated solvent peak. The order of citation in parentheses is (1) number 
of equivalent nuclei by integration, (2) multiplicity of peak (s, singlet; br, broad), 
and (3) assignment of proton environment. 
The 13C-NMR spectrum for the 2-MeNH synthesis was as follows: 
100 MHz (DMSO d6): δ 143.9 (aromatic), 134.8 (aromatic), 134.8 (aromatic), 133.4 
(aromatic), 131.87 (aromatic), 130.4 (aromatic), 123.6 (aromatic), 121.5 (aromatic), 
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119.2 (aromatic), 117.6 (aromatic), 113.0 (aromatic), 47.7 (N+CH3). Chemical shifts 
(δ) are quoted in parts per million (ppm) and are referenced to the appropriate 
solvent peak.  
Both of these spectra matched the spectra previously reported for the synthesis 
(Thatcher et al. 2012), thus demonstrating the successful synthesis of 2-MeNH. 
 
6.3.1.3. The 2-MeNH mass to charge ratio (m/z) was confirmed 
using mass spectrometry 
Infusion of a 1 mg/mL solution of 2-MeNH in methanol into the triple quadrupole 
mass spectrometer confirmed the m/z of 2-MeNH as 183.1, concurrent with its 













































































































6.3.2. Analysis of syntheses: 2,9-diMeNH 
6.3.2.1. Characteristics of the synthetic product 
The synthesis of 2,9-diMeNH yielded a golden paste with a yield of <5%. This did 
not match the 73% yield published by Cao et al. 2005. Due to the low yield, there 
was insufficient sample to perform melting point and MS analysis. 
 
6.3.2.2. NMR spectra for 2,9-diMeNH did not match those 
previously reported 
The 1H-NMR spectrum for the 2,9-diMeNH synthesis was as follows:  
400 MHz (DMSO d6): δ 8.05 (1H, d, J = 7.9 Hz, aromatic), 7.61 (1H, d, J = 8.4 Hz, 
aromatic), 7.47-7.51 (1H, m, aromatic), 7.41 (1H, d, J = 7.0 Hz, aromatic), 7.21-7.25 
(1H, m, aromatic), 7.02 (1H, d, J = 7.0 Hz, aromatic), 4.24 (3H, s, CH3), 3.57 (3H, s, 
CH3).  
Chemical shifts (δ) are quoted in parts per million (ppm) and are referenced to the 
residual protonated solvent peak. The order of citation in parentheses is (1) number 
of equivalent nuclei by integration, (2) multiplicity of peak (s, singlet; d, doublet; t, 
triplet; and m, multiplet), (3) the coupling constant (J) quoted in Hertz (Hz) and (4) 
assignment of proton environment.  
The 13C-NMR spectrum for the 2,9-diMeNH synthesis was as follows: 
100 MHz (DMSO d6): δ 155.85 (aromatic), 140.38 (aromatic), 130.04 (aromatic), 
126.53 (aromatic), 126.36 (aromatic), 123.94 (aromatic), 121.33 (aromatic), 120.89 
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(aromatic), 119.86 (aromatic), 110.53 (aromatic), 99.57 (aromatic), 36.19 (CH3), 
31.10 (CH3).  
The 13C-NMR spectrum for the synthesis of 2,9-diMeNH indicated that the product 
contained 13 carbon atoms and thus confirmed that di-methylation had taken 
place. However, while the 1H-NMR spectrum confirmed the presence of 2 methyl 
groups via 2 aliphatic singlets (δ 4.24 and δ 3.57) with an integrated size of 3 
protons, it also revealed that only 6 aromatic protons were present in the product 
(rather than 7), suggesting that 1 methyl group had become attached to an 
aromatic carbon, rather than the aliphatic nitrogen. As a result, the combined 
spectra did not match the one reported by Cao et al. (2005). Repeated attempts at 
synthesis resulted in no resolution of this, therefore, the synthesis and subsequent 
investigation of 2,9-diMeNH was not pursued further. 
 
6.3.2. Toxicity assays of SH-SY5Y and S.NNMT.LP cells incubated 
with 2-MeNH 
6.3.2.1. S.NNMT.LP cell viability was significantly less susceptible 
to the toxicity of 2-MeNH compared with SH-SY5Y cells 
A dose-response curve of cell viability, as measured using the MTT assay, derived 
from mean data from each experimental repeat (n = 4), is shown in figure 6.3. The 
individual curves from each experimental repeat, which were used to generate 1 
EC50MTT per cell line and 1 set of mean data for each of the individual experiments, 































Figure 6.3. The dose response curve of 2-meNH toxicity towards SH-SY5Y cells 
(green circles) and S.NNMT.LP cells (red circles) after a 5 day incubation. Cell 
viability was determined via MTT assay. All data are mean ± SEM, n = 4. ** = p < 





As summarised in table 6.4, 2-MeNH was toxic to SH-SY5Y cells at concentrations of 
250 µM, 500 µM, 1mM and 2 mM (all p < 0.001). For S.NNMT.LP cells, 2-MeNH was 
toxic at concentrations of 500 µM, 1mM and 2 mM (all p < 0.001). 2-MeNH also 
caused a significant increase in cell viability in S.NNMT.LP cells at 62.5 µM and 125 
µM (both p < 0.001), which was not observed for SH-SY5Y cells. The maximum 
increase in viability (+64 ± 7.3%) was measured at 125 µM.  
 
Table 6.4 The dose-dependent effects of 2-MeNH on SH-SY5Y and S.NNMT.LP cell 
viability. 
Cell line Toxicity (µM) Significance Increased 
viability (µM) 
Significance 
SH-SY5Y 250, 500, 1000, 2000 p < 0.001 N/A N/A 
S.NNMT.LP 500, 1000, 2000 p < 0.001 62.5, 125 p < 0.001 
 
 
A significant difference in toxicity was seen between cell lines at 125 µM (-3.9 on 
the log scale, p < 0.001) and 250 µM (-3.6 on the log scale, p < 0.01). The log 
EC50MTTs (in M) for SH-SY5Y and S.NNMT.LP cells exposed to 2-MeNH were -3.59 ± 
0.02 (equivalent to 257 µM) and -3.45 ± 0.03 (equivalent to 355 µM) respectively. 
The difference between the EC50MTTs was significant (p = 0. 009). 
A statistical comparison of the log EC50MTTs for NH from Chapter 5 with those 
presented here revealed that NH was more toxic than 2-MeNH to both SH-SY5Y 
cells (NH: –3.79 ± 0.06 (162 µM) vs 2-MeNH: -3.59 ± 0.02 (257 µM), p = 0.02) and 
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S.NNMT.LP (NH: -3.81 ± 0.05 (155 µM) vs 2-MeNH: -3.45 ± 0.03 (355 µM), p = 
0.0005). Comparisons between individual concentrations were not possible due to 
the differing concentration ranges used to produce the dose-response curves; these 
differences were necessitated in order to obtain optimal maxima and minima in cell 
viability for each toxin. Figure 6.4 shows the comparative toxicity profiles of the 2 





Figure 6.4. Comparative toxicity curves of NH (turquoise) and 2-meNH 
(brown) in SH-SY5Y cells (top) and S.NNMT.LP cells (bottom) following 5-day 
incubations. Cell viability was determined via MTT assay. All data are mean 



























































6.3.2.2. The ATP content of S.NNMT.LP cells was significantly 
protected against 2-MeNH compared with SH-SY5Y cells 
A dose-response curve of ATP content, derived from mean data from each 
experimental repeat (n = 4), is shown in figure 6.5. The individual curves from each 
experimental repeat, which were used to generate 1 EC50ATP per cell line and 1 set 




























Figure 6.5. The dose response curve of 2-meNH toxicity towards SH-SY5Y cells 
(green circles) and S.NNMT.LP cells (red circles) after a 5 day incubation. Cell 
viability was determined via ATP assay. All data are mean ± SEM, n = 4. *** = p < 





As summarised in table 6.5, 2-MeNH significantly reduced ATP content in SH-SY5Y 
cells at concentrations of 250 µM, 500 µM, 1mM and 2 mM (all p < 0.001). In 
S.NNMT.LP cells, 2-MeNH significantly reduced ATP content at 500 µM, 1mM and 2 
mM (all p < 0.001). 2-MeNH also caused a significant increase in ATP content in 
S.NNMT.LP cells 125 µM (p < 0.05). This effect was absent in SH-SY5Y cells. The 
maximum increase in ATP content (+40 ± 15%) was observed at 125 µM. 
 
Table 6.5. The dose-dependent effects of 2-MeNH on the ATP content of SH-SY5Y 
and S.NNMT.LP cells. 
Cell line Reduced ATP 
content 
occurred (µM) 




SH-SY5Y 250, 500, 1000, 
2000 
p < 0.001 N/A N/A 
S.NNMT.LP 500, 1000, 2000 p < 0.001 125 p < 0.05 
 
 
A significant difference in ATP content was seen between cell lines at 125 µM (-3.9 
on the log scale) and 250 µM (-3.6 on the log scale, figure 6.5, both p < 0.001). The 
log EC50ATPs (in M) for SH-SY5Y and S.NNMT.LP cells incubated with 2-MeNH were -
3.67 ± 0.114 (equivalent to 214 µM) and -3.41 ± 0.0321 (equivalent to 389 µM) 
respectively. The difference between the 2 log EC50ATPs was not significant (p = 0. 
07). 
A comparison of the NH ATP data from the previous chapter with the data 
presented here showed that NH was more effective at reducing ATP content by 
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50% than 2-MeNH in S.NNMT.LP cells as illustrated by the EC50ATPs (NH: -3.76 ± 
0.04 (174 µM) vs 2-MeNH: -3.41 ± 0.03 (389 µM), p = 0.0002). However, for SH-SY5Y 
cells, there was no difference between the NH and 2-MeNH log EC50ATPs (NH: –3.58 
± 0.05 (263 µM) vs 2me-NH: -3.67 ± 0.11 (214 µM), p = 0.47). Figure 6.6 shows the 






Figure 6.6. Comparative toxicity curves of NH (turquoise) and 2-meNH 
(brown) in SH-SY5Y cells (top) and S.NNMT.LP cells (bottom) following 5-day 
incubations. Cell viability was determined via ATP assay. All data are mean ± 





















































A t-test analysing the differences in 2-MeNH log EC50MTT and log EC50ATP showed 
that the 2-MeNH log EC50s were the same across the 2 assays in both SH-SY5Y cells 
(EC50MTT: -3.59 ± 0.02 (257 µM) vs EC50ATP: -3.67 ± 0.11 (214 µM), p = 0.51) and 
S.NNMT.LP cells (EC50MTT: -3.45 ± 0.03 (355 µM) vs EC50ATP: -3.41 ± 0.03 (389 µM), 
p = 0.38). 
 
6.3.3. Investigation of NNMT’s NH 2N-methyltransferase activity  
6.3.3.1. SRM transitions of 2-MeNH and THNH 
The infusion of 1 µg/mL synthesised 2-MeNH standard, followed by MS/MS at a 
collision energy of 33 V resulted in the identification of the following parent-
product ion transitions (in m/z): 183 → 168, 183 →140, 183 → 115. The full scan 
























































































































The infusion of 1 µg/mL THNH standard, followed by MS/MS at a collision energy of 
12 V resulted in the identification of a single parent-product ion transition (in m/z): 
173.1 → 144.  
 
6.3.3.2. Determination of NNMT NH 2N-methyltransferase 
specific activity 
2-MeNH was quantified via the 183 → 168 transition. 2-MeNH production 
increased with time in the proof-of-concept enzyme assay (figure 6.8). vi was 
determined as 0.63 nmol 2-MeNH/minute/mg NNMT. Accordingly, specific activity 
was determined as 38.1 nmol 2-MeNH/hour/mg NNMT. Data from t = 60 minutes 
were not included as peak-splitting and saturation of signal had occurred.  
 
Figure 6.8. The NNMT-mediated production of 2-MeNH over time 





























6.3.4. The kinetic parameters of NNMT NH 2N-methylation 
The Michaelis-Menten, Eadie-Hofstee and Hanes-Woolf plots of 2-MeNH 
production by NNMT are shown in figures 6.9, 6.10 and 6.11 respectively. The 
individual graphs at each NH concentration that were used to determine the points 
on the Michaelis-Menten plot can be found in appendix 3.  
  
Figure 6.9. Michaelis-Menten plot of NH 2N-methyltransferase activity of NNMT. 
 



































Figure 6.10. Eadie-Hofstee plot of NH 2N-methyltransferase activity of NNMT. 
  
Figure 6.11. Hanes-Woolf plot of NH 2N-methyltransferase activity of NNMT. 
 
  












































The calculations of Vmax and a Km derived from each plot are shown in table 6.6. 





The transformations for the Eadie-Hofstee and Hanes-Woolf plots (detailed in 
section 6.2.4.3) were used to determine Km and Vmax via the axes of each plot. In the 
Eadie-Hofstee plot Vmax was derived from the Y-intercept. Subsequently Km, was 
determined from the X-intercept by solving the equation: 




In the Hanes-Woolf plot, the x-intercept was used to obtain -Km. Subsequently, 
Vmax, was determined from the Y-intercept by solving the equation: 





Table 6.6. Km and Vmax calculations from various plots of enzyme assay data for 








Michaelis-Menten 0.0878 32.6 
Eadie-Hofstee 0.0634 30.0 





Summary of key findings 
 Synthesis of 2-MeNH was successful. However, the synthesis of 2,9-
diMeNH was unsuccessful 
 S.NNMT.LP cell viability and ATP content were less susceptible to 2-MeNH 
toxicity than SH-SY5Y 
 NNMT demonstrated NH methyltransferase activity 
 
6.4.1. The synthesis of 2-MeNH, but not 2,9-diMeNH, was 
successful 
The 2 NMR spectra, melting point analysis and m/z ratio all confirmed the 
successful synthesis of 2-MeNH. Unfortunately, this was not the case for 2,9-
diMeNH which did not show matching NMR spectra to the literature, nor was there 
a significant yield synthesised. The reasons for this are unclear but could be due to 
a lack of detail in the Cao et al. (2005) published method. The method described by 
Cao et al. produced a yield of 73%, vastly exceeding the yield achieved by the 
synthesis in this study (<5%). Furthermore, the small amount of product that was 
eventually produced did not match the published NMR spectra.  
There are 2 possible reasons for these differences. Firstly, the extraction in the 
reported method may have included and additional, unreported, step to further 
enhance the yield. Thus, in this study it is possible that the product remained in the 
aqueous phase following extraction. However, the fact that the extract did not 
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show matching NMR spectra suggests that even a better extraction may not have 
yielded the desired product. The second explanation is that the successful synthetic 
procedure performed by Cao et al. (2005) contained additional steps or conditions 
to ensure the correct product was formed that were omitted from the manuscript 
in error. This may have occurred as a result of the 2,9-diMeNH being a modification 
of another synthesis (2,9-Dibenzyl-1-methyl-NH) in the manuscript. Thus, the 
synthesis of the wrong product in this study may have resulted in the extraction 
producing a low yield.  
The NMR spectra of the product indicated that di-methylation had indeed occurred 
but likely not at both the 2N and 9N positions. This was unexpected considering 
that the aliphatic nitrogen was expected to more readily to bond the methyl group 
than an aromatic carbon due to its higher reactivity. However, considering, as 
mentioned above, that the 2,9-diMeNH method was based upon the synthesis and 
extraction of a 1-methyl NH derivative, it is possible that the 2nd methylation took 
place at the 1C position. However, this would need confirmation via additional 
experiments e.g. 2-dimensional NMR. 
Unfortunately, due to time constraints, it was not possible to establish an 
alternative protocol for synthesis of 2,9-diMeNH. However, future work will look to 
refine the process in order to achieve a successful synthesis of 2,9-diMeNH. 
Furthermore, as the 2N-methyation at NH’s pyridine ring is more likely for NNMT 
given its known activity, and due to the fact that it is the first step in the proposed 




6.4.2. S.NNMT.LP cell viability and ATP content were less 
susceptible to 2-MeNH toxicity than SH-SY5Y 
Both assays used in this study revealed significant differences between SH-SY5Y and 
S.NNMT.LP cells following 2-MeNH incubation. Furthermore, the lack of significant 
difference between EC50MTT and EC50ATP for each cell line suggested that the 
effects of 2-MeNH to each cell line were consistent across both assays. 
Not only did toxicity begin at significantly lower concentrations in SH-SY5Y cells, 125 
µM 2-MeNH significantly enhanced MTT reduction and ATP content in S.NNMT.LP 
cells but not SH-SY5Y. This lead to a significant difference in log EC50MTT between 
the cell lines but not the log EC50ATP. However, various other factors were 
significantly different in the ATP assay: the concentration at which a significant 
reduction of ATP began was higher in LP cells; the enhancement of ATP content 
occurred in S.NNMT.LP cells but not in SH-SY5Y cells; ATP content in S.NNMT.LP was 
significantly higher at 125 µM and 250 µM compared with SH-SY5Y. Furthermore 
the difference in EC50ATP (p = 0.07) was trending towards significance and thus, it is 
likely that, with further repetition, the difference in log EC50ATPs would become 
significant.  
The data discussed here are in line with previously reported data regarding the 
resistance of S.NNMT.LP cells to toxicity mediated by CxI inhibitors (Parsons et al. 
2011, Milani, Ramsden & Parsons 2013). In these studies, S.NNMT.LP cells were 
significantly less susceptible to the toxicity of rotenone and MPP+ compared with 
SH-SY5Y cells, an effect mediated by increased MeN production. Due to the fact 
that 2-MeNH is also a CxI inhibitor (Albores et al. 1990) it is, therefore, likely that 
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the S.NNMT.LP cells in this study were protected via similar mechanisms. 
S.NNMT.LP cells are protected by preventing the toxin-induced degradation of 
subunits of CxI (e.g. NDUFS3), thereby maintaining CxI activity and ATP production 
(Parsons et al. 2011). Maintenance of ATP content will conceivably also maintain 
cell viability, thus potentially explaining why the protective effects in this study 
were seen in both assays.  
In addition to the reduced susceptibility of S.NNMT.LP cells to 2-MeNH toxicity, as 
mentioned above, they also showed significantly increased viability and ATP 
content above that observed in untreated cells at 125 µM and also to a lesser 
extent at 62.5 µM (which only demonstrated viability enhancement in the MTT 
assay) 2-MeNH. As these significant enhancements were seen in both assays, it is 
possible that the mechanisms for this phenomenon are inter-linked. Indeed, it is 
hypothesised that the increased viability seen in S.NNMT.LP cells incubated with 
125 µM 2-MeNH arose as a result of the concomitantly increased ATP synthesis 
As discussed in chapter 4, simply expressing NNMT-V5 in SH-SY5Y cells is sufficient 
to increase ATP synthesis via an increased CxI activity (Parsons et al. 2011). 
Furthermore, NNMT-V5 expression in SH-SY5Y induces cell signalling such as the 
cytoprotective EFNB2 and Akt pathways (Thomas et al. 2013). Thus, it is possible 
that the synergy between NNMT-V5 expression and 2-MeNH may involve these 
pathways. As mentioned above, 2-MeNH is a CxI inhibitor. However, 2-MeNH’s 
activity at CxI is relatively weak with an IC50 almost 7-fold higher than MPP+ 
(Albores et al. 1990). Thus, an explanation for the enhanced viability and ATP 
content in S.NNMT.LP cells could be that the inhibition of 2-MeNH of CxI at those 
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concentrations is sufficient to trigger additional protective mechanisms mediated 
by NNMT without being excessively damaging to ATP production as a whole, thus 
the cell is able to compensate for the presence of the CxI inhibitor. This, however, is 
speculative and future studies will be required to confirm this. 
In general, 2-MeNH appeared to be less toxic to either cell line than its precursor, 
NH. This was true for both the EC50MTT and EC50ATP in S.NNMT.LP cells but only for 
the EC50MTT in SH-SY5Y cells. This may indicate that 2-MeNH and NH have different 
mechanisms of action and thus different toxicity. While Albores and colleagues 
(Albores et al. 1990) did not study NH specifically, they suggested that neutral βCs 
may act on complexes II and III of the mitochondrial respiratory machinery, in 
contrast to the cationic forms which predominantly work on CxI. However, a 
specific mechanism for NH toxicity is unknown as it is principally thought to be toxic 
following its di-N-methylation to 2,9-diMeNH (Pavlovic et al. 2006).  
Another reason for the difference in toxicity between NH and 2-MeNH may be 
related to the route of the compounds’ entry into the cell. Wernicke et al. (2007) 
reported that 2-MeNH toxicity is highly dependent upon the presence of DAT. In 
their study, 2-MeNH toxicity was equal to that of NH in HEK cells that did not 
express recombinant, human DAT. However, in HEK cells that did express DAT, 2-
MeNH EC50 was over 7x lower (Wernicke et al. 2007). In this study, NH was 
significantly more toxic than 2-MeNH to cell viability (as measured according to 
EC50MTTs). Thus, NH could be more readily getting into the cells than 2-MeNH and 
thus reaching higher intracellular concentrations. However, one caveat to 
comparing data from this study with the one performed by Wernicke and 
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colleagues is that the degree of DAT activity in the transfected HEK cells relative to 
that in the brain is not known. Therefore, it is possible that the successful 
transfection of DAT may have resulted in an overexpression and, thus, exaggeration 
of any DAT-dependent toxicity. Another caveat to comparing the data published by 
Wernicke and colleagues with the data shown here is that the HEK cells are derived 
from the kidney and are also embryonic rather than tumourigenic. Thus, cell line 
differences may be responsible for the differential toxicity observed.  
It is widely assumed that SH-SY5Y neurons express DAT (Cheung et al. 2009, Xie, Hu 
& Li 2010, Korecka et al. 2013). However, SH-SY5Y that have not been differentiated 
into a neuronal phenotype only express low levels of DAT (Presgraves et al. 2004). 
This lower expression in undifferentiated SH-SY5Y cells has been suggested as the 
principal reason for a lower susceptibility to MPP+ compared with cells with higher 
DAT expression (Fang, Zuo & Yu 1995, Presgraves et al. 2004). Therefore, in this 
study, it is possible that the lack of 2-MeNH toxicity in both cell lines occurred 
because low DAT expression did not permit sufficient 2-MeNH entry into the cell.  
In order to confirm whether the low 2-MeNH toxicity is due to the absence of DAT, 
the toxicity experiments should be repeated using cells expressing recombinant 
human DAT via an inducible expression system. Any alteration in 2-MeNH toxicity 
following DAT expression could be further investigated in the presence of the DAT-
inhibitor 1-(2-[bis(4-fluorophenyl)methoxy] ethyl)-4-(3 phenylpropyl) piperazine 
(GBR 12909).  
While the possibility of 2-MeNH toxicity being potentiated by DAT warrants 
investigation, both cell lines are expected to express DAT to a degree. Furthermore, 
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despite a theoretically lowered 2-MeNH uptake, due to the relatively long duration 
of the study a significant amount of 2-MeNH is expected to have entered the cell. In 
particular, the charged nature of 2-MeNH may facilitate its eventual sequestration 
into the mitochondria (Ramsay et al. 1989). Thus, 2-MeNH may genuinely be less 
toxic than NH in these cells.  
Should this indeed be the case, this raises interesting questions about the 2N-
methylation of NH. Namely, is it actually a toxicity-enhancing event or is 
detoxification occurring? The lower toxicity of 2-MeNH compared with NH in these 
studies suggests that conversion of NH to 2-MeNH in the brain may in fact be a 
detoxification pathway. If this is indeed the case, the conversion of NH to 2-MeNH 
may be protecting cells from the toxicity mediated by elevated levels of NH in PD 
brains.  
 
6.4.3. NNMT has NH 2N-methyltransferase activity  
The initial LC-MS data presented in section 6.3.3.1 confirmed the production of 2-
MeNH. Furthermore, the linear increase in 2-MeNH production over time suggested 
that no product inhibition of the reaction was occurring, a phenomenon that can 
occur with other enzymes (e.g. cysteine dioxygenase (Parsons et al. 1998)) As such, 
this is the first demonstration that NNMT has NH N-methyltransferase activity. 
The successful Michaelis-Menten curve fit of the specific activity data (figure 6.9) 
demonstrated that the reaction followed Michaelis-Menten kinetics, and allowed 
an estimation of Km and Vmax. However, the range of NH concentrations used in this 
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preliminary study did not include sufficient data points derived from concentrations 
within the linear portion of the curve, i.e. below 0.25 mM, although the plateau 
portion of the curve was well defined and a Michaelis-Menten curve with a good fit 
(r2 = 0.99) was obtained. Nevertheless, further data points below 0.25 mM would 
improve the calculation of Km and Vmax by improving the gradient of the linear 
portion of the curve. Furthermore, the values for Km and Vmax were derived from a 
single experiment. Thus, repetition of the assay will permit more accurate 
determination of the kinetic constant. Accordingly, the Km and Vmax derived from 
these data should be viewed primarily as an estimate.  
Due to the tendency for reciprocal data to amplify any experimental errors, the Km 
and Vmax of 0.0878 mM and 32.6 nmol/hour/mg NNMT respectively determined 
by the Michaelis-Menten plot, rather than the linear plots, should be viewed as the 
most reliable. The Hanes-Woolfe plot, which is often used as for confirmation of 
Michaelis-Menten-derived Km and Vmax (Nelson & Cox 2008), produced very 
similar constants. The Eadie-Hofstee-derived constants differed from the above 2 
plots but the plot was principally created to determine whether substrate inhibition 
had occurred, as is observed when nicotinamide is a substrate (Patel et al. 2013). 
Accordingly, the lack of divergent points from the linear regression analysis 
suggested that substrate inhibition of the reaction was not occurring.  
With the above considerations in mind, direct comparison of the Michaelis-Menten-
derived Km for NH reported here with other studies reporting Km values for 
nicotinamide indicated that NNMT may have a higher affinity for NH than 
nicotinamide. For example, Patel et al. (2013) reported that the Km for human 
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NNMT activity using nicotinamide was 1.36 mM, 15 times higher than the one 
reported here. However, in contrast, the Vmax reported by Patel et al. (123.4 
nmol/hour/mg protein) was almost 4-times higher despite being derived from 
homogenate and not isolated protein, and as such would be expected to be a lower 
estimate of Vmax than one calculated using isolated protein. The same trend was 
seen in a study by Rini et al. (1990). Here, Km of NNMT activity with nicotinamide as 
a substrate was 0.347 mM, 4-times higher than reported here. However, the Vmax 
was reported to be 51.5 nmol/hour/mg protein, 1.6-times the value determined 
here.  
Although the data presented here are only an estimate, the kinetic differences 
between NH and nicotinamide are in accordance with the detoxification theory 
presented above. While nicotinamide remains the primary substrate of NNMT, in 
the presence of growing concentrations of NH, the greater affinity of NH for NNMT 
will result in a favourable removal of NH from the cytosol, preventing its 
accumulation and limiting its ATP-reducing effects which occur at higher 
concentrations. Further experiments are required to confirm the kinetic differences 
between the 2 substrates. 
This is the first demonstration of NNMT’s ability to catalyse the 2N-methylation of 
NH, and is the first direct evidence of an N-methyltransferase with the capability to 
N-methylate NH. Coupled with the discovery that NNMT-V5-expressing cells are 
protected from 2-MeNH toxicity and that 2-MeNH was less toxic to all cells 
compared to its precursor NH, these findings reinforce the hypothesis that NNMT 
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expression in PD may be acting as a stress response to the disease pathogenesis. 
However, there are some caveats to this.  
Firstly, the ability of NNMT to produce 2-MeNH has only been demonstrated in 
purified protein and may be significantly different in the more physiologically-
relevant environment of the cell. For example, competition for the NNMT active 
site would likely occur between NH, nicotinamide and any other endogenous NNMT 
substrates. This would reduce the rate at which NNMT can produce 2-MeNH, 
especially as the apparent Vmax is substantially lower than that for nicotinamide. 
This is in accordance with the finding in chapter 5 that 200 µM NH reduced ATP 
content to a significantly greater extent in S.NNMT.LP cells than SH-SY5Y cells. Thus, 
NH, which is more toxic to S.NNMT.LP cells at this dose was likely not converted to 
2-MeNH at a sufficient rate to eliminate NH’s ATP reducing effects. However, this 
difference, while statistically significant, was not very large. Also, as mentioned in 
chapter 5, the concentrations used in the study were supraphysiological. Therefore, 
in the presence of the lower, physiological concentrations, NNMT-mediated NH 2N-
methylation may be sufficient to prevent an accumulation of NH to toxic 
concentrations.  
Secondly, should NNMT-expressing cells indeed be capable of producing 2-MeNH in 
situ, they will have produced a compound that is only 1 step away from becoming a 
much more potent toxin (2,9-diMeNH). Thus, NNMT’s ability to produce 2-MeNH 
could still implicate it in the bio-activation of βCs in PD. While NH 9N-
methyltransferase is yet to be fully characterised and identified, the lack of toxicity 
observed in S.NNMT.LP cells incubated with 2-MeNH suggests that NNMT itself 
236 
 
does not catalyse the formation of 2,9-diMeNH. Moreover, there are no reports of 
NNMT catalysed N-methylation moiety besides pyridine groups. Thus, on its own, 
NNMT is likely to act as a detoxification mechanism for NH by producing 2-MeNH. 
However, in the presence of a 2-MeNH 9N-methyltransferase, this step could in fact 
potentiate toxicity. This supports the notion that, in certain circumstances, the 
expression of NNMT in PD may represent a double-edged sword by providing 
neuroprotection on the one hand, but potentiating toxicity on the other. 
 
6.4.4. Summary 
S.NNMT.LP cells were significantly less susceptible to 2-MeNH toxicity than SH-SY5Y 
cells. This is likely to be due to the ability of S.NNMT.LP cells to resist the toxicity of 
CxI inhibitors due to the expression of NNMT-V5. Considering that NNMT was found 
to possess 2N-methyltransferase activity and, thus, the ability to produce 2-MeNH, 
this raises interesting questions about the interaction of βCs and NNMT in PD.  
Firstly, can NNMT catalyse the 2-N-methylation of NH in situ? Future work could 
determine this by replacing purified NNMT with homogenised S.NNMT.LP cells 
exposed to NH in a cell free assay. Also, S.NNMT.LP cells could be incubated with 
NH before being analysed for the production of 2-MeNH using mass spectrometry.  
Secondly, is 2-MeNH not as toxic as previously reported, or is the lack of toxicity in 
this study due to insufficient entry into the cell? This could be answered via studies 
involving SH-SY5Y and S.NNMT.LP cells transfected with DAT.  
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Finally, what is the mechanism for the S.NNMT.LP cells’ increased susceptibility to 
NH? It was originally hypothesised that the formation of 2-MeNH or possible 
downstream conversion to 2,9-diMeNH could have been responsible for the 
increased vulnerability of S.NNMT.LP cells to NH. However, these studies showing a 
decreased susceptibility to 2-MeNH by S.NNMT.LP cells cast doubt on this theory. 
Instead, it is possible that NH and 2-MeNH may have a different, but as of yet, 
undetermined action on NNMT-expressing cells, and that the conversion of NH to 
2-MeNH is in fact a detoxification pathway. In order to provide the most compelling 
evidence for NNMTs role in PD, future studies involving upregulated NNMT 
expression in vivo and in the presence of βCs are required. 
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7.1. The contribution of the project towards establishing the 
role of NNMT in PD 
7.1.1. Summary of the project thus far 
As discussed in chapter 1, PD is a disease in which the inherently high energy 
demands of SNpc dopaminergic neurons results in an innate degree of stress, both 
in terms of maintaining ATP production and in terms of limiting the production of 
ROS. As part of a multiple-hit hypothesis, many, sometimes minor, factors are 
thought to accumulate with time and gradually increase the strain upon SNpc 
neurons until they reach their cytotoxic threshold. This project investigated the 
possibility that NNMT is involved in this phenomenon, either as a propagator of 
toxicity or as a protective agent against the degenerative process.  
The studies carried out in this project have yielded 5 key points about the role of 
NNMT in cell survival. Firstly, NNMT expression enhanced cell viability in SH-SY5Y 
cells. Secondly, NNMT expression conferred an increased susceptibility to NH 
toxicity in vitro. However, this susceptibility was confined to loss of ATP content and 
only occurred at 1 concentration. Thirdly, NNMT expression conferred protection 
against 2-MeNH toxicity in vitro. Fourthly, 2-MeNH was less toxic than NH in both 
cell lines. Finally, purified NNMT was able to convert NH to 2-MeNH.  
 
7.1.2. The effects of NNMT expression on the cell 
In light of chapter 4 and publications from other disease areas (Cuomo et al. 1994, 
Mateuszuk et al. 2009, Kim et al. 2010, Sternak et al. 2010, Tang et al. 2011, Zhang 
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et al. 2014) it appears that increasing NNMT expression in PD may be protective by 
enhancing CxI activity and subsequently ATP production. In the PD brain, this would 
be expected to mitigate neurodegeneration by enhancing ATP content and 
preventing ROS production via electron leakage from damaged CxI. The 
enhancement of ATP production will additionally help reduce the damage caused 
by ROS by increasing the ATP-dependent production of the antioxidant glutathione, 
which itself is reduced in PD (Zeevalk, Razmpour & Bernard 2008). 
These findings raise interesting questions about the induction of NNMT expression 
in the brain of PD patients. Is the expression of NNMT, which is higher in the brains 
of patients with PD (Parsons et al. 2002, Parsons et al. 2003) induced as a protective 
response following the onset of PD or does the increased NNMT expression predate 
the onset of PD? If it is the former, then it would appear highly likely that NNMT 
expression can be induced to protect SNpc brain cells. However, if it is the latter 
and NNMT expression is elevated from birth then, considering its association with 
PD, the elevated expression of the enzyme could be contributing to the disease 
pathogenesis despite its protective effects. This could, therefore, implicate NNMT 
as a genetic susceptibility factor. Considering that the relative activity of NNMT is 
dependent solely on the levels of its mRNA rather than mutations in its gene coding 
region (Smith et al. 1998), genetic analysis of the NNMT gene in patients may not 
yield an answer to this question. Instead, it may be useful to investigate other 
genetic factors that could directly induce NNMT expression. Should SNPs in other 
genes become known that result in a higher production of NNMT mRNA, this could 
provide evidence for enhanced NNMT expression representing a genetic 
241 
 
predisposition rather than an adaptive response in PD. However, in the absence of 
this information, the current evidence suggests that NNMT may be upregulated by 
cells of the brain to protect CxI, maintain ATP content and promote Akt signalling in 
order to counteract the deleterious pathogenic mechanisms of PD. 
 
7.1.3. The effect of NNMT expression on the toxicity of NH  
While NNMT’s role as a protective agent appears plausible, data from chapter 5 
suggest that, in certain circumstances, NNMT expression may in fact be detrimental 
to the cell. The discovery that the NNMT-V5 expressing S.NNMT.LP cells were more 
susceptible than non-expressing cells to NH-mediated reduction in ATP content 
supports the hypothesis put forth by others that NNMT may increase the toxicity of 
βCs (Matsubara et al. 2002, Williams, Cartwright & Ramsden 2005). However, the 
difference in ATP content, while significant, only occurred at 1 concentration. 
Furthermore, this susceptibility was confined to the ATP assay, suggesting that NH 
did not reduce ATP content sufficiently to affect cell viability.  
In section 5.4.1 it was hypothesised that, over time, NH-mediated depletion of ATP 
may become sufficient to affect viability. In addition the NH-mediated depletion of 
ATP may combine with other PD-causing factors as part of the multiple-hit 
hypothesis, to further exacerbate ATP loss to the extent where cell death is 
initiated. However, this would need to occur via the accumulation of NH in the 
SNpc (Östergren et al. 2004), something which may be counteracted by the 
conversion of NH to 2-MeNH by NNMT (discussed more below). Indeed, the data in 
chapter 6, showing NNMT-mediated production of 2-MeNH, significant protection 
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of both ATP content and cell viability in S.NNMT.LP cells incubated with 2-MeNH, 
and a reduced toxicity of 2-MeNH compared to NH in both cell lines, suggest that 
conversion of NH to 2-MeNH may be a detoxification process. Thus, the steady 
conversion of NH to 2-MeNH in the brain could be acting as a buffer to prevent the 
accumulation and eventual toxicity of NH.  
 
7.1.4. The NNMT-mediated conversion of NH to 2-MeNH may be 
a detoxification pathway 
The data in chapter 6 represent the first demonstration of NNMT’s ability to 
convert NH to 2-MeNH. PNMT has previously also been reported as a βC 2N-
methyltransferase (Gearhart, Neafsey & Collins 2002), though this was for the 
conversion of 9-MeNH to 2,9-diMeNH. While this may imply that PNMT may be 
able to also catalyse the conversion of NH to 2-MeNH, there is no experimental 
data to support this. Indeed, the physiological relevance of this finding is unclear, 
given that 9-MeNH is reported not to occur naturally in the brain (Matsubara, 
Neafsey & Collins 1992). Should the estimated Km reported in chapter 6 for NNMT 
be confirmed in future studies, NNMT would appear to have a greater affinity for 
NH than nicotinamide. Accordingly, while nicotinamide concentration will always be 
in excess of NH, in the presence of rising intracellular concentrations of NH, NH will 
be able to out-compete nicotinamide for NNMT’s active site. Thus, NH produced in 
the cell can be quickly removed, preventing its accumulation and allowing it to be 
maintained at low concentrations. Comparison of Vmax suggests that NNMT’s overall 
ability to 2N-methylate NH appears to be lower than that reported for nicotinamide 
243 
 
(Rini et al. 1990, Patel et al. 2013). Accordingly, NNMT may not be a prolific 2N-
methylator of NH but may nevertheless favourably convert NH to 2-MeNH when 
the former is produced in the cell, allowing the mitigation of its potential toxicity.  
Interestingly, not only was 2-MeNH less toxic than NH, it was also significantly less 
toxic to S.NNMT.LP cells than SH-SY5Y cells. Moreover, 2-MeNH at its lower doses 
enhanced both cell viability and ATP content in S.NNMT.LP. This was very 
surprising, considering a previous report that 2-MeNH is a neurotoxin, capable of 
depleting dopamine levels following injection into the SN (Neafsey et al. 1989). 
However, the dose used in this study was extremely high (440 nmol in a 5 µL 
injection, 88 mM). Even at this high dose dopamine content was only reduced to 
40% of control. A later study using lower concentrations found that 40 mM 2-MeNH 
only reduced dopamine content to 64%. Moreover, injection of 8 mM 2-MeNH only 
reduced dopamine content to 80% of control (Neafsey et al. 1995). In, the study 
presented in chapter 6, the enhancement of cell viability and ATP content seen in 
the S.NNMT.LP cells occurred at concentrations of 125 µM and to a lesser extent 
62.5 µM (which only demonstrated cell viability enhancement without ATP 
enhancement). Accordingly, while one cannot directly compare the in vivo studies 
carried out by Neafsey and colleagues to the in vitro data here, the finding that 2-
MeNH may in fact be cytoprotective at low doses in S.NNMT.LP cells may be 
representative of an extension of the trend seen when lower doses of 2-MeNH 
were applied to rat brains, namely that at more physiologically relevant 
concentrations, 2-MeNH is not actually toxic at all. Instead, 2-MeNH may in fact be 
cytoprotective. It should, once again be noted that the concentrations used in the 
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toxicity assays of this project were likely higher than in the brain. However, as 
discussed in section 5.4.3, the concentrations used were high in order to determine 
the effects of these compounds over a much shorter space of time than will occur 
in PD. Accordingly, lower concentrations of 2-MeNH may also result in 
cytoprotection when acting over several years or decades.  
The finding of 2-MeNH cytoprotection has interesting parallels to the debate about 
MeN toxicity. As mentioned in section 1.3.4, some studies claimed that MeN was 
toxic in the brain (Fukushima et al. 1995, Fukushima et al. 2002, Mori et al. 2012). 
However, investigation of significantly lower concentrations of MeN revealed that 
MeN may in fact be protective to the cell (Chlopicki et al. 2007, Slomka et al. 2008, 
Sternak et al. 2010, Parsons et al. 2011, Milani, Ramsden & Parsons 2013). 
Accordingly a similar situation may be occurring here. This is particularly interesting 
considering that both MeN and 2-MeNH possess a charged pyridine ring. Thus there 
may be some structural ambiguity to this moiety, conferring toxicity on the one 
hand (2,9-diMeNH, MPP+, paraquat) yet protection/enhancement of cell viability on 
the other (MeN, 2-MeNH).  
The key caveat to the hypothesis of 2-MeNH-mediated cytoprotection is that 2-
MeNH, as discussed in section 1.3.5.2, is an intermediate in the biosynthetic 
pathway of 2,9-diMeNH, a compound that is considered significantly toxic both in 
vitro and in vivo (Bonnet et al. 2004, Hamann et al. 2006, Pavlovic et al. 2006, 
Wernicke et al. 2007). While, as discussed in chapter 6, the likelihood of NNMT-
mediated further N-methylation of 2-MeNH to 2,9-diMeNH is low, the presence of 
additional N-methyltransferases which are capable of performing this 2nd N-
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methylation reaction could lead to the eventual production of 2,9-diMeNH. Thus, 
while the conversion of NH to 2-MeNH may be a protective mechanism in NNMT 
expressing cells, in the presence of other enzymes this could still promote toxicity. 
One phenomenon that warrants investigation is the effect of NNMT expression on 
the susceptibility of SH-SY5Y cells to 2,9-diMeNH toxicity. NNMT expression, which 
is protective against toxin-mediated CxI inhibition (Parsons et al. 2011, Milani, 
Ramsden & Parsons 2013), may protect cells from 2,9-diMeNH which possesses 
similar CxI inhibitory potential to MPP+ (Albores et al. 1990). Unfortunately, the 
attempted synthesis of 2,9-diMeNH in this project was not successful and thus, it 
was not possible to test this hypothesis. However, should NNMT expression be 
protective against 2,9-diMeNH, this would provide the most compelling evidence 
for NNMT being a protective agent in PD to date. 
 
7.1.5. NNMT-V5 expression did not alter the toxicity of THNH 
and 4PP  
Other compounds studied in this project include THNH and 4PP. The fact that 
neither cell line showed any increased susceptibility to THNH during either MTT or 
ATP assays, and that it was significantly less toxic than NH, suggested that the 
compound may not be of great relevance to the toxicity of βCs. Instead, its 
relevance is derived from the fact that it can be oxidised to form the more toxic NH 
(Herraiz, Guillén & Arán 2008). However, there was no evidence to suggest that the 
expression of NNMT had an effect on this process. The degree of THNH conversion 
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to NH in both cell lines was not investigated further due to the desire to investigate 
the 2N-methylation of the more toxic NH in greater detail. 
The lack of toxicity shown by THNH may be attributable to the lack of a fully 
aromatic pyridine ring. However, 4PP, which contains a fully aromatic pyridine ring, 
was significantly less toxic than THNH to both cell lines following the ATP assay, 
with no difference in toxicity between THNH and 4PP observed during the MTT 
assay. Thus, while the only difference between NH and THNH is the aromatic 
pyridine ring, it is not clear to what extent aromatisation of this ring alone 
influences the toxicity of the βCs. 
The significant increase in ATP content seen when SH-SY5Y cells were incubated 
with 200 µM 4PP suggested that it may be able to sustain or increase ATP 
production in the cell. The absence of this increase in the S.NNMT.LP cells suggests 
that the expression of NNMT prevented this increase from occurring in response to 
4PP, although why this is the case remains unclear.  
The 4PP-mediated enhancement of ATP suggests that exposure to 4PP may be 
protective to some cells in the long term by preserving or increasing ATP levels. This 
is interesting considering that 4PP is found in oranges (Thomas & Bassols 1992) and 
mint (Snyder & D'Amato 1985) and is likely to be able to cross the blood brain 
barrier. Thus, consumption of 4PP as part of a healthy diet may have positive 
effects on the ATP production in the brain. Interestingly, 4PP has also been found in 
cigarette smoke (Heckman & Best 1981). Accordingly, these data may help to 
explain the reports that PD seems to be one of the few diseases that smoking 
appears to protect against (Kieburtz & Wunderle 2013). However, further research 
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is required to quantify the amount of 4PP that can reach the brain from both food 
and tobacco smoke and also whether 4PP can enhance ATP production in vivo in 
addition to in vitro. 
 
7.1.6. Conclusions drawn from the project 
Taking everything into account, the data presented in this project indicate that 
NNMT expression had a protective effect on SH-SY5Y cells, which occurred 
predominantly via increased CxI-mediated ATP production. In addition, NNMT 
appears to catalyse the detoxification of NH, as evidenced by (i) lower 2-MeNH 
toxicity compared with NH in both cell lines, (ii) S.NNMT.LP cells were significantly 
protected against 2-MeNH and (iii) 2-MeNH enhanced cell viability and ATP content 
in these cells. The caveat to this is that the conversion is yet to be demonstrated in 
situ. Furthermore, as indicated by the significantly lower ATP content of S.NNMT.LP 
cells compared with SH-SY5Y at 200 µM NH, the detoxification of NH may be 
overwhelmed at higher NH concentrations. However, at lower NH concentrations, 
such as those more likely to be found in vivo, NNMT may be able to remove 
sufficient NH from the cytoplasm to prevent NH accumulation and toxicity. It is 
possible that NNMT may be pro-toxic in certain circumstances, such as in the 
presence of sufficient NH substrate and enzymes that are capable of catalysing the 
9N-methylation of 2-MeNH. However, there are currently no experimental data to 
demonstrate this. Furthermore, the degree to which these theoretically pro-toxic 
events would contrast with the existing NNMT-mediated cytoprotective benefits 
would need to be determined. 
248 
 
7.2. Future work 
7.2.1. Further studies using established methods 
7.2.1.1. Optimisation of the NNMT enzyme assay 
As discussed in chapter 6, the Km and Vmax reported are only considered an 
estimate. This is due to the fact that the NH concentration range used in the study 
did not provide sufficient points in the linear portion of the Michaelis-Menten plot, 
although the data was successfully modelled using Michaelis-Menten non-linear 
regression analysis with a high degree of fit (r2 = 0.9935). Future refinement of the 
assay would involve the use of additional concentrations below 0.25 mM to further 
improve the accuracy of the Km and Vmax calculations. 
 
7.2.1.2. Synthesis of 2,9-diMeNH followed by repetition of enzyme 
assays and toxicity studies 
As discussed in chapter 6, the synthesis of 2,9-diMeNH was unsuccessful. Future 
refinement of the synthetic process, either by determining an alternative method of 
synthesis or by troubleshooting the Cao et al. (2005) method, should result in its 
successful production. If successful, 2,9-dimenNH would be used to investigate 
whether the expression of NNMT-V5 could confer greater susceptibility to the 
S.NNMT.LP cells incubated with 2,9-diMeNH or if NNMT-V5 expression protects the 
S.NNMT.LP cells in a similar manner to that seen with 2-MeNH.  
In addition, while the 9N-methylation of 2-MeNH is unlikely to be performed by 
NNMT (section 6.4.3), the possibility of this reaction still needs to be confirmed or 
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ruled out. Thus, synthesised 2,9-diMeNH would be used to create a MS-MS-based 
fingerprint such as that generated for 2-MeNH in chapter 6. This would then be 
used to determine whether purified NNMT can mediate the production of 2,9-
diMeNH using either NH or 2-MeNH as the substrate. 
 
7.2.1.3. Investigation of the mechanisms of βC toxicity/protection 
in S.NNMT.LP cells 
As discussed in section 6.4.2, differences in the susceptibility of S.NNMT.LP cells to 
NH and to 2-MeNH may suggest that both of these compounds exert their toxicity 
via different mechanisms. Accordingly, NNMT-mediated production of 2-MeNH 
from NH may represent a detoxification pathway of NH. Elucidating their respective 
mechanisms of toxicity may provide insight into why S.NNMT.LP cells are protected 
against one (2-MeNH) yet show some form of ATP-dependent vulnerability to the 
other (NH).  
The protection of S.NNMT.LP cells against 2-MeNH toxicity is likely due to the fact 
that it is a CxI inhibitor (Albores et al. 1990), something which NNMT expression has 
been shown to protect against (Parsons et al. 2011, Milani et al. 2013). However, 
the specific mechanisms of NH toxicity are yet to be determined. In addition to 
determining the apparently diverging mechanisms of the above 2 βCs it would be of 
interest to analyse the CxI inhibition of 2,9-diMeNH, which is more potent than 2-





7.2.1.4. Determination of NH 2N-methyltransferase activity in 
S.NNMT.LP cells  
In addition to determining the NH 2N-methyltransferase activity of purified NNMT, 
it will be necessary to determine whether this reaction can take place in situ within 
S.NNMT.LP, for example by measuring 2-MeNH production in S.NNMT.LP cells 
incubated with NH.  
In the context of the studies reported here, this discovery would build upon the 
chapter 5 and 6 discoveries that S.NNMT.LP cells were vulnerable to NH-mediated 
reduction in ATP content yet protected against 2-MeNH toxicity. Accordingly, a 
successful demonstration of S.NNMT.LP-mediated conversion of NH to 2-MeNH will 
strengthen the hypothesis that this reaction is a detoxification pathway in these 
cells.  
 
7.2.2. Improvement of physiological relevance via new methods 
7.2.2.1. Repetition of toxicity assays using differentiated cells 
Cellular differentiation of SH-SY5Y cells has been shown to increase levels of TH, 
DAT and NeuN, markers which indicate the differentiation of SH-SY5Y cells into a 
more dopaminergic neuron-relevant cell line (Presgraves et al. 2004). In this 
project, the primary goal was the determination of the effects of NNMT expression 
alone (chapter 4) and in the presence of 4PP and βCs (chapters 5 and 6). As such, 
these studies were collectively a proof-of-concept study to demonstrate the 
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inherent protective effects of NNMT and the potential for NNMT to alter the 
toxicity of βCs. However, as acknowledged in chapter 6, this comes at a 
compromise of not being able to maximise the physiological relevance to PD. The 
use of undifferentiated cells, however, was justified due to the fact that chemical 
differentiation via numerous growth factors and mitotic inhibitors can have 
profound biochemical effects upon the cell, such as altering ATP content (Korecka 
et al. 2013). Thus, using differentiated cells may have limited the value of the 
characterisation studies (chapter 4) as many of the effects observed from NNMT 
expression may have been masked by the differentiation process. 
Some attempts at inducing neuronal differentiation were made during the project 
but these were largely unsuccessful due to the fact that visual identification of 
neuronal differentiation under the microscope (reduced cell width, elongation and 
branching of neurites) was inconsistent. Furthermore, Western blotting analysis did 
not show any changes in neuronal markers (TH and NeuN). Therefore, due to time 
constraints, this part of the project was abandoned in favour of confirming the NH 
2N-methyltransferase ability of NNMT.  
Differentiation of SH-SY5Y cells is a frequently-discussed topic with multiple 
reported methods in existence (Encinas et al. 2000, Presgraves et al. 2004, 
Constantinescu et al. 2007, Cheung et al. 2009, Agholme et al. 2010, Lopes et al. 
2010, Korecka et al. 2013). All these methods centre upon the use of retinoic acid 
(RA) to induce differentiation but the extent of its effects on the cell and whether it 
is best used alone, in combination with other agents or indeed how to culture RA-
differentiated cells, are points of contention.  
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Lopes et al. (2010) reported that differentiation of SH-SY5Y cells into cells with 
higher expression of TH and NeuN as well as increased vulnerability to 6-
hydroxydopamine (6OHDA, a frequently used dopaminergic neuron specific toxin) 
was achieved via incubation of SH-SY5Y cells with 10 µM RA over 7 days in media 
containing only 1% FBS. On the other hand, Cheung et al. (2009) used a similar 
protocol over 7 days and reported no increase in TH expression and that 6OHDA 
toxicity was, conversely, reduced in these cells. One possible explanation for this 
difference may be the serum content used in the respective studies as the Cheung 
et al. study only reduced FBS to 3% during differentiation but these differences 
highlight the general trend of various groups professing differences in opinion 
about the use of RA in differentiation protocols.  
In a similar vein to Lopes et al. and Cheung et al., Korecka et al. (2013) used RA 
alone to produce differentiated SH-SY5Y cells. However, this was done at a 10-fold 
lower concentration of RA, 0.5% FBS and used SH-SY5Y cells cultured in matrigel. 
The result was the upregulation of numerous markers of neuronal differentiation 
(NeuN was not tested for), but no TH upregulation occurred. Other studies have 
used RA in combination with other factors and in different conditions. For example, 
Constantinescu et al. (2007), used a glass dish perfusion system of SH-SY5Y cells 
mounted on coverslips to produce differentiated cells with increased TH, NeuN and 
DAT expression following application of 10 µM RA followed by brain-derived 
neurotophic factor and various mitotic inhibitors. Finally, Presgraves et al. (2004) 
used SH-SY5Y cells grown in traditional cell culture plates but, after 3 days 
incubation with 10 µM RA, replaced RA with 12-O-tetradecanoyl-phorbol-13-
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acetate for 3 days to produce cells with significantly higher TH and DAT expression 
and increased susceptibility to MPP+. The large variability of differentiation 
methods and results highlights the fact that there is currently no gold standard 
protocol for the differentiation of SH-SY5Y cells. Accordingly, future work should 
focus on determining the most suitable and practical method for differentiating the 
SH-SY5Y and S.NNMT.LP cells, with particular reference to methods that increase 
DAT, TH and NeuN expression, in order for the toxicity assays in this study to be 
repeated with improved physiological relevance. 
 
7.2.2.1. Assessment of the effects of NNMT expression in vivo 
While determining the toxicity of NH, 2-MeNH and 2,9-diMeNH in differentiated 
SH-SY5Y and S.NNMT.LP cells will add to the physiological relevance of the model, 
the most compelling experimental evidence for NNMT’s potential involvement in 
PD will come from in vivo studies. The most likely candidate for in vivo 
determination of the effects of increased NNMT expression would be transgenic 
mouse models, as the practicalities of their breeding coupled with their strong 
genomic similarity to humans make them the animal of choice for the genetic 
analysis of human disease (Doyle et al. 2012). In particular, the use of a topical 
transgenic model, in which the genome is altered only at the desired target 
organ/tissue via the direct administration of a recombinant adeno-associated virus 
(rAAV) containing a cDNA insert of, or siRNA sequence targeted to, the gene of 
interest, would allow the effects of NNMT overexpression to be determined 
exclusively within the SNpc. Moreover, this would occur without the time, expense 
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and complications arising from the generation of transgenic animals (i.e. embryo 
lethality of expressed target protein) (Klein et al. 1998). 
Accordingly, the CxI protective, and overall cytoprotective effects of, NNMT 
expression could be investigated in vivo by injecting the brain with an rAAV 
containing a plasmid with a cDNA insert for NNMT, or an shRNA targeted to NNMT, 
under the control of a neuron-specific promoter, e.g. synapsin-1, in order to rapidly 
upregulate/downregulate NNMT expression. Furthermore, administration of βCs in 
high-expressing, endogenously-expressing, and NNMT knockdown models will allow 
the relationship between NNMT and βCs to be determined in a more physiological 
context. 
 
7.3. Concluding remarks 
This project has contributed to the field of PD research by reinforcing the findings 
made in other diseases that induction of NNMT expression enhances cell viability. 
Furthermore, this project has provided the first experimental evidence of NNMT’s 
NH 2N-methyltransferase activity and that this ability to convert NH to 2-MeNH 
may be a protective detoxification response by NNMT-expressing cells. Given that 
9N-methylation of 2-MeNH has been reported in the brain (Matsubara, Neafsey & 
Collins 1992, Gearhart et al. 2000), the possibility of NNMT and/or other N-
methyltransferases producing 2,9-diMeNH via step-wise di-N-methylation of NH 
cannot be ruled out. However, in the absence of an identified 9N-methyltransferase 
and any in vivo data showing an increased susceptibility to NH when NNMT is 
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overexpressed, these data suggest upregulation of NNMT in PD, at least initially, 
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Listed below are the individual dose response curves that were used to 
cumulatively produce the n = 5 for all the data presented in chapter 5. The mean 
data set from each curve below was input as a single repeat into the curves seen in 
chapter 5. The same is true for the 1-way ANOVAs that were calculated using the 
mean raw data from each of these curves. One EC50 was calculated from each 
curve and input as a single repeat into the comparison of EC50MTT and EC50ATP via 
Student’s t-test reported in chapter 5. Dark green curves and circles are indicative 






















































































































































































































































































































































































































































































































































































































































































































































































































































































Listed below are the individual 2-methylnorharman dose response curves that were 
used to cumulatively produce the n = 4 for all the data presented in chapter 6. The 
mean data set from each curve below was input as a single repeat into the curves 
seen in chapter 6. The same is true for the 1-way ANOVAs that were calculated 
using the mean raw data from each of these curves. One EC50 was calculated from 
each curve and input as a single repeat into the comparison of EC50MTT and EC50ATP 
via Student’s t-test reported in chapter 6. Dark green curves and circles are 
indicative of the SH-SY5Y data while dark red curves are indicative of the 



















































































































































































































































Listed below are the individual enzyme assay time course graphs that were used to 
calculated specific activity for each NH concentration and subsequently used to 
produce the Michaelis-Menten plot and linear derivations thereof presented in 
chapter 6.  
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No enzyme control 
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